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“For the first time I felt the truth that the sky begins a quarter of an inch from the 
ground. In the mornings the bush smelled like the best underarm deodorant you ever 
smelled, and I quickly got used to the mysterious movements of the trees, which 
heaved rhythmically like a man chloroformed. From time to time the night sky seemed 
uneven, closer in points, then smoothed out, like a tablecloth bunched up then 
suddenly pulled taut. I'd wake up to see low-lying clouds balanced precariously on 
the tops of trees. Sometimes the wind was so gentle it seemed to come from a child's 
nostril, while other times it was so strong all the trees seemed held tenuously to the 
earth by roots as weak as doubled-over sticky tape.”  
From: A fraction of the whole. Steve Toltz
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Outline of the thesis
11
Colorectal cancer is one of the leading causes of cancer related deaths.1 Surgery with 
curative intent is indicated for patients without distant metastases and in a subset of 
patients with resectable distant metastases.2 For irresectable metastatic colorectal 
cancer, only palliative treatment options remain. Current standard treatment consists 
of chemotherapeutic drugs (the fluoropyrimidines, oxaliplatin and irinotecan) and 
antibodies against vascular endothelial growth factor (VEGF; bevacizumab)3 and the 
epidermal growth factor receptor (EGFR; cetuximab and panitumumab).4-6 Even 
though the optimal use of these agents has not been defined, the most commonly 
applied first-line treatment consists of a fluoropyrimidine as monotherapy, or 
combined with oxaliplatin or irinotecan, plus bevacizumab, while the other drugs are 
used as salvage treatments.7,8 With the currently available regimens, the median 
overall survival of metastatic colorectal cancer patients is approximately two years.2 
Despite the improvement of prognosis of metastatic colorectal cancer patients from 
roughly 12 to 24 months in the past fifteen years2, the efficacy of these expensive and 
potentially toxic treatments remains limited and unpredictable. It is therefore desirable 
to develop predictive markers to aid better selecting patients for these treatments.   
 
In order to select patients for treatment, germline genetic variation between patients, 
as well as somatic mutations in their tumors can be used. As anti-cancer treatment 
exerts its effect in the tumor, it is reasonable to correlate the genetic mutations in the 
tumor to the anti-tumor response. Indeed, some of these mutations are used in 
routine clinical practice, such as EGFR mutation testing for the selection of non-small 
cell lung cancer patients for treatment with the small-molecule tyrosine kinase 
inhibitors against EGFR gefitinib and erlotinib9,10 and KRAS mutation testing for the 
selection of metastatic colorectal cancer patients for cetuximab or panitumumab 
treatment.11 A disadvantage of the use of somatic mutations, is that the tumor is 
genetically unstable, resulting in different genetic composition over time. Moreover, 
discordance in mutational status may be present between the primary tumor and 
corresponding metastatic lesions for some genetic variants, as well as discordance 
within one tumor sample.
Heritable germline variation in DNA derived from peripheral blood or other normal 
tissue is studied in the field of pharmacogenetics. Genetic polymorphisms may be 
present in drug target proteins, or in enzymes involved in the pharmacokinetics of the 
drug of interest. The presence of a genetic polymorphism in a gene can result in 
increased or decreased expression, or altered function of the protein. As a result, drug 
response – either efficacy or toxicity – may be altered. Advantages over tumor-derived 
genetic variation are that germline genotypes remain constant over time, and that 
the collection of blood or saliva is only mildly invasive. Moreover, the germline genetic 
variation is the same as in tumor tissue, but not vice-versa: somatic mutations that 













described and illustrated using sunitinib induced toxicity data from a previous study18 
(chapter 7). The MDR method was applied to explore the association and interaction 
of 17 frequently studied polymorphisms in different candidate genes in the control 
arm of the CAIRO2 study (chapter 8).
Currently, most pharmacogenetic studies include polymorphisms in so-called 
candidate genes. A limitation of this approach is that only mechanistically related 
genes and polymorphisms are studied, which is by definition restricted by our current 
understanding of the mechanism of action of the drugs of interest. To identify novel 
polymorphisms – and genes – that are associated with response to capecitabine, 
oxaliplatin and bevacizumab, a hypothesis-free genome wide association study was 
performed with an array including more than 700,000 polymorphisms (chapter 9). 
The results from these studies are summarized (chapter 10) and put into perspective 
in the general discussion (chapter 11). 
The aim of this thesis is to identify germline pharmacogenetic markers for predicting 
the response to palliative treatment of metastatic colorectal cancer.  
The first part of the thesis focuses on predictive germline markers for the efficacy of 
cetuximab. A review of pharmacogenetic studies for EGFR and VEGF targeted therapy 
is given in chapter 2. Germline DNA was obtained from patients in the CAIRO2 trial of 
the Dutch Colorectal Cancer Group (DCCG). In this randomized phase III study, patients 
with previously untreated metastatic colorectal cancer were treated with capecitabine, 
oxaliplatin and bevacizumab or the same regimen plus cetuximab. Surprisingly, the 
addition of cetuximab resulted in decreased median progression-free survival (PFS).13 
The influence of five different germline polymorphisms on the efficacy of cetuximab 
was investigated in patients of the CAIRO2 study (chapter 3). To further explore the 
mechanism underlying the results of this pharmacogenetic analysis, in vitro research 
on the influence of the FCGR3A Phe158Val polymorphism was performed. As a model 
for tumor-associated macrophages, type 2 macrophages were cultured from 
monocytes of healthy donors harboring the different FCGR3A genotypes. The 
activation of these type 2 macrophages under the influence of cetuximab was studied 
(chapter 4). 
In the second part of the thesis, predictive germline variation for the efficacy of 
capecitabine, oxaliplatin and bevacizumab – the treatment in the control arm of the 
CAIRO2 study – was studied. The literature on pharmacogenetics of cytotoxic therapy 
is reviewed in chapter 5. 
In the previous CAIRO study7, an exploratory study was performed with candidate 
polymorphisms in DNA repair genes.14 Polymorphisms in the ATM and ERCC5 genes 
were associated with the efficacy of an oxaliplatin-based regimen. To confirm these 
preliminary findings, the effects of these polymorphisms on treatment response were 
investigated in the control arm of the CAIRO2 study (chapter 6). 
In classic pharmacogenetic studies, each polymorphism is correlated with the clinical 
end-point. A limitation to this method is that the complexity underlying drug response 
is not fully taken into account. It is therefore not surprising that inconsistent results 
have been published for most pharmacogenetic markers.15,16 Since drug response 
involves many different proteins – such as therapeutic targets, molecules in the 
signaling pathway, metabolic enzymes or drug transporters – it is likely that the 
impact of polymorphisms in the corresponding genes exert their influence only in 
the presence of other polymorphisms. This concept is known as non-linear interaction, 
or epistasis.17 
To investigate epistasis in relation to drug response, novel methods such the 
multifactor dimensionality reduction (MDR) and classification and regression tree 
(CART) techniques can be applied. The technical aspects of these techniques are 
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EGFR and VEGF inhibition
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The treatment of solid tumours has changed in the past five years with the introduction 
of monoclonal antibody (MAb) drugs targeting growth factor pathways that are 
critical for tumour growth and invasiveness. The epidermal growth factor receptor 
(EGFR) targeting MAbs cetuximab and panitumumab and the vascular endothelial 
growth factor (VEGF) targeting MAb bevacizumab are approved for the treatment of 
metastasized colorectal cancer (mCRC). Cetuximab and bevacizumab are also 
approved for the treatment of advanced squamous cell carcinoma of the head and 
neck (SCCHN) and advanced non-squamous, non-small cell lung cancer (NSCLC) 
respectively. These MAbs are commonly administered in combination with first-line 
chemotherapy, whereas monotherapy is also applied in subsequent lines of therapy. 
Despite overall improving cancer treatment, the addition of these MAbs to 
chemotherapy increases response rates by only 10-20%1-3 and adverse events such as 
moderate to severe rash for the EGFR inhibitors and gastro-intestinal perforations and 
hypertension for bevacizumab are relatively common.1-3 Moreover, the introduction of 
these MAbs has almost doubled cost of treatment.4 
Therefore, selection of patients for treatment based on predictive factors for response, 
survival and/or toxicity could improve treatment success as well as cost-effectiveness. 
Pharmacogenetics is aimed at understanding and predicting an individual’s drug 
response based upon genetic variation. Whereas somatic mutations occur only in the 
affected organ or disease locus (tumour) and result in a different genetic composition 
of a tumour compared with other tissues in the body, germ-line polymorphisms have 
an ancestral origin and are heritable. In this review, we give an overview of heritable 
genetic factors that might predict drug induced anti-tumour response and toxicity of 
EGFR and VEGF targeting MAbs, based upon candidate genes for these pathways. 
Also, we give an overview of pharmacogenetic studies with drugs that target these 
pathways.
Epidermal growth factor (EGF) pathway
Cetuximab is a chimeric mouse/human IgG 
1
 type MAb, whereas panitumumab is a 
fully human IgG
2
 type MAb. Both MAbs bind specifically to the extracellular domain of 
the EGFR and are competitive inhibititors of the natural ligands EGF and transforming 
growth factor-α (TGFα). 
The small G protein k-ras, the protein kinase b-raf, and phosphoinositide 3-kinase 
(encoded by KRAS, BRAF and PIK3CA respectively) play a central role as intracellular 
mediators of EGFR signalling5, ultimately leading to induced transcription of several 
factors including interleukin-8 (IL8), VEGF and cyclin D1 (CD1, coded by CCND1). 
Cyclooxygenase-2 (COX2, encoded by PTGS2) is an upstream mediator of EGFR activity, 
presumably through the effect of prostaglandin E
2
 (see Figure 1). 
Abstract 
Even though treatment of several types of solid tumours has improved in the past few 
years with the introduction of the monoclonal antibodies against epidermal growth 
factor receptor (EGFR) and vascular endothelial growth factor (VEGF), response rates 
to these targeted therapies are modest. Pharmacogenetic factors have the potential 
to select patients with higher chance of response to agents that target these pathways. 
This review provides an overview over germ-line variations in genes that are potentially 
involved in the pharmacodynamics of the monoclonal antibodies cetuximab, 
panitumumab and bevacizumab, and which may underlie variable anti-tumour 
response. 




Heritable genetic variants in genes in the EGF pathway will be discussed below (see 
Table 1).
Epidermal Growth Factor Receptor (EGFR)
The first intron of the EGFR gene has an important regulatory function and contains a 
heritable polymorphic microsatellite sequence of 9 to 23 CA repeats. Most common 
alleles are the 16-repeat allele in Caucasians and Afro-Americans, and the 20-repeat in 
Asians.6,7 There is good to complete (93-100%) similarity of this polymorphism between 
normal and tumour tissue8-10, which is reassuring since the EGFR gene is highly sensitive 
to somatic alteration through loss of heterozygosity, mutations or copy number 
Pharmacogenetics of EGFR and VEGF inhibition
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Figure 1    Simplified overview of the EGF and VEGF pathways 
Abbreviations: ARNT: aryl hydrocarbon receptor nuclear translocator; braf: protein kinase b-raf; CD1: cyclin 
D1; COX2: cyclooxygenase 2; EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; HIF1α: 
hypoxia inducible factor 1α; HIF1α-OH: hydroxylated hypoxia inducible factor 1α; IL8: interleukin 8; IL8RA: 





PI3K/Akt: phosphoinositide 3-kinase/akt protein kinase; TGFα: transforming growth factor α; VEGF: vascular 


















































































































































































































































































































































































































































































































were homozygous for the short CA-repeat allele and simultaneously carrier of the 
-216T allele, had improved PFS and overall survival (OS).15  
In line with these findings, Amador et al. reported higher sensitivity to another EGFR 
inhibiting TKI, erlotinib, in cell lines with ≤35 CA-repeats compared with cell lines with 
>35 repeats. Also, the authors found increased incidence of skin toxicity in gefitinib 
treated CRC patients with ≤35 CA-repeats.10
 
Upstream regulators of EGFR
A SNP in the 5’-UTR of the EGF gene (61A>G) has been associated with higher EGF 
protein expression in vitro16 and in vivo.17 The 61GG genotype was associated with 
increased PFS in mCRC patients who were treated with cetuximab monotherapy.18 
A functional SNP in the promoter region of the PTGS2 gene (-765G>C) has been 
associated with lower promoter activity in vitro19 and with lower expression of the 
PTGS2 gene product, COX2 in vivo.20 Illustrative of its function is the strong association 
with decreased risk of myocardial infarction and stroke for the -765C allele.21 Recently, 
an association for increased PFS for the -765CC genotype was reported in mCRC 
patients treated with single agent cetuximab.18
Downstream signalling
The presence of somatic mutations in KRAS, but not in BRAF and PIK3CA, has been associated 
with decreased effect of cetuximab in CRC patients22,23, though not unequivocally.24 
However, no reports are available on heritable polymorphisms in these genes.
A SNP in the 5’-UTR of the IL8 gene (-251T>A) has been associated with increased IL8 
production.25 The IL8 receptor alpha, IL8RA (encoded by the gene CXCR1) contains a 
nonsynonymous SNP in exon 2 (2607G>C)26, whose function remains unclear. A SNP in 
the CCND1 gene (870G>A) has been associated with higher expression of CD1.27 
Zhang et al. investigated whether there was an association for the polymorphisms in 
the CCND1 (870A>G), PTGS2 (-765G>C), EGF (61A>G), EGFR (1808G>A and CA-repeats), 
IL8 (-251T>A) and VEGF (+936C>T) genes with the effect of cetuximab given as a single 
agent in advanced CRC patients.28 Homozygotes for the CCND1 870A allele had a 
shorter OS compared with carriers of the 870G allele.28 In combined analysis, patients 
who carried both a CCND1 870G allele and an EGF 61A allele had longer OS, whereas 
the other polymorphisms were not associated with survival.28 These results, though 
valuable, need to be interpreted with care, as this was an exploratory study. The fact 
that seven different polymorphisms were analyzed in a small population raises the 
alterations. A higher number of CA-repeats is associated with decreased expression of 
EGFR on both mRNA and protein level in vitro10,11, but this association was not 
consistently found in vivo.9,12 
Two single nucleotide polymorphisms (SNPs; see glossary box) in the promoter 
(-216G>T and -191C>A) are both associated with increased expression of EGFR.7,13 
A nonsynonymous SNP (1808G>A) in the extracellular domain of EGFR results in 
lower binding-affinity of EGF and TGF-α and attenuated growth response to these 
growth factors in vitro.14
Recently, two pharmacogenetic studies were published on the sensitivity of NSCLC 
patients to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. These studies are 
important examples of the utility of pharmacogenetics for EGFR inhibitors. 
Han et al. reported an increased response and time to progression (TTP) for patients 
with ≤37 CA-repeats in Korean NSCLC patients, regardless of the presence of somatic 
mutations.9 
Similarly, NSCLC patients of predominantly Caucasian origin, who were homozygous 
for two short CA-repeat alleles (defined as ≤16 CA-repeats per allele) had better 
progression free survival (PFS) compared with carriers of at least one allele with >17 
CA-repeats. Also, patients who carried the -216T allele had longer PFS. Patients who 




• SNP (Single Nucleotide Polymorphism): a change of a single base of germ-line DNA, as 
compared with wild-type, which occurs in ≥1% of the population. Because any individual 
carries two alleles, the SNP can be present in both alleles (homozygote), on only one allele 
(heterozygote) or not at all (wild-type).
• CNP (Copy Number Polymorphism): in contrast to a SNP, a CNP encompasses ≥1000 base pairs 
or more. Regarding heritability and population frequency, the definitions are the same. 
• Mutation: a change in DNA that occurs either very infrequently (≤1% in the population), or 
only in an affected organ. In the latter case, the mutation is not inherited. 
• Haplotype Block: SNPs are naturally inherited in neighboring clusters, which are called 
haplotype blocks. 
• ADCC (antibody dependent cell-mediated cytotoxicity): the recognition by natural killer cells 
of the Fc region of an antibody after binding to the antigen, followed by killing of the antigen 
presenting cell. 
• Prognostic factor: a marker for prognosis of a disease, not related to treatment 
• Predictive factor: a marker for response to a certain treatment
26 27
between the HIF1A SNPs and VEGF mRNA levels has been demonstrated, whereas no 
relationship with VEGF protein expression was found.45,47
ARNT is most commonly described as a subunit of aryl hydrocarbon receptor (AHR), 
which induces transcription of the cytochrome P450 isozyme CYP1A1 in response to 
exogenous stimuli such as cyclic aromatic hydrocarbons from cigarette smoke. As 
part of a dimer with HIF1α, ARNT induces VEGF transcription. Genetic variation of the 
ARNT gene may therefore be of importance for VEGF production. However, to date no 
functional polymorphisms in the ARNT gene have been described. 
Up to now, no pharmacogenetic studies have been published for agents that target 
the VEGF pathway. The publication of these studies is eagerly awaited, as they will 
provide a foundation for further, hypothesis testing research for this pathway. 
Polymorphisms for MAbs in general
The plasma half-life of MAbs is generally relatively long: the half life of bevacizumab 
(20 days) is similar to that of endogenous IgG
1
, whereas the half life of cetuximab and 
panitumumab is 70-100 hours and 7.5 days respectively. The shorter half life of the 
latter MAbs can in part be explained by internalization and degradation of the 
receptor-MAb complex after binding. It is postulated that antibodies of the IgG type, 
such as bevacizumab, are protected from degradation by the neonatal Fc receptor 
(FcRn, coded by FCGRT ).48 
probability of false positive associations. However, together with the other association 
studies of the EGF pathway, these findings provide an important starting point for 
adequately powered confirmation studies. 
Vascular endothelial growth factor (VEGF) pathway 
Bevacizumab is a humanized IgG
1
 type MAb directed against soluble VEGF, one of 
the key moderators in angiogenesis, which is thought to be important for tumour 
growth and invasiveness.29 VEGF exerts its pro-angiogenic effect via VEGF receptor-2, 
a tyrosine kinase receptor that is also referred to as kinase insert domain receptor 
(KDR). Transcription of VEGF is regulated by hypoxia inducible factor-1α (HIF1α) (see 
Figure 1).
To date, five functional SNPs in the 5’ and 3’ regions of the VEGF gene have been 
described (Table 2).30-32  
The variant alleles of the -1154G>A and +936C>T SNPs are associated with lower VEGF 
production32-35, whereas the variant allele of the -460C>T SNP results in increased 
promoter activity.36 There is less agreement on the functionality of the -2578C>A and 
+405G>C SNPs, as both increased as decreased VEGF production have been 
reported.31,34,35,37 
It must be noted though that the above mentioned SNPs are inherited in clusters in 
so called haplotype blocks (see glossary box).31,35,36,38-41 It is likely that only one SNP is 
truly functional with regard to VEGF expression, whereas the others are merely proxies 
for this one. This truly causal SNP, however, has so far not been identified.
There are several nonsynonymous SNPs in the coding region of the KDR gene (see: 
http://www.ncbi.nlm.nih.gov/projects/SNP). Nonetheless, only functionality of a 
CA-repeat polymorphism in intron 2 of the KDR gene (+4422(AC)
11-14
) has been 
determined. The 11-repeat polymorphism results in higher promoter activity in vitro.42 
Even though the 11- and 12-repeat alleles were most common in the Japanese 
population, the allele frequencies in other populations are unknown. 
The nonsynonymous SNP 1772C>T in the gene encoding HIF1α (HIF1A) has been 
associated with increased expression of HIF1α.43-45 The enzyme coded by the variant 
allele is also less sensitive to hydroxylation dependent degradation46, which results in 
further increased protein levels. Another nonsynonymous SNP (1790G>A) in the HIF1A 
gene has also been associated with increased HIF1α expression.43
As these SNPs result in increased abundance of the HIF1α protein, it is expected that 
the SNPs ultimately result in increased VEGF expression (see Figure 1). The relationship 
Pharmacogenetics of EGFR and VEGF inhibition
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Table 2    Overview of polymorphisms in genes that code for enzymes involved in 
the VEGF pathway  
Enzyme (gene) Polymorphism Phenotype Function Ref
VEGF (VEGF) -2578C>A lower or higher VEGF 34,35
-1154G>A lower VEGF 34,35
-460C>T increased promoter activity 36
+405G>C lower or higher VEGF 31,34,37
+936C>T lower VEGF 32,33
KDR (KDR) +4422(AC)
11-14
11 CA repeats higher promoter 
activity than 12 CA repeats
42
HIF1α (HIF1A) 1772C>T Pro582Ser higher HIF1α 43-46
1790G>A Ala588Thr higher HIF1α 43
28 29
Sachs et al. recently described a variable number of tandem repeats (VNTR) within the 
promoter of the FCGRT gene consisting of five different alleles with one to five repeats 
(VNTR 1-5).49 The allele frequencies of VNTR2 and VNTR3 were 0.075 and 0.92 
respectively in Caucasians. The VNTR3 allele was associated with higher FcRn 
expression both in vitro and in vivo. Also, binding of IgG was higher among VNTR3 
homozygotes compared with VNTR2/VNTR3 heterozygotes.49 Possibly, individuals 
carrying the VNTR3 allele have prolonged plasma half-life of bevacizumab, and even 
increased response.  
Cetuximab is a competitive inhibitor of EGFR, which results in decreased utilization of 
this pathway. As cetuximab is of the IgG
1
 type, it is likely that antibody dependent 
cell-mediated cytotoxicity (ADCC) also plays a role in its mechanism of action. The Fc 
region of the antibody can be recognized by Fcγ-receptors on cytotoxic immune 
effector cells such as natural killer cells and macrophages. Two activating Fcγ-receptors 
are CD16A and CD32A (encoded by respectively FCGR3A and FCGR2A) are polymorphic 
(see table 3). 
A SNP in the FCGR3A gene (559T>G; Phe158Val) has been studied since the early 1990’s. 
IgG
1
 binding is higher for the 158Val allele, which results in increased activation of 
ADCC but not in altered expression.50,51 Also, the affinity of the IgG
1
-type MAb against 
CD20 expressing B cells, rituximab, was highest for the 158Val allele.52 It is therefore 
not surprising that response and PFS to rituximab in follicular lymphoma was higher 
for homozygotes of the 158Val allele, compared with carriers of the 158Phe allele.53,54 
This SNP was not associated with clinical response to another IgG
1
 MAb against TNFα, 
infliximab, in Crohn’s disease, but increased biological response (decrease in C-reactive 
protein) was associated with the 158Val allele.55,56 
Even though the function of a SNP in the FCGR2A gene (535A>G; His131Arg) with 
regard to IgG
1
 has not been established, an association with worse response and PFS 
to rituximab in follicular lymphoma was found.54 However, this association was not 
confirmed by another study.53 
Very recently, Zhang et al. showed that mCRC patients treated with cetuximab 
monotherapy, who were homozygous for either the FCGR2A 131Arg or FCGR3A 158Val 
allele had shorter PFS and decreased response.57 The reason for this result, which for 
FCGR3A is opposite to what would be expected, is not known. A possible explanation 
is that copy number polymorphism (CNP) (see next paragraph) at the locus of FCGR3A 
plays a role. This, however, has not been investigated. It is also probable that this 
finding is a false positive discovery, since not only these two genotypes have been 
investigated, but also seven others in a previous analysis of the data.28  
Even though ADCC does not play a role for bevacizumab, it is likely that its effect is 
modified by similar mechanisms.








































































































































































































































































































































































a distinction between predictive and prognostic factors (see glossary box) can be 
established. This latter point is of great importance, because numerous studies have 
shown an association of polymorphisms within genes in the EGF and VEGF pathways 
with the risk and progression of several types of cancer.64 
Based upon these considerations and available studies, the predictive value of FCGR2A, 
FCGR3A, EGF and CCND1 genotyping should be investigated prospectively for 
cetuximab in cases and controls. For bevacizumab and panitumumab, hypothesis 
generating association studies, based upon the candidate genes in this review, are 
required for further research.  
In any pharmacogenetic association study, confounders must be carefully corrected 
for, in order to find independent predictive factors. Factors that need to be taken into 
account are gender and race, as these can impact on the response to therapy. 
Moreover, allele frequencies are usually different among populations. Also, care 
should be taken to reduce the chance of false positive associations when testing 
multiple genotypes. This can be accomplished by adjusting the level of significance 
based upon the number of genotypes tested, for example with the Bonferroni 
correction. 
Interestingly, there appears to be major interplay between these two pathways. For 
example, higher intratumoral VEGF levels were associated with resistance to single 
agent cetuximab in mCRC patients.65 Moreover, the combination of cetuximab and 
irinotecan in mCRC patients reduced circulating VEGF levels, and of these patients 
with the most prominent decrease of VEGF responded better as indicated by TTP and 
OS compared with patients who showed only a modest reduction in VEGF levels.66 
Therefore, it makes sense to look at multiple SNPs and CNPs within both pathways 
simultaneously.  
Finally, true usefulness of a predictive marker can only be assessed with the application 
of a validated predictive test in a prospective setting. The test should allocate different 
treatment options for patients with the genotype of interest, and solid endpoints 
should be investigated. 
In conclusion, pharmacogenetics (including germ-line SNPs and CNPs) of EGFR and 
VEGF inhibitors will most likely find its way to daily clinical practice, provided that the 
above suggestions for future research have been met. 
Copy number polymorphisms
An interesting novel field of pharmacogenetic research includes heritable variation of 
copy number of DNA segments of 1 kb or larger of the genome.58 Analogous to the 
definition of a SNP, a CNP is a structural variant that occurs at a frequency of >1% in 
the population. Since the first whole genome array studies of this phenomenon were 
published in 200459,60, an open-access online database has been developed in which 
structural variations of the human genome are assembled60,61 (see: http://projects.
tcag.ca/variation). 
Several studies have demonstrated that increased intratumoral EGFR copy number in 
advanced CRC patients is associated with effectiveness of cetuximab.22,24,62 However, 
is must be noted that this is a somatic phenomenon, which is probably involved in 
the aetiology of the tumour. In the Database of Genomic Variants, there are no CNPs 
on the EGFR locus. Also, no CNPs are reported at the loci that cover the TGFA, IL8, 
CXCR1, BRAF, KRAS, PIK3CA, PTGS2, VEGF, KDR, HIF1A or ARNT genes. There is an infrequent 
CNP in the EGF gene (one reference to loss of the locus in 36 subjects), but CNPs on 
the locus that covers the CCND1 gene occurs in 6 of 95 subjects. Also, the locus that 
contains the FCGRT gene shows heritable loss at a frequency of approximately 0.26. 
There is also considerable CNP covering the FCGR2A and FCGR3A genes, with equal 
amount of gain and loss of this locus. Illustrative of the influence of copy number 
variation was recently published, showing that copy number variation of the FCGR2A 
and FCGR3A containing region (that also contains the FCGR3B gene encoding CD16B) 
was associated with susceptibility to systemic autoimmune diseases.63
Discussion 
It is accepted that germ-line polymorphisms (both SNPs and CNPs) have the potential 
to predict outcome of therapy. Predicting outcome of therapy with cetuximab, 
panitumumab and bevacizumab is especially warranted, as response rates are 
moderate, with possible serious adverse events, at high financial cost. In this review, 
we give an overview of studies on polymorphisms in candidate genes in the EGF and 
VEGF pathways. 
To date, only few small studies have shown an association of genetic polymorphisms 
in genes of the EGF pathway with response to EGFR targeting therapies (see Table 1), 
whereas studies for the VEGF pathway are thus far lacking. 
However, these studies do not provide sufficient evidence to routinely genotype 
patients before applying these therapies. The associations need to be confirmed in 
one or more sufficiently powered prospective studies first. A requirement for these 
studies is the presence of a control group without the treatment of interest. Only then 




20.  Brosens LA, Iacobuzio-Donahue CA, Keller JJ, et al. Increased cyclooxygenase-2 expression in duodenal 
compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C 
COX-2 polymorphism. Clin Cancer Res 2005;11:4090-6.
21.  Cipollone F, Toniato E, Martinotti S, et al. A polymorphism in the cyclooxygenase 2 gene as an inherited 
protective factor against myocardial infarction and stroke. JAMA 2004;291:2221-8.
22.  Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab 
therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
23.  Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic 
colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9.
24.  Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor 
(EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 
2005;6:279-86.
25.  Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the 
interleukin 8 gene region in UK families. Thorax 2000;55:1023-7.
26.  Renzoni E, Lympany P, Sestini P, et al. Distribution of novel polymorphisms of the interleukin-8 and CXC 
receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 
2000;43:1633-40.
27.  Izzo JG, Wu TT, Wu X, et al. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression 
is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. 
J Clin Oncol 2007;25:698-707.
28.  Zhang W, Gordon M, Press OA, et al. Cyclin D1 and epidermal growth factor polymorphisms associated 
with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet 
Genomics 2006;16:475-83.
29.  Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
30.  Brogan IJ, Khan N, Isaac K, et al. Novel polymorphisms in the promoter and 5’ UTR regions of the human 
vascular endothelial growth factor gene. Hum Immunol 1999;60:1245-9.
31.  Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular 
endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 
2000;12:1232-5.
32.  Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the 
gene for vascular endothelial growth factor is associated with vascular endothelial growth factor 
plasma levels. J Vasc Res 2000;37:443-8.
33.  Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular 
endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003;106: 
468-71.
34.  Koukourakis MI, Papazoglou D, Giatromanolaki A, et al. VEGF gene sequence variation defines VEGF 
gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 
2004;46:293-8.
35.  Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are 
associated with acute renal allograft rejection. J Am Soc Nephrol 2002;13:260-4.
36.  Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human 
vascular endothelial growth factor gene promoter. Cancer Res 2003;63:812-6.
37.  Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5’-untranslated region of the VEGF 
gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002;51:1635-9.
38.  Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth 
factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. 
Genes Immun 2002;3:229-32.
References
1.  Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus 
placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an 
Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54.
2.  Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin 
for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
3.  Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell 
lung cancer. N Engl J Med 2006;355:2542-50.
4.  Garrison L, Cassidy J, Saleh M, et al. Cost comparison of XELOX compared to FOLFOX4 with or without 
bevacizumab (bev) in metastatic colorectal cancer. J Clin Oncol 2007;25:Abstr. 4074.
5.  Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. 
Nat Rev Cancer 2007;7:169-81.
6.  Liu W, Innocenti F, Chen P, et al. Interethnic difference in the allelic distribution of human epidermal 
growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9:1009-12.
7.  Gregorc V, Cusatis G, Spreafico A, et al. Association of germline mutations in EGFR and ABCG2 with 
gefitinib response in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2005;23:Abstr. 
3022.
8.  Etienne-Grimaldi MC, Pereira S, Magne N, et al. Analysis of the dinucleotide repeat polymorphism in the 
epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann Oncol 2005;16:934-
41.
9.  Han SW, Jeon YK, Lee KH, et al. Intron 1 CA dinucleotide repeat polymorphism and mutations of 
epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. 
Pharmacogenet Genomics 2007;17:313-9.
10.  Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism 
mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64:9139-43.
11.  Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by 
a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999;274:13176-80.
12.  McKay JA, Murray LJ, Curran S, et al. Evaluation of the epidermal growth factor receptor (EGFR) in 
colorectal tumours and lymph node metastases. Eur J Cancer 2002;38:2258-64.
13.  Liu W, Innocenti F, Wu MH, et al. A functional common polymorphism in a Sp1 recognition site of the 
epidermal growth factor receptor gene promoter. Cancer Res 2005;65:46-53.
14.  Moriai T, Kobrin MS, Hope C, Speck L, Korc M. A variant epidermal growth factor receptor exhibits 
altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad 
Sci U S A 1994;91:10217-21.
15.  Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical 
outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 
2008;8:129-38.
16.  Shahbazi M, Pravica V, Nasreen N, et al. Association between functional polymorphism in EGF gene and 
malignant melanoma. Lancet 2002;359:397-401.
17.  Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with 
increased frequency in glioblastoma multiforme patients and is associated with more aggressive 
disease. Cancer Res 2004;64:1220-3.
18.  Nagashima F, Zhang W, Gordon M, et al. EGFR, Cox-2, and EGF polymorphisms associated with progres-
sion-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single agent 
cetuximab (IMCL-0144). J Clin Oncol 2007;25:Abstr. 4129.
19.  Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene 
expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 
2002;22:1631-6.




60.  Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet 
2004;36:949-51.
61.  Zhang J, Feuk L, Duggan GE, Khaja R, Scherer SW. Development of bioinformatics resources for display 
and analysis of copy number and other structural variants in the human genome. Cytogenet Genome 
Res 2006;115:205-14.
62.  Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab 
in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin 
Oncol 2006;24:4914-21.
63.  Fanciulli M, Norsworthy PJ, Petretto E, et al. FCGR3B copy number variation is associated with 
susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 2007;39:721-3.
64.  Hirsch FR. EGFR: a prognostic and/or a predictive marker? J Thorac Oncol 2006;1:395-7.
65.  Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 
2005;23:3536-44.
66.  Vincenzi B, Santini D, Russo A, et al. Circulating VEGF reduction, response and outcome in advanced 
colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics 2007;8:319-27.
39.  Jin Q, Hemminki K, Enquist K, et al. Vascular endothelial growth factor polymorphisms in relation to 
breast cancer development and prognosis. Clin Cancer Res 2005;11:3647-53.
40.  Lee SJ, Lee SY, Jeon HS, et al. Vascular endothelial growth factor gene polymorphisms and risk of primary 
lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14:571-5.
41.  Lu H, Shu XO, Cui Y, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer 
survival. Cancer Res 2005;65:5015-9.
42.  Kariyazono H, Ohno T, Khajoee V, et al. Association of vascular endothelial growth factor (VEGF) and 
VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr Res 
2004;56:953-9.
43.  Tanimoto K, Yoshiga K, Eguchi H, et al. Hypoxia-inducible factor-1alpha polymorphisms associated with 
enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003;24:1779-83.
44.  Yamada N, Horikawa Y, Oda N, et al. Genetic variation in the hypoxia-inducible factor-1alpha gene is 
associated with type 2 diabetes in Japanese. J Clin Endocrinol Metab 2005;90:5841-7.
45.  Koukourakis MI, Papazoglou D, Giatromanolaki A, et al. C2028T polymorphism in exon 12 and 
dinucleotide repeat polymorphism in intron 13 of the HIF-1alpha gene define HIF-1alpha protein 
expression in non-small cell lung cancer. Lung Cancer 2006;53:257-62.
46.  Fu XS, Choi E, Bubley GJ, Balk SP. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) 
polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 
2005;63:215-21.
47.  Kuwai T, Kitadai Y, Tanaka S, et al. Expression of hypoxia-inducible factor-1alpha is associated with tumor 
vascularization in human colorectal carcinoma. Int J Cancer 2003;105:176-81.
48.  Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-
containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A 1996;93:5512-6.
49.  Sachs UJ, Socher I, Braeunlich CG, et al. A variable number of tandem repeats polymorphism influences 
the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology 
2006;119:83-9.
50.  Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by 
natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 
1997;90:1109-14.
51.  Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor 
function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70.
52.  Dall’Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence 
of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-9.
53.  Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody 
and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
54.  Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict 
response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
55.  Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding 
gene and biological response to infliximab in Crohn’s disease. Aliment Pharmacol Ther 2004;19:511-9.
56.  Louis EJ, Watier HE, Schreiber S, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to 
infliximab in Crohn’s disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 
2006;16:911-4.
57.  Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical 
outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated 
with single-agent cetuximab. J Clin Oncol 2007;25:3712-8.
58.  Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. Nat Rev Genet 2006;7:85-97.
59.  Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymorphism in the human genome. 
Science 2004;305:525-8.




Correlation between germline 
polymorphisms and the efficacy of 
cetuximab in metastatic colorectal cancer
Jan Pander • Hans Gelderblom • Ninja F. Antonini • Jolien Tol  
Johan H.J.M. van Krieken • Tahar van der Straaten • Cornelis J.A. Punt
Henk-Jan Guchelaar




Previous studies indicated that germline polymorphisms in specific genes may predict 
efficacy and toxicity of cetuximab in metastatic colorectal cancer (mCRC) patients.
Methods
Germline DNA was isolated from 576 mCRC patients who were treated in the phase III 
CAIRO2 study with chemotherapy and bevacizumab alone or with cetuximab. 
Associations of epidermal growth factor (EGF) 61A>G, EGF receptor (EGFR) CA
14-22
, 
cyclin D1 (CCND1) 932G>A, fragment-C gamma receptor (FCGR) 2A 535A>G and FCGR3A 
818A>C polymorphisms with progression-free survival (PFS) were studied with regard 
to KRAS status. 
Results 
In the cetuximab arm, the FCGR3A818C-allele was associated with decreased PFS, both 
overall and in the KRAS wild-type subgroup (HR=1.56, 95%CI=1.14-2.15 and HR=1.57, 
95%CI=1.06-2.34, respectively) and decreased incidence of grade 2-3 skin toxicity 
(OR=0.48, 95%CI=0.24-0.94). The EGFR≥20 genotype was associated with decreased 
PFS, both overall and in the KRAS wild-type subgroup (HR=1.60, 95%CI=1.17-2.19 and 
HR=1.58, 95%CI=1.06-2.35, respectively). The FCGR3A and EGFR polymorphisms were 
not associated with PFS in the no-cetuximab arm. In KRAS mutated patients, the 
EGF61G-allele was associated with decreased PFS in the cetuximab arm, and increased 
PFS in the no-cetuximab arm (HR=2.22, 95%CI=1.24-3.96 and HR=0.59, 95%CI=0.36-
0.98, respectively).
Conclusion
EGFR, FCGR3A and EGF polymorphisms are associated with PFS in mCRC patients 
treated with cetuximab, bevacizumab and chemotherapy. Confirmation is needed 
before these markers could be applied clinically. 
Introduction
Cetuximab is an IgG
1
-type chimeric monoclonal antibody that targets the epidermal 
growth factor receptor (EGFR). Its principal mechanism of action is the inhibition of 
ligand induced EGFR activation, resulting in reduced cell proliferation, cell survival 
and angiogenesis. Also, cetuximab may induce antibody-dependent cell-mediated 
cytotoxicity (ADCC) by recruitment of immune effector cells.1  
Cetuximab is effective in patients with chemotherapy-refractory metastatic colorectal 
cancer (mCRC).2,3 A modest clinical benefit was shown for cetuximab when added to 
first-line chemotherapy.4-6 Recently, it has been demonstrated that the efficacy of 
cetuximab is limited to patients with wild-type KRAS tumors.7,8 However, the KRAS 
mutation status does not completely predict the response to cetuximab and other 
tumor characteristics such as BRAF mutation status have been investigated.9,10 The 
severity of acneiform skin rash is also associated with the efficacy of cetuximab2,3, but 
as this adverse event occurs after therapy has started, it cannot be used to predict 
response before start of treatment. Therefore, additional predictive markers are 
needed to better identify patients who will benefit from cetuximab.
Germline polymorphisms in genes involved in the mechanism of action of cetuximab 
have been investigated previously.11-14 A CA-repeat polymorphism in intron 1 of the 
EGFR gene and the single nucleotide polymorphisms (SNPs) EGF c.61A>G, cyclin D1 
(CCND1) c.932G>A and fragment-C gamma receptors 2A (FCGR2A) c.535A>G and 3A 
(FCGR3A) c.818A>C have previously been associated with the efficacy of cetuximab in 
chemotherapy-refractory mCRC patients who were treated with cetuximab either as 
monotherapy11,12 or in combination with irinotecan.13,14 However, these findings have 
been investigated in relation to KRAS mutation status in only one small study.14 
Furthermore, these former studies were hypothesis generating, and lacked a control 
group. 
To provide more robust data, we investigated the associations of these germline 
polymorphisms in combination with KRAS mutation status with the efficacy of 
cetuximab in a large cohort of mCRC patients who were treated in first-line with 
capecitabine, oxaliplatin, bevacizumab and cetuximab and included a control group 
treated with the same regimen but without cetuximab. 
Materials and methods
Study population
Blood samples were collected from 576 of 755 previously untreated mCRC patients 
who participated in a multicenter prospective, randomized phase III study and were 
treated with capecitabine, oxaliplatin and bevacizumab or the same regimen plus 




according to the criterion applied by Zhang and colleagues.11 Patients with two alleles 
containing less than 20 CA-repeats were designated ‘EGFR<20’, whereas patients with 
either one or two alleles with 20 CA-repeats or more were designated as ‘EGFR≥20’. 
All genotype frequencies were in Hardy-Weinberg equilibrium. 
The KRAS mutation status was determined in patients from whom primary tumor 
tissue was available. Tumor DNA was extracted and KRAS mutation status was analyzed 
using a commercially available real-time PCR-based assay (DxS, Manchester, UK) and 
by direct sequencing.18 
Statistical analysis
The primary objective was to assess the association of the EGFR, EGF, CCND1, FCGR2A 
and FCGR3A polymorphisms with PFS according to KRAS mutation status in mCRC 
patients treated with cetuximab added to chemotherapy and bevacizumab. The 
secondary objective was to assess the association between these polymorphisms 
and cetuximab-related skin toxicity (grade 0-1 versus 2-3). 
The PFS of each polymorphism was analyzed per treatment arm. Survival curves were 
estimated using the Kaplan-Meier method. The hazard ratios and 95% confidence 
intervals (95%CI) were estimated using a multivariate Cox proportional hazards model 
per treatment arm, using the most appropriate of a dominant or recessive model. The 
effects of the genotypes were assessed with the wild-type genotype as the reference, 
as this is the most frequent and therefore ‘normal’ genotype. Since age (<65 versus 
≥65 years) and gender potentially affect the influence of a genetic polymorphism19, 
these factors were included in the multivariate analysis in addition to serum LDH 
(normal versus abnormal), which was an independent prognostic factor in the CAIRO2 
study.15 For the analysis of KRAS wild-type and mutant combined, KRAS mutation 
status was added to the multivariate model (wild-type versus mutant). 
For patients in cetuximab arm, the association between the genotype and cetuximab-
related skin toxicity (grades 0-1 versus 2-3) was analyzed and odds ratios (ORs) and 
95%CIs were estimated using a univariate logistic regression model. 
A Predictive Score for PFS was generated by assessing the interaction between 
treatment arm and previously published baseline prognostic variables for mCRC in a 
multivariate Cox proportional hazards model. Baseline prognostic factors for PFS were 
identified from a Medline search for original articles on clinical trials of mCRC patients 
who were treated with first-line chemotherapy.20-25 Factors that were significantly 
associated (p<0.05) with PFS in a multivariate analysis including treatment arm were 
considered prognostic factor, and the cut-off values from these studies were used 
subsequently. Prognostic factors for OS were not included because these could also 
be related to subsequent lines of treatment. The resulting baseline prognostic 
variables were gender, age (<65 vs. ≥65 years), performance status (0 vs. 1), number of 
organs involved (1 vs. >1), LDH (normal vs. above normal), alkaline phosphatase 
cetuximab, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG).15,16 Patient 
eligibility criteria are described in detail elsewhere.15 Patients were stratified according 
to prior adjuvant chemotherapy, serum LDH, number of affected organs and per 
institution. Membrane expression of EGFR in the tumor was not required. 
Cetuximab was administered intravenously at a dose of 400 mg/m2 on the first day, 
followed by 250 mg/m2 weekly thereafter. Dose reductions were carried out according 
to the study protocol. The duration of a treatment cycle was three weeks. Treatment 
was continued until disease progression, death or unacceptable toxicity, whichever 
occurred first. 
The collection of a peripheral blood sample for pharmacogenetic research was 
pre-specified in the study protocol and required additional written informed consent. 
The protocol was approved by the local institutional review boards of all participating 
centers. 
Clinical evaluation and toxicity criteria
Progression-free survival (PFS) was calculated using tumor response assessments 
every three cycles by CT scan according to RECIST 1.0 criteria.15 PFS was defined as the 
interval from the date of randomization to the date of disease progression, death, or 
last follow-up, whichever occurred first. Toxicity was scored according to the National 
Cancer Institute Common Toxicity Criteria version 3.0. Cetuximab-related skin toxicity 
was defined as any skin toxicity with the exception of hand-foot syndrome. 
Analysis of genetic variants
Germline DNA was isolated from peripheral white blood cells by the standard manual 
salting-out method. Genotyping was performed on a TaqMan 7500 (Applied 
Biosystems, Foster City, CA, USA) with pre-designed assays for EGF c.61A>G (rs4444903), 
CCND1 c.932G>A (rs9344; also referred to as 870G>A), FCGR2A c.535A>G (rs1801274; 
resulting in amino-acid change of histidine to arginine at position 131) and FCGR3A 
c.818A>C (rs396991; resulting in amino-acid change of phenylalanine to valine at 
position 158), according to the manufacturer’s protocol. Negative controls (water) 
were included. In addition, genotypes were confirmed on the Biomark (Fluidigm, 
South San Francisco, CA, USA) according to the protocol provided by the manufacturer 
using the same TaqMan assays. The FCGR3A polymorphism was also analyzed by 
Pyrosequencing for 15% of the samples, which confirmed the Taqman results.
The EGFR (CA)n polymorphism was analyzed by fragment analysis. Briefly, 10 ng of 
DNA was PCR amplified using primers FAM-5’-CCAAAATATTAAACCTGTCTT-3’ and 
5’-AACCAGGGACAGCAATCC-3’. PCR products were run on an ABI PRISM® 3730xl 
Analyzer and analyzed with Genemapper v3.5 software (Applied Biosystems). Plasmids 
with an EGFR insert containing 14 to 21 CA-repeats were used as a control.17 For the 
purpose of this analysis, the EGFR CA-repeat polymorphism was dichotomized 




(normal vs. above normal), prior adjuvant chemotherapy (yes vs. no), white blood cell 
count (<8 000 vs. ≥8 000 cells per μL), hemoglobin (<11 vs. ≥ 11 g/dL) and total bilirubin 
(normal vs. above normal).20-25 Additionally, the interaction terms of treatment arm 
and KRAS mutation status and the polymorphisms in CCND1, EGFR, EGF, FCGR2A and 
FCGR3A were included. Using the resulting Cox proportional hazards model, the 
regression coefficients of the significant interaction terms were converted into a 
Partial Score analogous to the method used by Chow and colleagues.26 By using the 
regression coefficients of the interaction term instead of the regression coefficient of 
the variable itself, correction took place for cetuximab-unrelated prognostic value of 
the variable. A Predictive Score for a given patient was obtained by the sum of the 
Partial Scores.
All statistical analyses were performed using the Statistical Analysis Software version 
9.1 (SAS Inc. Bethesda, Maryland, USA).
Results
Study population
Germline DNA was obtained from 576 included patients, of which 564 received the 
allocated treatment (282 in each arm). The baseline clinical characteristics, KRAS 
mutation status, median PFS and OS, and the incidence of cetuximab-related skin 
toxicity of these patients were not statistically significant different from the 172 
patients of whom no blood sample was available (Table 1). 
Association with outcome in the cetuximab arm
Progression free survival
KRAS wild-type patients
In the cetuximab arm, patients who were carriers of the FCGR3A C-allele (AC and CC 
genotypes combined) had a significantly decreased PFS compared with patients with 
the FCGR3A AA genotype (median PFS, 8.2 versus 12.8 months, respectively; HR 1.57; 
95%CI 1.06 to 2.34; P=.025, table 2). Patients in the cetuximab arm with the EGFR<20 
genotype had significantly decreased PFS compared with patients with the EGFR≥20 
genotype (median PFS, 7.6 versus 12.4 months, respectively; HR 1.58; 95%CI 1.06 to 2.35; 
P=.024, table 2). The other polymorphisms were not significantly associated with PFS. 
KRAS mutant patients 
In the cetuximab arm, patients who were carriers of the EGF G-allele (AG and GG 
genotypes combined) had a significantly decreased PFS compared with patients with 
the EGF AA genotype (median PFS, 7.4 versus 13.3 months, respectively; HR 2.22; 95%CI 
1.24 to 3.96; P=.007, table 3). The other polymorphisms were not significantly associated 
with PFS.















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































KRAS wild-type and mutant combined
When the associations were assessed in the entire cohort without subdivision by KRAS 
mutation status but with KRAS mutation status as a covariate, patients who were 
carriers of the FCGR3A C-allele had a significantly decreased PFS compared with 
patients with the FCGR3A AA genotype (median PFS, 7.8 versus 12.1 months, 
respectively; HR 1.56; 95%CI 1.14 to 2.15; P=.006, table 4). Also, patients with the 
EGFR<20 genotype had a significantly decreased PFS compared with patients with the 
EGFR≥20 genotype (median PFS, 8.8 versus 10.8 months, respectively; HR 1.60; 95%CI 
1.17 to 2.19; P=.003, table 4). The other polymorphisms were not significantly associated 
with PFS. KRAS mutation status was not significantly associated with PFS in the 
multivariate analyses. There was significant interaction between treatment arm and 
the FCGR3A and EGFR polymorphisms (P=.015 and P=.009, respectively). 
In figure 1A and 1B, the PFS curves for the cetuximab arm are shown for KRAS mutation 
status combined with the EGFR and FCGR3A polymorphisms, respectively.
Cetuximab-related skin toxicity
In the overall cetuximab arm (i.e. not subdivided by KRAS mutation status), patients 
who were carriers of the FCGR3A C-allele had significantly decreased incidence of 
grade 2-3 cetuximab related skin toxicity compared with patients with the FCGR3A AA 
genotype (OR, 0.46; 95%CI 0.27 to 0.78; table 5). In the multivariate analysis including 
age, gender, KRAS mutation, and serum LDH, the FCGR3A polymorphism remained 
associated with the incidence of grade 2-3 skin toxicity (OR, 0.48; 95%CI 0.24 to 0.94). 
The other polymorphisms were not significantly associated with cetuximab related 
skin toxicity.
Association with outcome in the no-cetuximab arm
In the no-cetuximab arm, KRAS mutant patients who were carriers of the EGF G-allele 
had significantly increased PFS compared with patients with the EGF AA genotype 
(median PFS, 13.6 versus 10.6 months, respectively; HR 0.59; 95%CI 0.36 to 0.98; P=.041, 
table 3). The other polymorphisms were not significantly associated with PFS.
Predictive Score for PFS
The variables that showed significant interaction with treatment for the prediction of 
PFS were: gender (regression coefficient, 0.56), white blood cell count (WBC <8 000 vs. 
≥8 000 cells per μL; regression coefficient, 0.44) and the FCGR3A polymorphism (AA 
genotype versus C-allele carriers; regression coefficient, 0.58). KRAS mutation status 
showed no significant interaction with treatment arm (regression coefficient, 0.06). A 
score of one point was awarded to each of the following parameters: females, FCGR3A 
C-allele carriers and patients with ≥8 000 WBCs per μL. By summarizing the Partial 
Scores, a Predictive Score per patient was derived, which ranged from 0 to 3. The 32 

































































































































































































































































































































































































































































































































































































































































































patients with a Predictive Score of 0 in the cetuximab arm had significantly improved 
PFS compared with all patients in the no-cetuximab arm (median PFS 15.4 versus 10.8 
months, respectively; HR 0.61; 95%CI 0.39 to 0.95). Grouping of patients with a 
Predictive Score of 0 and 1 (a total of 142 patients) led to a non-significant improvement 
of PFS for the cetuximab arm compared with the no-cetuximab arm (HR 0.83; 95%CI 
0.66 to 1.05).
Pharmacogenetics of cetuximab in advanced colorectal cancer
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Figure 1A    Progression-free survival for the EGFR CA-repeat polymorphism and KRAS 
mutation status for patients with metastatic colorectal cancer treated with 
first-line capecitabine, oxaliplatin, bevacizumab and cetuximab 
Figure 1B    Progression-free survival for the FCGR3A 818A>C polymorphism and KRAS 
mutation status for patients with metastatic colorectal cancer treated 
with first-line capecitabine, oxaliplatin, bevacizumab and cetuximab 
Table 5    Analysis of the incidence of grade 2-3 cetuximab-related skin toxicity  
for patients with metastatic colorectal cancer treated with first-line 




AC or CC 0.46 0.27 to 0.78 .005
FCGR2A 535A>G
AA 1.00
AG or GG 1.66 0.97 to 2.84 .062
EGFR CA-repeat
EGFR<20 1.00
EGFR≥20 1.11 0.67 to 1.84 .693
EGF 61A>G
AA 1.00
AG or GG 1.28 0.76 to 2.13 .351
CCND1 870G>A
GG 1.00
GA 1.21 0.67 to 2.17 .535
AA 0.86 0.43 to 1.73 .679
1 Odds ratios (OR), 95% confidence intervals (95% CI) and P values were calculated from the logistic regression 
model, with the wild-type genotype as the reference. 
Abbreviations: CCND1, cyclin-D1; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; 
FCGR, immunoglobulin-G fragment C receptor
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Our finding that patients with a lower number of CA-repeats for the EGFR polymorphism 
experience longer PFS is in line with the study by Graziano and colleagues13, even 
though the categorization of genotypes was different. However, another study did 
not find a significant association between this EGFR polymorphism and PFS in 
cetuximab treated mCRC patients27. 
The biological mechanism for the association of the EGFR polymorphism is concordant 
with the finding that patients with the EGFR≥20 genotype had shorter PFS. Transcription 
of the EGFR gene is lower for increased number of CA-repeats38. Although EGFR 
expression, as measured by immunohistochemistry, is not a predictor of the efficacy 
of cetuximab,39,40 the number of EGFR gene copies is associated with the response to 
cetuximab treatment41. 
It would be expected that the EGFR CA-repeat polymorphism is only associated with 
PFS in KRAS wild-type patients, because EGFR is upstream of KRAS. Since VEGF 
expression is regulated by the EGFR pathway, a role of the EGFR polymorphism in the 
response to cetuximab in combination with bevacizumab cannot be excluded.
In our study, patients who carried the EGF G-allele had increased PFS. In two other 
studies, the G-allele was associated with decreased PFS in advanced colorectal cancer 
patients treated with cetuximab13,27.
Skin toxicity is a major side effect of cetuximab treatment and the severity of skin 
toxicity is associated with the response to cetuximab,5,42 but the underlying mechanism 
is not yet unraveled. Since we demonstrate a relationship between the FCGR3A 
polymorphism with the incidence of grade 2-3 skin toxicity, the involvement of 
immune effector cells is likely. Unexpectedly, we did not confirm previous findings 
that a lower number of CA-repeats is associated with increased incidence of skin 
toxicity during anti-EGFR therapy.13,43 However, previous findings could have been 
biased by the correlation between the response to anti-EGFR therapy and the 
incidence of skin toxicity.
Even though the previous pharmacogenetic studies on cetuximab have used 
peripheral blood12,13, normal tissue14 or tumor tissue27, this should not have influenced 
the results, because there is an almost perfect degree of concordance between 
germline genotype in tumor and normal tissue.44 
Importantly, the polymorphisms in FCGR3A and EGFR are only predictive for the 
efficacy of cetuximab and do not influence the PFS in patients not treated with 
cetuximab. 
Biomarker- and genetic association studies are hampered by divergent and inconsistent 
results.45 Retrospective pharmacogenetic studies must therefore be interpreted as 
hypothesis generating that require confirmation in an independent cohort. 
Although our large study was set up to confirm previously published associations and 
included a control group11-14, the results are conflicting and therefore remain 
inconclusive. It is likely that heterogeneity among the different studies, such as the 
Discussion 
We demonstrate that the FCGR3A 818C-allele and the EGFR≥20 genotype were 
associated with a decreased PFS in a large group of KRAS wild-type mCRC patients 
treated with cetuximab, bevacizumab and chemotherapy in a randomized trial, 
compared with patients with the FCGR3A 818AA or EGFR<20 genotype, respectively. 
Moreover, the predictive role of these polymorphisms appears to be independent of 
KRAS mutation status. KRAS mutant patients who carried the EGF 61G-allele had shorter 
PFS when treated with cetuximab, bevacizumab and chemotherapy, and longer PFS 
when treated with bevacizumab and chemotherapy alone, compared with patients 
with the EGF 61AA genotype. Patients who carried the FCGR3A 818C-allele had 
decreased risk of cetuximab related skin toxicity, compared with patients with the 
FCGR3A 818AA genotype. 
Bibeau and colleagues recently also reported that the FCGR3A polymorphism is 
independent of KRAS mutation status. However, in their study patients who were 
homozygous for the C-allele had longer PFS compared with carriers of the A-allele14, 
which is not in agreement with our data. In one other previous study, the FCGR3A 
C-allele was also associated with decreased PFS in previously pretreated mCRC patients 
who were treated with cetuximab as a single agent12, though this was not confirmed 
in an extended analysis of this study with more patients.27 This indicates that the 
earlier association could have been a false positive finding, making it not suitable for 
comparison with our study. Another study with 110 patients who received cetuximab 
monotherapy as salvage treatment for mCRC did also not find a significant association 
between the FCGR3A polymorphism and the efficacy of cetuximab.13
A possible mechanism for the opposite association of the FCGR3A polymorphism 
could be that the high affinity C-allele28-30 results in increased activation of tumor 
associated macrophages (TAMs) by cetuximab through cross-linking of the Fc gamma 
receptor31, instead of increasing ADCC in our study. As a result of TAM activation, 
pro-angiogenic mediators are released in the tumor microenvironment, such as VEGF 
and matrix metalloproteinases (MMPs).32,33 In our study, patients had not received 
palliative chemotherapy before, whereas patients in the other studies had been 
exposed to irinotecan and/or other lines of chemotherapy prior to cetuximab12-14,27, 
which could have altered the infiltration of cells of the myeloid lineage, such as TAMs.34 
However, it must be noted that the FCGR3A C-allele was associated with increased 
efficacy of the IgG 
1
-type monoclonal antibodies rituximab in lymphoma35,36 and 
trastuzumab in advanced breast cancer.37 Therefore, fundamental research should be 
performed to support our highly speculative hypothesis. However, because this is an 
extracellular mechanism, and therefore independent of intracellular KRAS signaling, it 
explains why the effect of the FCGR3A polymorphism was independent of KRAS 
mutation status. 
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In a recent randomized phase III clinical trial in metastatic colorectal cancer patients, 
the addition of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody 
(MAb) cetuximab to bevacizumab and chemotherapy resulted in decreased efficacy. 
In order to explain this unexpected clinical observation, we undertook the current 
hypothesis driven study. Antibody-dependent cell-mediated cytotoxicity (ADCC) by 
natural killer (NK) cells is generally proposed as one of the anti-tumor mechanisms of 
MAbs. However, we found that CD163-positive, type 2 macrophages (M2s) are much 
more abundant in colorectal carcinomas. In vitro analysis of M2 macrophages revealed 
high levels of Fc-gamma receptors (FcγRs) and PD-L1, and production of IL-10 and 
VEGF, but not IL-12. These anti-inflammatory and tumor-promoting mediators were 
released upon co-culture with EGFR-positive tumor cells that were pulsed with low 
concentrations of cetuximab. Macrophage activation depended on EGFR expression 
on the tumor cells, FcγRs, target specificity of the MAb and mobility of antibody 
complexes. Cetuximab-mediated macrophage responses seemed more pronounced 
for FCGR3A 158-valine carriers, which is the high affinity variant. These results suggest 
that tumor-promoting type 2 macrophages are activated by this therapeutic MAb in 
the local tumor microenvironment and argue that this immune mechanism should be 
taken into account for the application of therapeutic antibodies.
 
Introduction 
Monoclonal antibodies (MAbs) have become important agents for the treatment of 
many types of malignancies. Generally, their principal mechanism of action is blocking 
growth factor pathways that are essential for tumor growth and progression. So far, all 
clinically applied MAbs contain the Fc region of human IgG, which efficiently mediates 
activation through Fcγ receptors (FcγRs) on several types of immune cells. These 
receptors actually contribute to the clinical effect of MAbs, in addition to their direct 
inhibition on tumor growth.1 The role of immune activation is corroborated by several 
studies describing an association between the rs396991 polymorphism (FCGR3A 
158PheVal) in the gene encoding FcγRIIIA (also known as CD16), and clinical 
outcome after treatment with the therapeutic MAbs rituximab (anti-CD20), 
trastuzumab (anti-HER2/neu) and cetuximab (anti-epidermal growth factor receptor, 
EGFR).2-4 The high affinity valine allele has been associated with increased clinical 
response and survival in these studies, which is in line with in vitro studies indicating 
that antibody-dependent cellular cytotoxicity (ADCC) is more extensive for this 
allele.5
Recently, the addition of cetuximab to bevacizumab plus chemotherapy resulted in 
decreased progression-free survival in a large clinical trial in metastatic colorectal 
cancer (CAIRO2 study)6, which was especially significant for patients carrying the high 
affinity valine allele.7 Possibly, the detrimental effect of cetuximab is a consequence of 
activation of tumor promoting immune cells, rather than triggering tumoricidal ADCC. 
Tumor-associated macrophages are characterized as M2-type cells and are known to 
possess anti-inflammatory, pro-angiogenic and tumor-promoting properties.8 Recent 
literature even implies an active involvement of FcγRs and myeloid cells in carcinoma 
development.9 We therefore hypothesized that therapeutic antibodies, such as 
cetuximab, might locally cross-link FcγRs on intratumoral M2-type macrophages by 
EGFR-binding on tumor cells, resulting in activation and release of tumor-promoting 
mediators. These molecular interactions might explain the negative effect of the 
addition of cetuximab to bevacizumab and chemotherapy in the CAIRO2 trial.
Materials and methods
Immunohistochemical stainings
Formalin fixed and paraffin embedded tumors from ten untreated stage III colorectal 
cancer patients were selected form the pathology archive of the Leiden University 
Medical Center. Staining for NK cells and M2 macrophages was described before.10 





Colorectal adenocarcinoma cell lines LoVo and HCT-15 were kindly provided by Dr. 
van Wezel (Leiden University Medical Center, the Netherlands) and epidermoid skin 
cancer line A431 was obtained from ATCC (Manassas, VA, USA). M2-type macrophages 
and dendritic cells (DCs) were differentiated from purified CD14+ monocytes (MACS, 
Miltenyi Biotec, Bergisch Gladbach, Germany) and differentiated as previously 
described10, using M-CSF (R&D, Minneapolis, USA) or GM-CSF (Invitrogen) with IL-4 
(Invitrogen). Cells were activated by 250 ng/ml LPS (Sigma-Aldrich, St. Louis, USA) or 
tumor cells with MAbs cetuximab (Erbitux®, Merck, Darmstadt, Germany), rituximab or 
bevacizumab (Mabthera® and Avastin®, respectively; Roche, Welwyn Garden City, UK). 
Experimental conditions
At day 6 of the monocyte differentiation cultures, tumor cell lines were plated in a density 
of 50.000 cells per well in 48-wells plates. After 2 h, 250 ng/ml LPS or MAbs were added 
together with M2 macrophages in a density of 100.000 cells per well. After 24 h, supernatants 
were collected and analyzed for IL-10 (Sanquin, Amsterdam, Netherlands), IL-8, VEGF 
(eBioscience, Vienna, Austria) and IL-12p70 (BD-Biosciences, Minneapolis, MN, USA) 
production. Macrophages were removed from the culture plates by scraping and stained 
with monoclonal antibodies (all purchased from BD-Biosciences, except for anti- PD1-L from 
eBioscience). Samples were recorded using a FACS Calibur with Cellquest software 
(BD-Biosciences). Data were analyzed with FlowJo software (Tree star, Ashland, USA). 
Macrophages were separated from tumor cell-lines by gating for HLA-DR. 
Genotyping 
Genomic DNA was isolated from monocytes with MagnaPure Compact (Roche, 
Almere, Netherlands) and genotyping for FCGR3A c.818A>C (C_25815666_10; rs396991) 
was performed as previously described.7 
Results
Colon carcinomas are heavily infiltrated with type 2 macrophages, but not 
with NK cells
To investigate immune cell infiltration of primary stage III colorectal cancers, we 
stained ten tumors for the common macrophage marker CD68, and the scavenger 
receptor CD163, which is typically expressed by M2-type cells. All colorectal tumors 
were extensively infiltrated with this type of macrophages (figure 1a). By contrast, 
hardly any NK cells were observed using the NK-lineage specific receptor NKp46. We 
thus envisage that cetuximab treatment might impact on these infiltrating 
macrophages, and that local ADCC via NK cells plays a minor role. 
Activation of type 2 macrophages by cetuximab
4
Chapter 4
Figure 1    Detection and characterization of M2 macrophages in colorectal cancer 
A, Two representative examples of two color immunofluorescent staining of stage III colorectal cancers 
with high (left panel) and low (right panel) infiltration of CD68+ (green) macrophages expressing the typical 
type 2 marker CD163+ (red). B, Flow cytometry analysis of M2 macrophages and monocyte-derived 
dendritic cells (mDC). Fcγ receptors are indicated by the CD nomenclature: FcγRI (CD64), FcγRII (CD32) and 
FcγRIII (CD16). C, Production of IL-10, IL-12p70, IL-8 and VEGF by mDCs and M2 macrophages after overnight 









































Effect of FCGR3A polymorphism
Addition of cetuximab to bevacizumab and chemotherapy in the CAIRO2 trial 
decreased the progression-free survival of metastatic colorectal cancer patients, 
especially for those with high affinity FcγRIII genotype encoding the valine residue.6,7 
We examined the influence of this polymorphism on the degree of M2 macrophage 
activation by cetuximab using 22 healthy donors, consisting of 12 homozygous 
158-Phe and ten 158-Val carriers (figure 4). Analysis of IL-10 release and CD16 down-
The influence of cetuximab on macrophages was studied on freshly isolated 
monocytes that were differentiated in vitro into CD1a-CD14+CD163+ macrophages.10 
The expression of Fcγ receptors FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) and 
release of cytokines after activation by the strong TLR stimulus LPS was examined 
(figure 1b, c). M2 macrophages strongly displayed all three Fc-binding receptors and 
produced high amounts of the anti-inflammatory IL-10, as well as IL-8 and the 
pro-angiogenic VEGF, but not the immunostimulatory IL-12. Control monocyte-de-
rived DCs displayed an opposite profile, which is in line with their T-cell stimulating 
function. These data strongly suggested that M2-type macrophages could potentially 
be stimulated by MAbs to exert an anti-inflammatory and pro-angiogenic role in the 
tumor microenvironment.   
Cetuximab induces activation of type 2 macrophages
M2 macrophages were then activated by cetuximab in the presence of tumor cells. 
Three tumor lines were used (A431, LoVo and HCT-15) and flow cytometry analysis 
showed that A431 highly expressed EGFR, whereas EGFR staining of LoVo and HCT-15 
was much lower (figure 2a). Importantly, co-culture of macrophages with cetuximab-
opsonized A431 tumor cells resulted in production of IL-10 and IL-8, whereas EGFR-low 
tumors LoVo and HCT-15 did not activate macrophages (figure 2b, figure S1). Notably, 
the release of IL-8 upon cetuximab treatment exceeded that of the positive control 
LPS (figure S1). The A431 tumor cells spontaneously produced VEGF, so this mediator 
could not be used in succeeding experiments to determine macrophage activation. 
To corroborate the notion that macrophage activation was the result of cross-linking 
Fcγ receptors, we incubated tumor cells with MAbs specific for the non-expressed 
CD20 (rituximab), or the soluble VEGF (bevacizumab), both containing the same IgG1 
isotype. This did not lead to IL-10 production (figure 2c). Furthermore, competition of 
Fc-binding by high concentrations of rituximab resulted in a dose-dependent 
decrease of IL-10 production (figure S2). Interestingly, IL-10 was also not detected 
when cetuximab was coated on culture plates (figure 2c), suggesting that the 
molecular interaction of EGFR-cetuximab-FcγR required the flexibility of fluid 
membranes for proper cross-linking. 
The cetuximab mediated activation of M2 macrophages was dose-dependent 
(figure 3) and concentrations as low as 10 ng/ml were sufficient to down-regulate cell 
surface levels of CD16 and to up-regulate the inhibitory molecule PD1-L (figure 3a) 
and to release IL-10 and IL-8 (figure 3b, figure S1). These data showed that very low 
concentrations cetuximab induced the release of anti-inflammatory mediators from 
M2 macrophages through cross-linking of Fcγ receptors. 
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Figure 2    FcγR cross-linking by cetuximab activates M2 macrophages 
A, Flow cytometry analysis of EGFR expression on tumor cell lines A431, HCT-15 and LoVo. Filled histograms 
represent isotype control antibody, solid lines indicate staining with anti-EGFR antibody. B, IL-10 production 
by M2 macrophages upon co-culture with tumor cells and 1 μg/ml cetuximab (c’mab). Addition of LPS (250 
ng/ml) served as positive control. C, IL-10 production by macrophages depends on interaction of 
macrophages and cetuximab-pulsed A431 tumor cells. Plate-bound cetuximab (10 μg/ml) (‘coated’) could 
not replace the EGFR-expressing tumor cells and control antibodies rituximab (r’mab, 1 μg/ml) or 









































































known to actively contribute to tumor growth via angiogenesis and immune 
suppression.8 Previous research on the immune mechanisms of therapeutic MAbs has 
focused on anti-tumor effects such as ADCC or phagocytosis. ADCC mediated by NK 
cells or PBMCs has been described for cetuximab5, however, staining for NK cells in 
regulation on M2 macrophages showed an apparent stronger activation of cells with 
the high affinity valine allele (figure 4). These differences did not reach statistical 
significance for cytokine release, most likely due to high variation within the groups 
and very high production (figure 4b and figure S1, respectively). In conclusion, our 
data show that cetuximab can induce the release of anti-inflammatory mediators 
from M2 macrophages and that this effect might explain the negative clinical effect 
of this MAb in the recent CAIRO2 study.  
Discussion
Our data show that type 2 macrophages are abundantly present in colon carcinoma 
and are activated by cetuximab-opsonized tumor cells, resulting in anti-inflammatory 
and tumor promoting mediators, including IL-10 and VEGF. M2 macrophages are 
Activation of type 2 macrophages by cetuximab
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Figure 3    Degree of M2 macrophage activation depends on cetuximab 
concentration 
A, Flow cytometry analysis of PD1-L up-regulation and CD16 down-regulation on M2 macrophages upon 
co-culture with EGFR-positive A431 tumor cells and different cetuximab (c’mab) concentrations. Rituximab 
(r’mab) served as negative control, LPS as positive control. B, Macrophage-derived IL-10 was measured in 
overnight supernatants. 
Figure 4    Activation difference of FCGR3A (CD16)-typed M2 macrophages 
M2 macrophages of twelve homozygous 158-Phe (solid squares) and ten 158-Valine allele carriers (open 
circles are heterozygous and solid circles are homozygous) were activated by cetuximab (c’mab) and 
EGFR-positive A431 tumor cells. A, CD16 down-regulation and B, IL-10 release were measured. Lines represent 





























































stage III colorectal carcinoma revealed that these cells are rare in colorectal cancers. 
Fcγ receptors are also expressed by macrophages and these cells were abundantly 
present in this tumor type (figure 1). M2 macrophages are efficient in phagocytosis of 
rituximab-opsonized B cells11, but we question the relevance of this FcγR-mediated 
process for solid tumors like colorectal carcinoma. We here report that cetuximab-
mediated cross-linking of Fcγ receptors leads to release of tumor-promoting 
mediators. 
The detrimental effect of cetuximab addition in the CAIRO2 trial was unanticipated6, 
since the combination of cetuximab and anti-VEGF therapy appeared effective in 
mouse models.12-14 However, the Fcγ receptor-mediated effects by cetuximab could 
not be evaluated in these models, as the human Fc-region of cetuximab does not 
interact with the murine FcγRs. Our results indicate that the release of multiple anti-
inflammatory and pro-angiogenic mediators by M2 macrophages could account for 
the decreased therapy efficacy for those patients that were treated with the 
combination of cetuximab, the anti-VEGF MAb bevacizumab and chemotherapy.6 The 
fact that M2 macrophages encoding the high affinity FcγRIIIA (valine-carriers) 
displayed a more pronounced activation (figure 4) corroborated the finding that 
patients with this high affinity receptor had an even worse progression-free survival 
than those with 158-Phe homozygosity.7 Notably, bevacizumab binds soluble VEGF 
and therefore does not cross-link FcγRs. Moreover, the use of previous or concomitant 
chemotherapy could influence the infiltration of myeloid cells because of bone 
marrow suppression.15 Also, expression of EGFR on tumor cells could be up-regulated 
by chemotherapy such as fluoropyrimidines and irinotecan.16 
In conclusion, clinical testing of engineered MAbs with Fc-regions with increased 
affinity to FcγRs should be performed very carefully1,17, because tumor-promoting 
effects by intratumoral M2 macrophages could lead to tumor promotion instead of 
tumor repression. 
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Figure S1    IL-8 production upon Fc-mediated M2 activation 
A, IL-8 production after 24 h co-culture of M2 macrophages with cetuximab (c’mab, 1 μg/ml) opsonized 
A431 tumor cells (white bars), LoVo cells (light grey bars) and HCT-15 cells (dark grey bars). Addition of LPS 
(250 ng/ml) served as positive control. B, IL-8 production by macrophages depends on interaction of 
macrophages and cetuximab opsonized tumor cells. Plate-bound cetuximab (10 μg/ml) (‘coated’) could not 
replace the EGFR-expressing tumor cells and control antibody rituximab (r’mab, 1 μg/ml) or bevacizumab 
(b’mab 1 μg/ml) could not replace cetuximab. C, Overnight IL-8 production by M2 macrophages is 
dependent on the concentration of cetuximab. D, Both the phenylalanine homozygote donors (solid 
squares, n = 12) and valine allele carriers (Phe/Val [open circles] and Val/Val [solid circles] donors combined; 
n = 10) were activated by cetuximab (c’mab) and EGFR-positive A431 tumor cells.  IL-8 release was measured 
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Figure S2    Competition for Fc-binding by rituximab 
A431 tumor cells were loaded without cetuximab (c’mab 0) or with a sub-optimal dose of 0.1 µg/ml 
cetuximab (c’mab 0.1) Rituximab (r’mab) was added in higher (10 ug/ml), equal (0.1 ug/ml) or lower 











C’mab   0       0.1     0.1     0.1     0.1




Current insights in the role of heritable 
genetic variation in the pharmacokinetics 
and pharmacodynamics of anti-cancer drugs
Jan Pander • Hans Gelderblom • Henk-Jan Guchelaar
Expert Opinion on Pharmacotherapy 2007 Jun;8(9):1197-210
74 75
Abstract
Pharmacogenetics in oncology ideally will allow oncologists to individualise therapy 
based upon a genetic test result. Severe toxicity and clinically significant under-dosing 
may be avoided, whereas predicted non-responders can be offered alternative 
therapy. 
This manuscript gives an overview of heritable variants in the genes of nine enzymes 
or pathways that have been studied most extensively in anti-cancer chemotherapy. 
Even though many pharmacogenetic association studies have been published, there 
is need for more research. In particular, there is need for replication of data and 
development of predictive models. Prospective trials are required to establish clinical 
value and cost-effectiveness of pharmacogenetic testing in oncology. 
Introduction
Pharmacogenetics studies the association between heritable functional variants in 
DNA (genotype) with outcome of therapy (phenotype). In the recent years, pharma-
cogenetics in oncology has become an increasing field of research. Ideally, pharmaco-
genetic testing will allow oncologists to individualise therapy, with respect to the 
choice of a drug and the dose of the drug administered, based upon a genetic test 
result. Severe toxicity may be avoided, whereas predicted non-responders can be 
offered alternative therapy. 
A polymorphism is an inheritable variant that occurs within at least 1% of the population. 
Moreover, a polymorphism is a neutral variant: the variant may have functional 
consequences on the protein level, without influencing existence of the individual. 
Variants in DNA can be single nucleotide polymorphisms (SNPs), deletions or insertions 
of a number of base pairs (bp) or variable number of tandem repeats resulting in 
changes in exons, introns or in untranslated regions (UTR), such as the promoter 
region of the gene. When DNA is transcripted into mRNA, some of these variants may 
result in altered mRNA stability. Some variants result in different amino acid 
composition of proteins or truncated proteins which may lead to altered enzyme 
activity and thus functionality (non-synonymous variants), whereas other variants do 
not result in amino acid change (synonymous or silent variants). Finally, variants in a 
UTR of a gene can alter the transcriptional activity of a gene and thus change the 
expression of an enzyme.
As specific regions in DNA are conserved though generations, variants are often 
inherited as so called haplotypes, which can be measured by assessing linkage 
disequilibrium (LD).  
In contrast to somatic variants, heritable (germ-line) variants in DNA are inherited 
from parents, and the presence of a variant can be either heterozygous (carrier of one 
normal and one variant allele) or homozygous (carrier of two variant alleles) as 
compared to wild-type (two normal alleles). The determination of germ-line variants 
in, for example DNA isolated from peripheral blood is much more feasible than 
determination of variants in DNA isolated from tumour samples. Interestingly, in a 
recent paper it was shown that there is a high degree of concordance between 
germ-line and somatic variants for a number of SNPs.1 However, genetic mutations 
related to the origin of the malignant phenotype are by definition in discordance to 
the germ-line phenotype. 
In this manuscript, we give an overview of heritable variants in the genes encoding 
nine enzymes or pathways that have been studied most extensively in patients 






An alkylating agent commonly used in maintenance treatment of acute lymphoblastic 
leukaemia (ALL) 6-mercaptopurine (6MP), which is deactivated by the enzyme thiopurine 
S-methyltransferase (TPMT). Approximately 0.3% and 10% of the population has 
undetectable and intermediate TPMT enzyme activity respectively.2,3 TPMT activity is 
inversely associated with exposure to the cytotoxic metabolite of 6MP, 6-thioguanine 
(6TGN), in red blood cells4 and in ALL blasts.5 Because of severe haematological 
treated with anti-cancer drugs (Figure 1). The variants in these genes are summarised 
in Table 1. 
Medline was systematically searched (from July 1st to September 30th 2006) with the 
following set of keywords: pharmacogenetics, pharmacogenomics, polymorphism, 
SNP, genotype, phenotype, antineoplastic (protocols), chemotherapy, combined with 
the names of genes and enzymes, limiting results to human research published in 
English. 
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Figure 1    Schematic overview of enzymes involved in cellular response and 
metabolism to anti-cancer drugs 
Abbreviations: CYP2D6: cytochrome P450 2D6; 4-OH-tam: 4-hydroxy-tamoxifen; DPD: dihydropyrimidine 
dehydrogenase; 5FU: 5-fluorouracil; MTHF: methylene tetrahydrofolate; MTHFR: methylene tetrahydrofolate 
reductase; MTX: methotrexate; THF: tetrahydrofolate; 6-MP: 6-mercaptopurine; dUMP: deoxyuridine 
monophosphate; TPMT: thiopurine S-methyltransferase; TS: thymidylate synthase; DHF: dihydrofolate; 
dTMP: deoxythymidine monophosphate; UGT: uridine diphosphate glucuronosyl transferase; ERCC: excision 
repair cross complementing; XRCC: X-ray repair cross complementing; SN-38: active metabolite of irinotecan; 

























































Table 5    Enzymes involved in response to anti-cancer drugs and their common 
polymorphisms 
enzyme variant allele polymorphism phenotype
TPMT TPMT*2 238G>C Ala80Pro
TPMT*3A 460G>A + 719A>G Ala154Thr + Tyr240Cys
DPD DPYD*2A IVS14+1G>A Δ exon 14
UGT UGT1A1*28 (TA)
7
TAA reduced enzyme activity
GST π GSTP1-105 313A>G Ile105Val
GST µ GSTM1-null deletion of gene
GST θ GSTT1-null deletion of gene
P-glycoprotein ABCB1 = MDR1 1236C>T silent
3435C>T silent
2677G>T/A Ala893Ser/Thr
BCRP ABCG2-421 421C>A Gln141Lys
ERCC1 ERCC1-118 496C>T Asn118Asn
XPD ERCC2-321 965G>A Asp321Asn
ERCC2-751 2251A>C Lys751Gln
XRCC1 XRCC1-399 1301G>A Arg399Gln
CYP2D6 CYP2D6*4 1846G>A null enzyme activity
MTHFR MTHFR-677 677C>T Ala222Val
TS TYMS TSER 28 bp insert in TSER increased expression
TYMS G>C at bp 12 in TSER-3 restored enzyme activity
TYMS 3’ UTR 1494 6bp indel decreased expression
TPMT: thiopurine S-methyltransferase; DPD/DPYD: dihydropyrimidine dehydrogenase; UGT: uridine diphosphate 
glucuronosyl transferase; GST: glutathione S-transferase; ABCB1: ATP-binding cassette B1; MDR1: multi drug 
resistance 1; BCRP: breast cancer resistance protein; ABCG2: ATP-binding cassette G2; ERCC1: excision repair 
cross complementing group 1; XPD: xeroderma pigmentosum group 1; ERCC2: excision repair cross 
complementing group 2; XRCC1: X-ray repair cross complementing group 1; CYP2D6: cytochrome P450 2D6; 
MTHFR: methylene tetrahydrofolate dehydrogenase; TS/TYMS: thymidylate synthase; TSER: thymidylate 
synthase enhancer region; UTR: untranslated region; bp: base pair; indel: insertion/deletion 
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a DPD deficient patient experiencing severe haematological toxicity to 5FU was 
described in 198826 many mutations in the DPYD gene that result in decreased DPD 
activity have been identified. Apart from association studies between DPD enzyme 
activity and 5FU toxicity, genetic associations have also been described. It must be 
noted that not all 5FU related toxicity can be attributed to decreased DPD activity 
though. 
Despite having an allele frequency of <1% in Caucasians27,28, a SNP in the 5’ invariant 
splice donor sequence in intron 14 of the DPYD gene (IVS14+1G>A; deletion of exon 
14; DPYD*2A) seems to be one of the key mutations resulting in low DPD activity and 
increased incidence of 5FU toxicity.29 Two studies have shown considerable effect of 
this polymorphism on the incidence of 5FU toxicity. In 60 cancer patients who 
experienced grade 3-4 toxicity (according to the National Cancer Institute Common 
Toxicity Criteria (NCI-CTC) [202]) to 5FU containing chemotherapy, the frequency of 
the DPYD*2A allele was 15%, which was significantly higher than 0.91% in the control 
population (P=0.001).30 Also, 50% of patients who experienced NCI-CTC grade 4 
neutropenia carried the DPYD*2A allele.31 The DPYD*2A allele has not been detected in 
Asian populations.32,33 
Other variants of the DPYD gene that have been linked to 5FU toxicity include the 
DPYD*4 (1601G>A; Ser534Asn), DPYD*11 (1003G>T; Val335Leu), DPYD*12 (62G>A; 
Arg21Gln + 1156G>T; Glu386Ter) and DPYD*13 (1679T>G; Ile560Ser) alleles.34,35 On the 
other hand, methylation of the promoter region of the DPYD gene also seems to 
reduce DPD activity due to a decrease of transcription.36 
Homozygous patients with two low DPD activity alleles are rare, but multiple cases 
have been described of lethal outcome to 5FU treatment in these patients.27,28
Uridine diphosphate glucuronosyl transferase
Uridine diphosphate glucuronosyl transferase (UGT) is a phase II metabolic enzyme 
responsible for glucuronidation of several endogenous (such as bilirubin) and 
exogenous compounds. SN-38, the active metabolite of the topo-isomerase I inhibitor 
irinotecan, is predominantly inactivated by the isoforms UGT1A1 and UGT1A9 in the 
liver and by UGT1A7 in the upper gastro-intestinal tract.37 
A TA insert polymorphism in the TATA box of the promoter region of the UGT1A1 gene 
has been studied extensively. The UGT1A1*28 allele has 7 TA repeats, whereas wild-type 
has 6 TA repeats. This polymorphism is associated with Gilbert’s syndrome, a condition 
of reduced bilirubin glucuronidation38 and has also been associated with decreased 
SN-38 glucuronidation in vitro39 and in vivo.40,41 The allele frequency of UGT1A1*28 is 
higher in Caucasians (22-39%)41-44 than in Asians (7-17%)44-49, and even higher in Blacks 
(~45%).45,46 
Patients with metastatic colorectal cancer (mCRC) or other solid tumours who were 
treated with irinotecan, and who were homozygous for the UGT1A1*28 allele had 
toxicity, 6MP dose must be reduced6, with as much as 90% and 50-66% for the 
respective phenotypes.7 Because dose intensity proved to be a prognostic marker for 
outcome in ALL patients treated with 6MP, it is important to administer the right dose 
with regard to toxicity8 and efficacy.4
Therefore, TPMT activity is a determinant for predicting the occurrence of toxicity. 
However, it must be noticed that TPMT activity is influenced by several common 
factors in ALL, such as methotrexate (MTX)/trimethoprim treatment9 or administration 
of red blood cells transfusions.10   
The molecular basis of decreased TPMT activity was found in 1995. A 238G>C SNP 
resulting in amino acid change of alanine to proline in codon 80 (Ala80Pro), and in 100 
fold decrease in enzyme activity was found in a patient who experienced severe 
toxicity to 6MP.11 This allele is referred to as TPMT*2. 
The variant allele TPMT*3A was found a year later (460G>A; Ala154Thr + 719A>G; 
Tyr240Cys) in a patient with almost absent TPMT activity.12 To date, at least 25 variant 
alleles have been found, and their functional significance has been described.13,14 
However, approximately 85-95% of all variant alleles in Caucasians is TPMT*2, TPMT*3A 
and TPMT*3C.15,16 The TPMT*3A has an allele frequency of 4%17 but is absent in African 
and Asian populations.16,18-21 In these populations, the TPMT*3C allele (719A>G; 
Tyr240Cys) is the most frequent variant allele16,18-21 and its functional impact has been 
demonstrated in Japanese children with ALL.22 
A strong relationship between genotype and phenotype has been demonstrated, 
resulting in 90% sensitivity and 99% specificity (variants TPMT*2-*18).3 However, in 
another report no TPMT*2, TPMT*3A and TPMT*3C allele was detected in 5 of 9 patients 
with intermediate TPMT activity.7 
Even though cost effectiveness models of TPMT genotyping have been reported 
recently23, and the Food and Drug Administration (FDA) has included more information 
on inherited TPMT deficiency in the 6MP label [201], only few institutions commonly 
genotype patients prior to 6MP treatment.24
Interestingly, exposure to the cytotoxic metabolite 6TGN is not only related to toxicity, 
but also to efficacy of 6MP therapy as shown by Stanulla et al. They found a 2.9 fold 
lower occurrence of residual disease in ALL patients who were heterozygous for any 
TPMT*2, TPMT*3A, TPMT*3C or TPMT*9 (356A>C; Lys119Thr) allele and treated with a 
similar 6MP dose. They did not find a difference in the occurrence of toxicity.25 
Dihydropyrimidine dehydrogenase
An important anti-metabolite used for a vast number of different types of solid 
tumours is 5-Fluorouracil (5FU). Over 80% of 5FU is inactivated in the liver by the 
enzyme dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD. Since 




The gene for GST π, GSTP1, is known to be polymorphic. One polymorphism resulting 
in a non-synonymous SNP at codon 105 (313A>G; Ile105Val) in exon 5 causes decreased 
GST π activity.57 The allele frequency is approximately 20%, 30% and 40% in Asian, 
Caucasian and African American populations respectively.57-60 
A significant association toward better survival after cyclophosphamide containing 
chemotherapy was found for breast cancer patients carrying the variant 105Val 
allele.58,59 The variant allele was also associated with increased survival in 107 mCRC 
patients who were treated with a combination of 5FU and oxaliplatin.61 Survival was 
24.9, 13.3 and 7.9 months for Val/Val, Val/Ile and Ile/Ile genotypes respectively 
(P=0.001).61 The variant allele was also associated with better response and longer 
survival in gastric cancer patients who were treated with 5FU and cisplatin.62 Colorectal, 
gastric and pancreatic cancer patients carrying at least one GSTP1-105Val allele 
experienced less toxicity to oxaliplatin containing chemotherapy.63 
The genes for subclasses GST µ (GSTM1) and GST θ (GSTT1) both have ‘null’ poly-
morphisms, where the total gene is deleted on both alleles. Both null genotypes were 
associated with increased survival among breast cancer patients, irrespective of 
treatment (either chemotherapy or radiation).64 However, this association was not 
found in another cohort of breast cancer patients59, nor in a cohort of colorectal 
cancer (CRC) patients.61 Survival of ovarian cancer patients treated with platinum 
containing chemotherapy was also better for GSTM1 null patients.65,66 
These studies demonstrate that, because of decreased inactivation of the respective 
anti-cancer agents, carriers of the less active variant GST alleles have increased 
response and survival to chemotherapy.
Drug transporters
ABCB1
The ATP-binding cassette (ABC) B1 gene (ABCB1), formerly known as multi-drug 
resistance (MDR1) gene, encodes the P-glycoprotein (PGP), an ATP-dependent efflux 
pump that exports exogenous substances across the cell membrane. Through this 
mechanism, substances such as cytostatics are unable to retain sufficient intracellular 
concentrations to exert their anti-tumour activity. Two synonymous SNPs in exons 12 
and 26 (1236C>T and 3435C>T respectively) and a non-synonymous SNP in exon 21 
(2677G>T/A; Ala893Ser/Thr) have been studied extensively. These variant alleles occur 
together in a common haplotype (MDR1*2), with a frequency of 27%, 31-49% and 6.5% 
in Caucasians, Asians and Blacks respectively.67-69 The MDR1*2 haplotype was associated 
with lower irinotecan and SN-38 clearance69 and with lower C
max
 for glucuronidated 
SN-38 (SN-38G).70 
The individual polymorphisms have been associated with decreased PGP function in 
vivo.71,72 Cancer patients homozygous for the 1236C>T variant allele had higher 
significant higher occurrence of grade 3 or 4 diarrhoea (according to criteria of the 
World Health Organization (WHO)50) 51 and NCI-CTC grade 3 or 4 neutropenia40,43 
compared with patients who carried at least one wild-type allele. Other studies have 
shown higher incidence of NCI-CTC grade 3 or 4 diarrhoea in mCRC patients52 and 
higher incidence of grade 3 or 4 diarrhoea and/or grade 4 leukopenia (according to 
criteria of the Japan Society for Cancer Therapy53) in patients with solid tumours47 
when carriers of the variant allele were compared with homozygote wild-type patients. 
In a recent report of 250 mCRC patients, the odds ratio for the incidence of NCI-CTC 
grade 3 or 4 haematological toxicity was 8.63 for patients homozygous for the variant 
allele compared with patients who were homozygote wild-type. However, this was 
only significant after the first cycle of treatment.54 Interestingly, response to irinotecan 
therapy was also improved for homozygote individuals for the variant allele compared 
with homozygote individuals for the wild-type allele because of increased SN-38 
exposure.54 
From these studies it is clear that the UGT1A1*28 allele is associated with increased risk 
for neutropenia in patients receiving irinotecan. Due to increased exposure to SN-38, 
the active metabolite of irinotecan, it may also be expected that carriers of this allele 
experience increased efficacy but this has not yet been proven.
A SNP in the phenobarbital responsive enhancer module (PBREM) of the UGT1A1 gene 
(-3279T>G; UGT1A1*60) has been associated with severe toxicity (grade 4 leukopenia 
and grade 3 or 4 diarrhoea; Japanese criteria) in Japanese cancer patients treated with 
irinotecan.55 However, the UGT1A1*60 variant allele was linked to the UGT1A1*28 
variant.39 
Several SNPs in various regions of the UGT1A1, UGT1A7 and UGT1A9 genes have been 
found to be in linkage disequilibrium (LD).44,48,49,56 The functional and clinical relevance 
of these haplotypes has not yet been established.
In 2005, the FDA approved the Invader® UGT1A1 molecular assay, a test for the 
UGT1A1*28 variant allele [203]. Also, the package insert of irinotecan was modified in 
2005 by the FDA, to include information on UGT1A1 variability [204]. Unfortunately, 
because no studies have determined the optimal dose per genotype, no advice for 
dose adjustment is made. 
Glutathione S-transferase 
Glutathione S-transferases (GSTs) make up a family of phase II enzymes that catalyze 
the conjugation of reduced glutathione to toxic substances. Members of this family 
are GST π, GST µ and GST θ, which are products of distinct loci in the genome. Among 
substrates for GSTs are cyclophosphamide, etoposide, doxorubicin, cisplatin, 
carboplatin and oxaliplatin and their metabolites. Theoretically, reduced activity of 
these enzymes would result in increased exposure to these drugs, possibly resulting 
in increased efficacy and toxicity. 




Ovarian cancer patients who carried the variant allele had reduced risk of platinum 
resistance, but survival was not affected by genotype.84 
One would expect that the SNP leading to reduced ERCC1 expression and hence to 
decreased DNA repair of DNA-platinum adducts, would result in increased platinum 
sensitivity and consequently to increased response and survival. However, most 
studies that are presented show the opposite result. The occurrence of linkage 
disequilibrium of the evaluated variant with other variants with opposing effects on 
enzyme function as well as that of other enzymes and pathways with a role in the 
drug’s pharmacokinetics and clinical variables could be of importance and explain 
this discrepancy. 
Excision repair cross complementing group 2
The enzyme xeroderma pigmentosum group D (XPD) is coded by the excision repair 
cross complementing group 2 (ERCC2) gene, and is also involved in the NER pathway. 
Two SNPs in this gene (965G>A, Asp321Asn and 2251A>C, Lys751Gln) are associated 
with reduced DNA repair capacity.91 The allele frequency of the XPD-321 variant allele 
was 0.32 in a general Western population.92 The allele frequency of the XPD-751 variant 
allele is 0.44 in Caucasians, 0.16 in Blacks and 0.09 in Asians.83 
Patients with mCRC who were homozygous for the variant ERCC2-751 allele and who 
were treated with oxaliplatin based chemotherapy had higher mortality compared 
with patients carrying the wild-type allele.83,93 The two SNPs in the ERCC2 gene were 
not associated with response and survival in cisplatin treated NSCLC patients87,88, but 
the wild-type ERCC2-751 allele was associated with increased incidence of WHO grade 
2 or higher neutropenia.88 In stage III-IV NSCLC patients treated with platinum 
containing chemotherapy, homozygote individuals for the ERCC2-321 variant had 
worse survival compared to carriers of a wild-type allele.92 
X-ray repair cross complementing group 1
The X-ray repair cross complementing group 1 (XRCC1) enzyme is involved in repair of 
single-strand breaks in DNA. A SNP in the XRCC1 gene (1301G>A, Arg399Gln, allele 
frequency of 0.35 in Caucasians, 0.36 in Blacks and 0.22 in Asians83) has been associated 
with worse response to oxaliplatin and 5FU in mCRC patients94, but there was no 
difference in time to progression or survival.83 In stage III NSCLC patients, survival was 
shorter for individuals homozygote for the variant allele compared with carriers of the 
wild-type allele.92 
An increased number of variant alleles of the ERCC2 and XRCC1 genes have been 
associated with worse survival in NSCLC patients who were treated with platinum 
containing chemotherapy.92 In contrast, in patients with squamous cell cancer of the 
head and neck (SCCHN) treated with cisplatin containing therapy, an increased 
number of variant alleles of  ERCC2-321, ERCC2-751, XRCC1-399 and ERCC1 (8092C>A in 
exposure to both irinotecan and SN-38.73 In 58 patients with solid tumours, all patients 
homozygous for the 3435T variant allele experienced grade 3-4 neutropenia (specified 
as neutrophil count between 0.5 and 1.0 x 109/L and less than 0.5 x 109/L respectively) 
to docetaxel, compared with 77% and 54% for heterozygote and wild-type individuals 
respectively.74  As exposure to docetaxel is increased in carriers of the variant allele, 
this finding would be expected. 
ABCG2
Another ATP binding cassette, formerly known as the breast cancer resistance protein 
(BCRP) is coded by the gene ABCG2. Overexpression of this enzyme is related to the 
occurrence of resistance to several anticancer agents such as SN-38, mitoxantrone, 
topotecan, daunorubicin and etoposide.75 A SNP in exon 5 (421C>A; Gln141Lys) has an 
allele frequency of 34%, 12% and 1-5% in Han Chinese, Caucasians and Blacks 
respectively76, and results in lower BCRP expression and higher SN-38 and topotecan 
sensitivity in vitro.77 However, this SNP has found not to be associated with pharma-
cokinetic parameters of irinotecan and its metabolites in a cohort of cancer 
patients.76 
DNA repair
Excision repair cross complementing group 1 
As part of the nucleotide excision (NER) pathway, excision repair cross complementing 
group 1 (ERCC1) is involved in DNA damage repair caused by platinum containing 
compounds such as cisplatin, carboplatin and oxaliplatin.78,79 Increased ERCC1 
expression has been shown to lead to cisplatin resistance in vitro80 and to lower 
response in cisplatin treated bladder cancer patients in vivo.81 A prospective ERCC1 
mRNA expression guided phase III study is ongoing.82 A silent SNP has been identified 
in exon 4 at codon 118 in the ERCC1 gene (496C>T; Asn118Asn). The allele frequency of 
the T allele is 0.58 in Caucasians, 0.24-0.36 in Asians and 0 in Blacks.83,84 
Even though encoding the same amino acid, the variant codon is believed to occur 
less commonly, therefore resulting in reduced ERCC1 expression.85,86 
Homozygote ERCC1 wild-type patients with stage IIIb-IV non-small cell lung cancer 
(NSCLC) who were treated with cisplatin containing chemotherapy had longer survival 
than patients carrying the variant allele.87 This same association was found in another 
cohort of NSCLC stage IIIb-IV patients treated with cisplatin and docetaxel.88 
Homozygote wild-type mCRC patients were also found to have longer survival 
compared to carriers of the variant allele when treated with oxaliplatin and 5FU83, 
whereas in another cohort of mCRC patients, the variant genotype was associated 
with better response to oxaliplatin and 5FU.89
In melanoma patients (stage IV) treated with cisplatin containing chemotherapy, the 
wild-type genotype was associated with worse response and shorter overall survival.90 




MTHFR activity is 70% and 35% for heterozygote and homozygote individuals 
respectively.109 In vitro assays showed that cell lines with the variant allele are more 
sensitive to 5FU and less sensitive to MTX.115 
Of six patients who experienced severe toxicity to adjuvant CMF (cyclophosphamide, 
MTX, 5FU) for breast cancer, five were homozygous for the 677T allele.116 In a cohort of 
cancer patients who were treated with the 5FU analogue raltitrexed, patients with 
677TT genotype had significant more therapy related toxicity.117 Leukaemia patients 
homozygous for the 677T allele experienced more MTX related toxicity compared 
with patients who carried at least one wild-type allele.118 Also, ovarian cancer patients 
who were treated with MTX and were homozygous for the 677T allele experienced 
significant more WHO grade 3/4 side effects.112
In mCRC patients, the 677T allele has been associated with improved response to 5FU 
based chemotherapy in several studies119-121, whereas another study did not find a 
significant association.122 No association was found in a cohort of advanced gastric 
cancer patients treated with 5FU and cisplatin.62
Thymidylate synthase (TS)
TS is the central enzyme in the de-novo thymidine synthesis. In vitro resistance to 5FU 
is associated with increased TS activity, which is also induced by 5FU itself.123 The TS 
promoter enhancer region (TSER) of the gene encoding TS (TYMS) has been shown to 
contain either two or three tandem repeats designated as TSER*2 and TSER*3 
respectively. The TSER*3 genotype results in increased TS expression, either through 
higher mRNA levels or increase in efficiency of mRNA translation.124,125 The allele 
frequency of the TSER*2 allele is 0.40-0.46 in Caucasians and Blacks126,127, compared to 
0.18-0.21 in Asian populations.126,128-130
The TSER*3 allele was associated with increased response in CRC patients treated with 
5FU.121 On the other hand, the TSER*2 allele was associated with improved response to 
capecitabine in CRC patients.131 
These conflicting results could in part be explained by a G>C SNP in the 12th base pair 
of the TSER*3 allele132 that results in TS activity similar to that of the TSER*2 allele.133 
This TSER*3C allele is found in 29%-57% of all TSER*3 alleles.132,134,135 
Carriers of the TSER*3G allele had significantly worse response, disease free survival 
and overall survival in a cohort of mCRC patients treated with 5FU.135 The TSER*3G 
allele was also associated with worse survival in advanced gastric cancer patients who 
were treated with 5FU.62
As expected, most studies show that the TSER*3 allele, and especially the TSER*3G 
allele, is associated with lower response and survival to fluoropyrimidine therapy. 
Conflicting results could be explained by the G>C SNP in the TSER*3 allele. 
the 3’UTR) was associated with increased survival.95 Moreover, cisplatin treated 
patients with muscle invasive bladder cancer who carried one or more variant 
ERCC2-751 or XRCC1-399 allele had better survival compared to wild-type patients.96 
These inconsistent and non-intuitive findings could in part be explained by the 
reasons that are given for conflicting results for ERCC1.  
CYP2D6
Tamoxifen is a widely used agent in treatment of breast cancer and is hydroxylated 
into the 100 times more active metabolites 4-hydroxy-tamoxifen and endoxifen by 
the cytochrome P450 iso-enzyme CYP2D6.97-99 The CYP2D6*4 (1846G>A) allele results 
in gene deletion and thus in absent CYP2D6 activity and has a frequency of 15-20% in 
the general population in Western countries.100-105 Other alleles resulting in lower 
CYP2D6 activity are CYP2D6*3 (Δ2549A), CYP2D6*5 (deletion of entire CYP2D6 gene) 
and CYP2D6*6 (Δ1707T). The CYP2D6*4 allele has been linked to reduced conversion of 
tamoxifen into 4-hydroxy-tamoxifen106 and the CYP2D6*3-6 genotypes have been 
related to lower endoxifen formation.103,104 
As expected, breast cancer patients treated with adjuvant tamoxifen who were 
homozygous for the CYP2D6*4 allele had significant worse relapse-free time and 
shorter disease free survival compared with carriers of the wild-type allele. However, 
significance was not retained in multivariate analysis. Homozygote CYP2D6*4 patients 
did not experience moderate to severe flashes, which is a side effect of (the active 
metabolite of) tamoxifen.102 A similar finding was reported in a case control study for 
prevention of breast cancer with tamoxifen in hysterectomised women. The frequency 
of the CYP2D6*4/*4 genotype was higher in women who developed breast cancer 
during follow up than in women free of cancer.107 
Contradictory to this, another study found that oestrogen receptor positive (ER+) 
breast cancer patients who carried the CYP2D6*4 allele had significant longer 
recurrence free survival when treated with adjuvant tamoxifen compared with 
CYP2D6*4 carriers who were not treated with tamoxifen. This difference was not 
observed for wild-type patients.100 Selection bias in this study may have influenced 
the outcome of this study.108  
Methylene tetrahydrofolate reductase (MTHFR)
The enzyme MTHFR is one of the key enzymes in the folate pathway (see figure 1). 
Reduced MTHFR expression results in reduced sensitivity to the MTHFR inhibitor MTX. 
On the other hand, abundance of the MTHFR substrate 5,10-methylene tetrahydro-
folate (5,10-MTHF) facilitates the inhibition of thymidylate synthase (TS) by 5FU, 
therefore increasing sensitivity to this agent.
A SNP in the MTHFR gene, 677C>T results in an amino-acid change of alanine to valine 
at codon 222 (Ala222Val). The allele frequency in all populations is 0.27-0.57.62,109-114 





There is ample evidence that pharmacogenetic traits are able to predict pharma-
codynamics of several anti-cancer drugs. Polymorphisms that result in decreased 
metabolic enzyme levels or activity have shown to result in either increased toxicity 
or increased efficacy or both. Other polymorphisms lead to increased exposure to 
chemotherapy through decreased expression of membrane efflux pumps, whereas 
others lead to decreased capability to repair DNA damage caused by chemotherapy. 
Variants in genes that code for enzymes involved in the mode of action of anti-cancer 
drugs give altered response to chemotherapy. Despite emerging evidence, pharma-
cogenetic testing has not yet found its way to routine patient care. 
Expert Opinion
Many pharmacogenetic studies that point towards association of heritable genetic 
variants and cytotoxic drug response have been presented in this paper. These genes 
and variations have been studied most extensively until now. This does not necessarily 
imply that these genes hold most promise for implementation in the standard of 
oncology care in the near future. Possibly, other genes and variations may emerge as 
potential predictors of response or toxicity. 
Consequently, there is a need for additional, but also for other types of research in 
pharmacogenetics to find its way to routine patient care. Obviously, there is need for 
replication of apparent conflicting findings, such as for the TSER polymorphism in the 
TYMS gene, or polymorphisms in the DNA repair genes, in larger cohorts in routine 
patient care environment.142 
Also, cost-effectiveness of testing needs to be determined for pharmacogenetic tests. 
In this light, it is important to develop tests that are sensitive and specific, as well as 
simple and cheap. 
Genetic variability is only one of the determinants of drug response. Therefore, 
another type of research that holds promise for the future is the development of 
prediction models that not only include pharmacogenetic data, but also non-genetic 
traits such as WHO performance status and organ function. Such models are only 
starting being developed, for instance regarding MTX response in rheumatoid 
arthritis.143 
Until now, genes are selected mainly through the candidate pathway gene approach. 
Obviously, this mechanistic approach seems logical. However, the disadvantage of 
this approach is that it is limited by current knowledge of pathophysiology and the 
mechanism of action of a drug. Therefore, future research will use hypothesis-free 
whole genome approach such as SNP arrays.144 
A six base pair deletion (-6bp) in the 3’ UTR of the TYMS gene results in decreased 
mRNA stability and lower TS expression.136 The -6bp mutation is in linkage 
disequilibrium (LD) with the TSER*3 allele, and the +6bp allele is in LD with TSER*2.137 
The -6bp variant allele is associated with decreased survival in mCRC patients treated 
with 5FU and oxaliplatin83 and with decreased response to 5FU based chemotherapy 
in advanced gastric cancer patients.138 
CRC patients treated with 5FU who were either homozygous for the TSER*3 allele 
(regardless of 3’ UTR genotype) or heterozygous for the TSER allele combined with 
homozygous for the +6bp genotype had significant better disease free survival (DFS) 
and overall survival (OS) compared with the other genotypes.139 In a cohort of gastric 
cancer patients, non-carriers of the TSER*3G allele together with one or two -6bp 
alleles had significant better DFS and OS compared to carriers of TSER*3G and two 
copies of +6bp.140 The haplotype TSER*3C and -6bp was associated with significant 
better OS compared with the haplotype TSER*2 and +6bp in CRC patients treated 
with 5FU.141 
Multiple gene studies 
Drug response is a complex phenotype, especially in anti-cancer therapy, where 
multiple drug regimens are often applied. Only few studies have explored the 
influence of polymorphisms of multiple genes that are involved in the pathway of the 
drug.  
The role of polymorphisms in genes involved in response to 5FU (TYMS) and 
metabolism of cisplatin (GSTP1) was investigated by Ruzzo et al. Advanced gastric 
cancer patients treated with 5FU and cisplatin who were both homozygous for the 
GSTP1-105Ile allele and carrier of the TSER*3G allele had significant shorter progression 
free survival and over all survival compared with patients who were carriers of the 
GSTP1-105Val allele or patients who did not carry the TSER*3G allele.62 
Stoehlmacher et al. looked at genes involved in response and metabolism of oxaliplatin 
(ERCC1, ERCC2 and GSTP1) and 5FU (TYMS). Favourable genotypes in mCRC patients 
were ERCC2-751 Lys/Lys, ERCC1-496 C/C, GSTP1-105Val/Val and TYMS-3’UTR +6bp/+6bp. 
Patients who carried none of these genotypes had median survival of 5.4 months, 
compared with 10.2 and 17.4 months for patients with one or ≥ two favourable 
genotypes (P<0.001).83 
When multiple variants in genes or variants in multiple genes are surveyed for example 
in combination chemotherapy regimens, both sample size and power are of great 
importance since opposite effects of different genetic variants can obliterate each 
other in small samples, whereas multiple testing may reveal false-positive associations.
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Sir, 
We earlier reported in this journal results from an explorative pharmacogenetic study 
for the efficacy of second-line treatment of oxaliplatin combined with capecitabine of 
advanced colorectal cancer (ACC).1 These results were obtained using a DNA repair 
array (Asper Biotech, Tartu, Estonia) to identify novel single nucleotide polymorphisms 
(SNPs) that are associated with progression-free survival (PFS) for oxaliplatin/
capecitabine combination therapy.2 After correction for multiple testing for five DNA 
repair pathways investigated, SNPs in the genes encoding ataxia telangiectasia 
mutated (ATM rs1801516) and excision repair cross-complementing group 5 (ERCC5 
rs1047768) were significantly associated with PFS in the final multivariate analysis. 
Owing to the explorative nature of the study, we concluded that confirmation was 
required in a separate cohort of oxaliplatin/capecitabine-treated patients. We, 
therefore, tested the associations of the same SNPs in the ATM and ERCC5 genes with 
PFS in patients treated in another cohort – the CAIRO2 study. Blood samples were 
available of 560 patients who were treated with oxaliplatin combined with capecitabine 
and bevacizumab, with or without cetuximab, as first-line treatment of ACC.3 Germline 
DNA was isolated from peripheral white blood cells by the standard manual salting-out 
method. We genotyped the ATM and ERCC5 polymorphisms using a Taqman 7500 
(Applied Biosystems, Foster City, CA, USA) with pre-designed assays according to the 
manufacturer’s protocol. Negative controls (water) were included. The collection of 
blood samples for pharmacogenetic research was approved by the local institutional 
review boards of all participating centers, and all patients gave written informed 
consent. 
The genotype frequencies in the CAIRO2 patients were not significantly different 
from the earlier study (P=0.38 and P=0.68 for ATM and ERCC5, respectively), and were 
in Hardy-Weinberg equilibrium. However, the frequency of ATM homozygote mutants 
was 1.6% in the CAIRO2 patients vs 4.4% in patients in the earlier study. 
The results for the associations with PFS are shown in table 1. As opposed to our initial 
observation, the ATM and ERCC5 polymorphisms were not significantly associated 
with PFS in the CAIRO2 patients. 
Several reasons could underlie the lack of replication of association. First, our initial 
results1 may have been false positive findings. Even though we had corrected for 
multiple testing, this approach may have been ineffective to correct for false positives. 
On the other hand, the frequency of ATM homozygote mutant patients in the CAIRO2 
was lower than in the earlier study, which could have impacted the power to detect 
the association. However, the HR for PFS was 4.25 (95%CI 1.45 to 12.44; homozygote 
mutants vs wild-type) in our initial study, whereas it was 0.90 (95%CI, 0.37 to 2.18) in 
the CAIRO2 patients, indicating lack of association regardless of genotype frequency. 
Second, our initial findings were derived from patients receiving second-line therapy 
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therapy with the addition of bevacizumab and cetuximab also. We also recently also 
reported an opposite association of the FCGR3A Phe158Val polymorphism with PFS for 
cetuximab in the first-line setting for ACC compared with results from third-line 
settings.4 As the DNA repair array should theoretically be applicable to any platinum-
containing regimen, this explanation is less likely for the present finding. 
Finally, it is possible that the addition of cetuximab could have negatively influenced 
the efficacy of oxaliplatin in the cetuximab-arm in the CAIRO2 study5,6, which may 
have obscured the associations when both treatment arms were combined for 
analysis. However, the outcome of our analysis did not change when we restricted 
this to patients treated without cetuximab in the CAIRO2 study (data not shown).   
We, therefore, conclude that the ATM and ERCC5 SNPs have no relevant impact on the 
PFS of oxaliplatin-based therapy for ACC. The negative result of this  study underlines 
the importance of validating and reporting the findings from retrospective explorative 
studies.7  
ATM and ERCC5 polymorphisms and oxaliplatin efficacy
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Table 1    Associations of ATM (rs1801516) and ERCC5 (rs1047768) polymorphisms  
with PFS 








Wild-type 371 9.1 (8.3-10.4) 1 - 1 -
Heterozygote 127 12.4 (9.6-13.5) 0.88 (0.70-1.09) .245 0.93 (0.75-1.17) .543
Homozygote mutant 8 11.8 (7.2-∞)† 0.61 (0.27-1.36) .225 0.94 (0.42-2.12) .881
ERCC5 rs1047768
Wild-type 180 10.6 (9.1-12.5) 1 - 1 -
Heterozygote 267 9.2 (8.2-10.6) 1.13 (0.93-1.39) .227 1.15 (0.93-1.42) .194
Homozygote mutant 77 10.1 (8.5-12.2) 0.96 (0.72-1.29) .797 0.94 (0.69-1.28) .689
# Hazard ratios (HR), 95% confidence intervals (95%CI) and P-values computed using a Cox proportional 
hazards model with the wild-type as reference
* Covariates included in the multivariate model: age, gender, serum LDH (normal vs above normal) and 
treatment arm (oxaliplatin, capecitabine and bevacizumab vs oxaliplatin, capecitabine, bevacizumab and 
cetuximab)
† The upper limit of the 95%CI for PFS of the ATM homozygote mutants could not be estimated because of 
the low number of patients
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Disappointing results from replicating pharmacogenetic association studies have 
prompted the search for novel statistical techniques to analyze the data, while taking 
into account the biological complexity underlying drug response. Two of these 
techniques – multifactor dimensionality reduction and classification and regression 
tree – will probably be applied in increasing numbers of future pharmacogenetic 
studies. In this article, we describe the concepts underlying both techniques and 
illustrate their application in a recent pharmacogenetic study. 
Pharmacogenetic studies aim at predicting drug response. These studies commonly 
test associations between single candidate genetic polymorphisms and the efficacy 
or toxicity of drugs. Often, genetic polymorphisms in genes that have a putative 
impact on the function of the corresponding protein are selected. For their part, these 
proteins are assumed to have an impact on drug response, being enzymes involved 
in the pharmacokinetics or pharmacodynamic targets of the drug of interest. Each 
polymorphism is then separately associated with drug efficacy or toxicity. 
Unfortunately, initial results from these candidate gene approach studies are often 
not replicated in subsequent studies.1 This is clearly illustrated in large pharmacoge-
netic studies across different diseases.2-4 Even when a study is successfully replicated, 
the effect of a polymorphism on drug response is often lower than initially described.5 
This is one of the reasons that only a handful of pharmacogenetic markers are actually 
useful to individualize treatment in clinical practice.6 
An explanation for the disappointing results could be that the classic candidate gene 
approach does not take into account the full complexity underlying drug response. 
Drug response is likely to be influenced simultaneously by different biochemical 
components, such as pharmacokinetic enzymes and molecular targets within a 
biochemical pathway. Furthermore, it is recognized that the interplay between these 
different molecular components is extensive and complex. From a biological point of 
view, it seems therefore not only appropriate to study polymorphisms in candidate 
genes collectively – the so called candidate pathway approach7 – but also to assess 
the interaction between the polymorphic genes. This interaction means that the 
impact attributed to one genetic polymorphism depends on one or more others.8 
In some cases, haplotype analysis can reveal relevant but simple interactions between 
polymorphisms, such as combined analysis of CYP3A4 and CYP3A5 variation for 
docetaxel pharmacokinetics.9 However, for genes that are located on different 
chromosomes, haplotype analysis is usually not possible. 
Genetic interaction studies have already been published investigating susceptibility 
to several complex diseases; thus, the concept itself not new.10-15 However, the 
application of this concept in pharmacogenetic studies is scarce.16-18 
Since results from the candidate gene approach have been disappointing 2-4, and 
because the biologic rationale supports studying gene-gene interactions, we 
anticipate that novel techniques for analysis will be applied to pharmacogenetic 
studies in the near future. 
To determine which interactions are most important for drug response, statistical 
techniques must be used. The most widely used technique in genetics is (logistic) 
regression analysis with interaction. The advantage of this technique is its availability 
in common statistical packages, and that covariate adjustments can be made in the 
same analysis. However, assumptions on the genetic model must be made beforehand, 
which may not be accurate in complex interaction analysis. Moreover, (logistic) 




– dimensions – is reduced into a straightforward high-/low-risk factor. From all the 
possible combinations of genotypes, the MDR method presents the combination – or 
genetic classifier – that predicts drug response or toxicity the best.
The MDR method selects the best genetic classifier based upon accuracy – or lowest 
classification error. Genotypes that are individually associated with drug response 
contribute to a higher accuracy, and will therefore usually end up in the best genetic 
classifier, while it is uncertain whether they provide substantial information gain. 
However, it is possible that a polymorphism with a main effect also contributes 
substantially to the interaction model. Therefore, excluding polymorphisms could be 
disadvantageous. Currently, the MDR software is being updated, so that it is possible 
to adjust for main effects of individual polymorphisms. However, as the method of 
covariate adjustment has not proved its value, we excluded individually associated 
polymorphisms from the MDR analysis. Furthermore, haplotypes disturb the selection 
of the best genetic classifier because of over-fitting due to the increased number of 
genotype groups based upon haplotype combinations. Therefore, preferably only 
single nucleotide polymorphisms should be included in the analysis. In the example 
of our previous sunitinib analysis, polymorphisms in NR1I3 (7738A>C and 7837T>G), 
VEGFR (-92G>A and 1718T>A), CYP1A1 (2455A>G) and FLT3 (738T>C) had to be excluded 
from the analysis because of their individual associations. Next, every possible 
combination of genotypes is evaluated, and the software computes how well the 
best genetic classifier predicts drug response. The analysis is performed across tenfold 
cross-validation samples to correct for over-fitting, and the combination with the 
highest accuracy in the cross-validation is considered the best genetic classifier. In our 
example, the combination containing three polymorphisms, NR1I3 5719C>T, ABCB1 
3435C>T and CYP1A2 -163A>C, showed the highest accuracy of 61.8% (P=.008 obtained 
by permutation 23,102) which means that the average classification error in the prediction 
sets from cross-validation is 38.2%. Other combinations of polymorphisms resulted in 
lower accuracies. The distribution of patients with and without leukopenia across the 
three polymorphisms is shown in figure 1A. The interaction dendrogram for this 
genetic classifier is shown in figure 1B. The orange and red lines indicate a synergistic 
interaction between the polymorphisms. The short red lines between the ABCB1 and 
NR1I3 polymorphisms indicate that the interaction between these polymorphisms is 
the strongest in this model. 
The results can be used to create a genetic classifier of response. This classifier can 
then be used in regular statistical analysis to compute an odds ratio (OR), and to 
perform a multivariate analysis. In the sunitinib example, the multivariate logistic 
regression analysis was performed including age, gender, WHO performance status, 
the genetic classifier, and the polymorphisms that were individually associated with 
leukopenia. The genetic classifier obtained by MDR has a corrected OR of 4.06 (95% 
confidence interval (CI), 1.99 to 8.31), whereas only the polymorphisms in CYP1A1 and 
regression analysis is of only limited application with increasing numbers of 
polymorphisms, as the number of possible interactions increases substantially with 
increasing numbers of polymorphisms. For instance, the total number of possible 
two-, three- and four-way interactions for ten polymorphisms is 375, whereas it is 
more than 4,000,000 for 100 polymorphisms. This illustrates the complexity of the 
interaction analysis, and has lead to the application and development of more 
advanced techniques for interaction analysis. 
These techniques rely on algorithms that reduce the number of dimensions – that is, 
possible combinations of polymorphisms – in order to establish a genetic classifier to 
predict drug response. An important aspect of these genetic classifiers is that the 
combination of different polymorphisms results in information gain (the 1+1=3 
principle). This concept of synergy illustrates the impact of interaction most intuitively, 
but it must be noted that other types of interaction exist, as reviewed by Perez-Perez 
et al.19 
Two of these advanced techniques will be described: ‘multifactor dimensionality 
reduction’ (MDR) 20,101 and ‘classification and regression tree’ (CART) analysis, for their 
application in pharmacogenetics. Since these methods use different and unique 
approaches, we have no explicit preference. To illustrate the application of both 
techniques, genetic classifiers were created to predict the incidence of leukopenia 
(grade 0 versus grade ≥1 according to the National Cancer Institute Common Toxicity 
Criteria) in patients treated with single-agent sunitinib, using data from a candidate 
gene analysis for sunitinib induced toxicity.21 In this cohort of 198 Dutch patients 
(predominantly with metastatic renal cell carcinoma and gastrointestinal stromal 
tumors) who were assessable for leukopenia, 31 polymorphisms were analyzed in 12 
genes that encode enzymes in the pharmacokinetic and pharmacodynamic pathways 
of sunitinib. Genotyping was performed on the BiomarkTM 48.48 Dynamic Array 
(Fluidigm, San Francisco, CA, USA) using Taqman® assays (Applied Biosystems, 
Nieuwekerk aan den IJssel, the Netherlands) according to the manufacturer’s protocol 
as previously described.21 There are more than 36,000 possible two-, three- and 
four-way interactions possible for these 31 polymorphisms, emphasizing the 
complexity of the problem and the need for advanced statistical techniques. 
Multifactor dimensionality reduction
The theoretical application of the MDR analysis software to pharmacogenetic studies 
has previously been reviewed by Ritchie et al.22 The essence of the MDR analysis is 
that all possible combinations of genotypes are evaluated to predict drug response. 
Each combination of genotypes contains a ratio of responders to non-responders, 
which is used to classify patients. In this way, the complexity of genotype combinations 




these two methods, besides the fact that every possible interaction could not be 
assessed using logistic regression.  
When the polymorphisms with a main effect were also included in the MDR analysis, 
all top models contained at least either the NR1I3 7738A>C or FLT3 738T>C poly-
morphism. 
Classification and regression tree  
The essence of the CART analysis is that patients are divided into groups with a unique 
genotype combination that predicts drug response. During the CART analysis, patients 
are subdivided successively, in such a way that a so-called ‘classification tree’ is grown. 
Each subgroup is split by the most discriminating polymorphism, which could be a 
different polymorphism for each subgroup. This procedure is continued until the 
pre-specified maximum tree depth is reached, or when each subgroup reaches a 
pre-specified minimum number of patients. Each terminal subgroup of the tree 
contains a ratio of responders to non-responders, which can be used to classify 
patients. Since each subgroup can be split by a different polymorphism, interaction 
can be detected, meaning that the influence of each polymorphism depends on the 
polymorphisms that split the subgroup in a previous level of the tree. 
For the CART analysis, polymorphisms that are associated individually with drug 
response can be included, as well as haplotypes. In the sunitinib example, all 
polymorphisms and haplotypes were included as previously reported.21 The maximum 
tree depth was set to three levels, and no subgroup was allowed to contain less than 
25 patients. Each subgroup was split based upon the highest χ2 value. In figure 2, the 
classification tree is shown. The tree contained the polymorphism in FLT3 (738T>C, 
step 1), the haplotype in NR1I3 (step 2) and the polymorphism in RET (2251G>A, 
step 3). Each terminal group of the tree can be seen as a unique combination of 
genotypes – a genetic classifier. As in the MDR analysis, the genetic classifier was used 
in a regular statistical analysis to compute the OR. In a logistic regression analysis 
including WHO performance status, age and gender, the OR for the genetic classifier 
was 3.36 (95%CI, 1.84 to 6.15). 
When a logistic regression analysis was performed with the three-way interaction 
between the FLT3 738T>C and RET 2251G>A polymorphisms and the NR1I3 haplotype, 
the interaction term was not significantly associated with leukopenia, again 
emphasizing the fundamental difference between these two methods.
FLT3 remained statistically significant (P=.043 and P=.010, respectively) in the 
multivariate analysis. 
When a logistic regression analysis was performed with the three-way interaction 
between the NR1I3 5719C>T, ABCB1 3435C>T and CYP1A2 -163A>C polymorphisms, 
the interaction term was not significantly associated with leukopenia. Each poly - 
morphism was included as an ordinal factor, whereas the MDR method did not rely 
on this a priori assumption. This underlines the fundamental difference between 
The 1 + 1 = 3 principle
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Figure 1    Multifactor dimensionality reduction analysis of sunitinib induced 
leukopenia 
(A) The genetic classifier consisting of polymorphisms in CYP1A2, NR1I3 and ABCB1 resulted in the highest 
accuracy of 61.8% in the cross-validation sample. For each genotype combination, the number of patients 
with and without leukopenia is shown. Combinations with low chance of leukopenia are shaded light grey, 
whereas combinations with high chance of leukopenia are shaded dark grey. Since in the total group of 
patients, 59.1% experienced leukopenia, a combination is considered to give a high chance of leukopenia 
when the percentage of patients experiencing leukopenia exceeds 59.1%. (B) Interaction dendrogram for 
the polymorphisms included in the genetic classifier obtained by multifactor dimensionality reduction. 
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Interpretation and validation of the genetic classifier
Both MDR and CART analyses result in genetic classifiers that are associated with drug 
efficacy or toxicity. Since these methods rely on different ways to create this genetic 
classifier, they result in different classifiers that do not necessarily contain the same 
polymorphisms. In the MDR analysis, a genetic classifier is created in addition to 
polymorphisms that were individually associated with drug response, so that the 
genetic contribution to drug response is further explored. In the CART analysis, the 
genetic contribution to drug response is analyzed taking into account that a 
polymorphism may only have impact on drug response under the condition that 
another polymorphism is present. The similarity between the methods is that 
combinations of genotypes are investigated, rather than individual polymorphisms. 
This is more plausible from a biological point of view, because drug response is a 
complex trait and involves many proteins. Importantly, the CART and MDR methods 
detect statistical interaction, and the models do not necessarily contain polymorphisms 
in genes encoding enzymes that interact biologically. The interpretation of the 
genetic classifiers from a biological point of view is therefore not straightforward. The 
genetic classifiers contain polymorphisms that only exert their influence under the 
condition that other polymorphisms are present. In the MDR analysis of our sunitinib 
example, three polymorphisms in metabolic enzymes were included in the genetic 
classifier. From a biological point, it is likely that metabolic routes compete, and that 
the effect of one polymorphism on the metabolic capacity can be altered by others. 
When interpreting the genetic classifier obtained by CART in our sunitinib example, it 
appears that genetic variation in the metabolic enzyme NR1I3 is only relevant for 
carriers of the FLT3 738C-allele and not for carriers of the FLT3 738TT genotype, possibly 
because the latter are more sensitive to sunitinib-induced leukopenia regardless of 
the plasma levels of sunitinib.  
Critical choices have to be made before these techniques can be applied, such as the 
number and selection of patients, the selected polymorphisms and the settings of 
the software. Importantly, when large numbers of polymorphisms are included in the 
interaction analysis, the number of possible interactions becomes enormous. In the 
current era of whole-genome profiling of more than a million polymorphisms, 
intelligent filtering of polymorphisms must be performed before interaction analysis, 
due to the computational requirement of such analysis.24 Furthermore, both MDR and 
CART may result in genetic classifiers that predict drug response in the original 
patients better than in new patients because of potential over-fitting. The ORs for the 
genetic classifiers in our examples are therefore likely to be biased, and the true OR 
has to be obtained in an independent validation cohort. For these genetic classifiers 
to be applied in clinical practice, the genetic classifier should therefore be confirmed 
in independent cohorts.25 Before the effort of external validation is undertaken, 
The 1 + 1 = 3 principle
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Figure 2    Classification and regression tree analysis of sunitinib-induced leukopenia 
Each branch of the tree is divided by the polymorphism or haplotype with the highest χ2 value. Terminal 
groups are shaded light grey or dark grey for relatively low and high risk of sunitinib-induced leukopenia, 
respectively. Since 59.1% of the patients experienced leukopenia (grade 1 or higher), a genetic classifier is 
considered high chance of leukopenia when the percentage of patients experiencing leukopenia exceeds 
59.1%. 
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•	 	Recent pharmacogenetic association studies on frequently studied polymorphisms 
failed to replicate initial findings.
•	 	Drug response is a complex phenomenon, and involves many different 
biochemical components, such as pharmacokinetic enzymes and molecular 
targets within a biochemical pathway.
•	 	Traditional statistical analytical methods, such as (logistic) regression, are not 
suitable for detecting complex gene-gene interactions. 
Multifactor dimensionality reduction and classification and regression tree
•	 	Statistical analysis testing for gene-gene interactions can be performed using 
multifactor dimensionality reduction (MDR) or classification and regression tree 
(CART) analysis.
•	 	The MDR and CART techniques have been applied successfully to identify genetic 
classifiers of sunitinib-induced toxicity.
Interpretation and validation of the results
•	 	The MDR and CART techniques both result in genetic classifiers that predict drug 
response.
•	 	These genetic classifiers must be validated in new patients before they can be 
used to individualize treatment.
Conclusion and future perspective
•	 	The MDR and CART methods are more rational approaches to individualizing 
drug treatment when compared with traditional methods. 
internal validation can be performed to correct for over-fitting using for instance 
cross-validation. 
Conclusion
Statistical techniques to analyze high-order interactions between polymorphisms, 
such as the MDR and CART techniques, create genetic classifiers that predict drug 
response. They have the major advantage over classic pharmacogenetic association 
studies that the complexity underlying drug response is studied and may therefore 
be more likely to be successfully replicated. When validated, these genetic classifiers 
can provide a novel and more rational approach to individualizing drug treatment. 
Future perspective
We believe that complex interaction between polymorphisms will increasingly be 
studied in the near future, since the results from traditional pharmacogenetic 
association studies have been disappointing. The MDR and CART methods will 
probably be the most widely used, as they are widely available and relatively easy to 
apply. However, for the resulting genetic classifiers to reach the clinic, thorough 
validation must be performed using independent patient populations. Only when 
validation has been successful can the genetic classifiers be used to guide 
individualized therapy. 
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Pharmacogenetic markers related to drug metabolism and mechanisms of action 
could help to better select patients with metastatic colorectal cancer (mCRC) for 
treatment. Genetic interaction analysis is used as a rational tool to study the 
contribution of polygenic variation in relation to drug response. 
Patients and methods
A selection of 17 polymorphisms in genes encoding drug targets, pathway molecules 
and detoxification enzymes was analyzed in 279 previously untreated mCRC patients 
treated with capecitabine, oxaliplatin and bevacizumab (CAPOX-B). Multifactor 
dimensionality reduction analysis was used to identify a genetic interaction profile for 
progression-free survival (PFS). 
Results
Median PFS was 10.9 (95%CI, 9.4 to 12.4) months. A genetic interaction profile consisting 
of the TYMS enhancer region and VEGF +405G>C polymorphisms was significantly 
associated with PFS. Median PFS was 13.3 (95%CI, 11.4 to 15.3) and 9.7 (95%CI, 7.6 to 
11.8) months for the beneficial and unfavorable genetic profiles, respectively, 
corresponding to a hazards ratio for PFS of 1.58 (95%CI, 1.14 to 2.19). None of the 
studied polymorphisms were individually associated with PFS. 
Conclusions
Our results support a genetic interaction between the TYMS enhancer region and 
VEGF +405G>C polymorphisms as a predictor of the efficacy of CAPOX-B in mCRC 
patients.
Introduction
The combination of a fluoropyrimidine, such as 5-fluorouracil (5-FU) or capecitabine, 
oxaliplatin and the vascular endothelial growth factor (VEGF) blocking antibody 
bevacizumab (CAPOX-B) is a frequently used standard first-line treatment strategy for 
metastatic colorectal cancer (mCRC).1,2 However, since not all patients respond to this 
regimen, better criteria to select patients for this treatment are warranted. For this 
purpose, pharmacogenetic studies have been carried out with germline poly -
morphisms in genes that encode metabolic enzymes and drug targets (Table 1). 
However, the findings from these studies are not consistent.3 As a result, none of these 
polymorphisms are currently used in general practice to identify patients with an 
increased chance of response. 
An explanation for these results could be that current analytical methods ignore or 
underestimate the complexity underlying drug response. Drug response involves 
many different proteins, such as therapeutic targets, molecules in the signaling 
pathway, metabolic enzymes or drug transporters. It may therefore be likely that the 
impact of polymorphisms in the corresponding genes exert their influence only in 
the presence of other polymorphisms. This concept is known as non-linear interaction, 
or epistasis.4 Studying the interaction between polymorphisms could therefore 
provide more reliable information compared with separate analyses of associations 
between individual polymorphisms and response.5 The resulting information can be 
transformed into genetic profiles that may have a prognostic and/or predictive value 
for mCRC patients. 
The multifactor dimensionality reduction (MDR) methodology has been developed 
to study non-linear patterns of interactions between genetic profiles and drug 
response.6 In this study, we applied genetic interaction analysis using the MDR method 
to evaluate interaction between candidate polymorphisms in relation to the efficacy 
of CAPOX-B as first-line treatment in mCRC patients. 
Materials and methods
Study population
Blood samples were collected from 279 of 368 previously untreated mCRC patients 
who were treated with CAPOX-B in the control arm of the multicenter prospective 
randomized phase III CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG).1 
Capecitabine 1000 mg/m2 (increased to 1250 mg/m2 from cycle 7) was administered 
orally twice daily on days 1 to 14 of each 3-week treatment cycle. Oxaliplatin 130 mg/
m2 (maximum of six cycles) and bevacizumab 7.5 mg/kg were administered i.v. on 
day 1 of each treatment cycle. Treatment was continued until disease progression, 




death or unacceptable toxicity, whichever occurred first. Patient eligibility criteria and 
further details of the study have been previously described.1 The collection of a 
peripheral blood sample for pharmacogenetic research was pre-specified in the study 
protocol and required additional written informed consent. The protocol was 
approved by the local institutional review boards of all participating centers.
Patients in the experimental cetuximab-containing study arm of the CAIRO2 study were 
not included in this pharmacogenetic study since the addition of cetuximab resulted in 
a decreased progression-free survival (PFS), the primary endpoint of the study.1 
Genotyping
The studied genetic polymorphisms are shown in Table 1. These polymorphisms were 
selected primarily on the basis of the pharmacokinetics and pharmacodynamics of 
capecitabine, oxaliplatin and bevacizumab and on the known functional effects at 
the protein level.7 Moreover, these polymorphisms have been included in previous 
pharmacogenetic association studies of 5-FU, capecitabine or oxaliplatin in mCRC.8-29 
Since results of only two pharmacogenetic studies for bevacizumab have been 
reported30,31, polymorphisms in VEGF and its receptor (kinase domain receptor, KDR) 
were selected.32 Germline DNA was isolated from peripheral white blood cells by the 
standard manual salting-out method. Genotyping was carried out on a Biomark 
system (Fluidigm, South San Francisco, CA, USA) according to the protocol provided 
by the manufacturer using pre-designed TaqMan assays (Applied Biosystems, Foster 
City, CA, USA). 
The polymorphisms in the thymidylate synthase enhancer region (TSER) in the 
promoter of the TYMS gene (two or three 28-bp repeats including the C>G 
polymorphism in the third repeat; TYMS-TSER) were analyzed by direct sequencing. 
The genotype was expressed as non-carriage of the 3G-allele (2/2, 2/3C and 3C/3C 
genotypes) versus carriage of the 3G-allele (2/3G, 3C/3G and 3G/3G), since the 3G 
allele results in increased TYMS activity.33,34 The 6-bp insertion/deletion (TYMS +/-6bp) 
polymorphism in the 3’ untranslated region was determined using fragment analysis. 
Each assay was conducted with 10% duplicates, with water as negative control. The 
overall call rate was 0.948 (0.803 to 0.989) and none of the polymorphisms significantly 
deviated Hardy-Weinberg equilibrium (P>0.01). 
Statistical analysis
Genotypes that are individually associated with drug response will usually end up in 
the best genetic profile in the genetic interaction analysis without providing 
substantial information gain. Therefore, the association between each individual 
polymorphism (treated as an ordinal variable, representing an additive model) and 
PFS as dependent variable was tested using a Cox proportional hazards model 
including serum LDH, age and gender as covariates. Polymorphisms significantly 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The genotype combination with the highest accuracy in the validation sample was 
recoded into a genetic profile predictive for PFS. This genetic profile was subsequently 
used for all 279 patients in the CAIRO2 study from whom a blood sample was available, 
including the patients from the intermediate PFS group, to estimate survival curves 
using the Kaplan-Meier method. The difference in PFS from the beneficial genetic 
profile versus the unfavorable genetic profile was estimated using the log-rank test. 
A Cox proportional hazards model including the genetic profile, age, gender, prior 
adjuvant chemotherapy (yes versus no), number of affected organs (1 versus >1), serum 
LDH and any polymorphisms that were individually associated with PFS was used to 
compute the adjusted hazards ratio (HR) and 95% confidence interval (95%CI). Given 
the exploratory nature of this study, no adjustment for multiple testing was carried out, 
and a P value of <0.05 was considered significant. The Kaplan-Meier and Cox proportional 
hazards analyses were carried out using SPSS version 17.0 (SPSS, Chicago, IL, USA).
Results
At the time of analysis, the primary end point of PFS was reached in 225 of 279 eligible 
patients (80.6%). Median PFS was 10.9 months (95%CI, 9.4 to 12.4 months). Two patients 
were censored in the shortest quartile, and were excluded from the genetic interaction 
analysis, since the actual PFS of these patients was unknown. Censored events in the 
longest quartile were not excluded, since PFS for these patients was at least longer 
than the 75% quartile cut-off point. The shortest and longest quartiles for PFS were 
below 6.7 and above 15.5 months, respectively, each consisting of 70 patients. 
None of the genetic polymorphisms were individually associated with PFS in the Cox 
proportional hazards analysis (Table 2). Therefore, all polymorphisms were included in 
the genetic interaction analysis with PFS. 
The combination of the TYMS-TSER and VEGF +405G>C had the highest accuracy of 
0.650 (P=0.027, 1000-fold permutation testing; 0.624 after exclusion of missing data), 
meaning that 65% of the patients were correctly classified according to the genetic 
profile (Figure 1a). The distribution of patients in the shortest and longest PFS quartiles 
for the combination of TYMS-TSER and VEGF +405G>C genotypes is shown in Figure 
1b. All other combinations of two, three and four polymorphisms each resulted in 
lower accuracies in the genetic interaction analysis, and were therefore not considered 
for further evaluation. 
When all 246 patients with complete genotype data were used, 137 and 109 patients 
were in the beneficial and unfavorable profiles for PFS, respectively. In Figure 2, the 
frequency distribution of the genetic profile across the four quartiles for PFS is shown. 
Interestingly, the frequency of the unfavorable profile decreases for every quartile, 
even for the two middle quartiles (P<0.001, χ2 test for trend). 
associated with PFS (P<0.05) were excluded from the subsequent interaction analysis, 
but would be introduced in the final multivariate analysis (see below). Also, haplotypes 
disturb the selection of the best genetic profile because of over fitting the data due 
to the number of possible haplotype combinations and were therefore also not used 
in the interaction analysis. No haplotype was individually associated with PFS in our 
study (data not shown). 
To study interaction between the polymorphisms in relation to response, the MDR 
software was used (version 2.0 beta 6; available on http://sourceforge.net/projects/
mdr/).6 The software requires a complete dataset with no missing data. Therefore, 
missing data for polymorphisms with ≤5% missing data were imputed by genotypes 
based upon the genotype frequency of the polymorphism, taking the distribution of 
other polymorphisms in the same gene into account. Missing data for polymorphisms 
with >5% missing data (TYMS-TSER, TYMS +/-6bp, VEGF -1154G>A and VEGF +936C>T) 
were considered a separate ‘missing genotype group’ in the genetic interaction 
analysis. If the genetic interaction analysis resulted in a combination consisting of a 
genotype with a ‘missing genotype group’, the procedure was repeated without this 
group and results were compared with the initial results.
Our study is designed to identify a subgroup of patients with increased PFS. The 
median PFS in our study population was 10.9 months. However, it is assumed that 
the patients with beneficial genetic profiles have a PFS much longer than the median, 
whereas patients with unfavorable genetic profiles have PFS much shorter than the 
median. We therefore included patients in the shortest and longest quartiles for 
PFS in the genetic interaction analysis, in order to increase discriminating power.35-37 
The entire cohort was used in the final analysis of the genetic profile (see below). 
Sensitivity analysis showed that when the patients with censored data before the 75% 
quartile cut-off point were included in the longest quartile, or when tertiles were 
used instead of quartiles, results remained unchanged (data not shown), indicating 
that our choices regarding censoring and enrichment do not influence the results of 
the study.  
In the genetic interaction analysis, the ratio between patients in the shortest quartile 
to patients in the longest quartile for each genotype combination is evaluated. 
Combinations with more patients in shortest quartile than in the longest quartile are 
considered high chance of short PFS, and vice versa. This procedure was carried out 
across 10-fold cross-validation samples to avoid over fitting, and was repeated for all 
possible combinations of two up to four polymorphisms. The genotype combination 
with the highest accuracy (fraction of correctly classified patients) in the validation 
sample was considered the combination that best predicts PFS, and was selected for 
further analysis. A P-value for the statistical significance of the accuracy was obtained 
using 1000-fold permutation testing (software available on https://sourceforge.net/
projects/mdr/files/mdrpt/). 




The PFS curves for the genetic profile for all patients are shown in Figure 3. The median 
PFS was 13.3 (95%CI, 11.4 to 15.3) and 9.7 (95%CI, 7.6 to 11.8) months for the beneficial 
and unfavorable profiles, respectively (P<0.001, log-rank test). 
In the multivariate Cox proportional hazards model including age, gender, prior 
adjuvant chemotherapy, number of affected organs and serum LDH, the HR for the 
genetic profile for PFS was 1.58 (95%CI, 1.14 to 2.19; P=0.006).  
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Table 2    Individual associations of polymorphisms with progression free survival in 
mCRC patients treated with capecitabine, oxaliplatin and bevacizumab as 
first-line therapy 
Polymorphism allelic HR* 95% CI P
MTHFR 677C>T 1.00 0.81-1.23 0.991
MTHFR 1298A>C 0.91 0.74-1.13 0.393
TYMS 1494 +/- 6bp 1.10 0.87-1.40 0.410
TYMS VNTR 2/3C/3G 1.02 0.77-1.36 0.884
ERCC1 496C>T 1.12 0.92-1.37 0.243
ERCC2 499C>A 1.15 0.94-1.40 0.185
ERCC2 2251A>C 1.00 0.82-1.21 0.968
ERCC2 965G>A 0.80 0.63-1.01 0.058
XRCC1 1301G>A 0.98 0.81-1.18 0.811
GSTP1 313A>G 0.98 0.81-1.19 0.837
KDR 1719A>T 1.08 0.88-1.33 0.465
KDR -604T>C 1.03 0.86-1.24 0.738
VEGF -1154G>A 1.09 0.90-1.33 0.381
VEGF 405G>C 0.97 0.81-1.18 0.785
VEGF 936C>T 0.98 0.74-1.29 0.889
VEGF -2578C>A 1.03 0.86-1.23 0.763
VEGF -460C>T 1.00 0.84-1.20 0.990
* Hazard ratios (HR), 95% confidence intervals (95%CI) and P-values were calculated for each polymorphism 
using a Cox proportional hazards model with age, gender and serum LDH as covariates.
Abbreviations: ERCC1, excision repair cross-complementing group 1; ERCC2, excision repair cross- complementing 
group 2; GSTP1, glutathione s-transferase pi 1; KDR, kinase domain receptor (=vascular endothelial growth factor 
receptor 2); MTHFR, methylene tetrahydrofolate reductase; TYMS, thymidylate synthase; VEGF, vascular endothelial 
growth factor A; VNTR, variable number of tandem repeats; XRCC1, X-ray cross-complementing group 1.
Figure 1    Genetic interaction profile for CAPOX-B 
A: Algorithm based upon the results of the genetic interaction analysis to translate the genotype- 
combinations of the TYMS-TSER and VEGF +405G>C polymorphisms into a risk factor – or genetic profile – 
for PFS. B: Distribution of patients in the short (white bars) and long PFS quartiles (black bars) across the 
different genotype combinations of TYMS-TSER and VEGF +405G>C. Combinations with more patients  
in the short quartile are shaded white (unfavorable profile), whereas combinations with more patients in 
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VE G F  +405 G G   and  T Y MS  no 3G  allele,  then ‘unfavorable prole’  
VE G F  +405 C  allele  and  T Y MS  no 3G  allele,  then ‘benecial prole’  
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the TYMS-TSER polymorphism and the VEGF +405G>C polymorphisms are dependent 
of each other in their impact on PFS. 
VEGF is the natural ligand for the VEGF receptor, through which it induces angiogenesis. 
Bevacizumab neutralizes VEGF, resulting in decreased tumor angiogenesis, which in 
turn affects intratumoral hypoxia, nutrition status and/or disposition of concurrent 
chemotherapy.39 The functional consequence of the VEGF +405G>C polymorphism 
remains to be elucidated. One in vitro study reported increased VEGF release by li-
popolysaccharide-stimulated peripheral monoclonal blood cells with the VEGF 
+405G-allele40, but another study showed that VEGF serum levels were highest for 
healthy volunteers with the VEGF +405CC genotype.41 The fluorodeoxyuridine 
monophosphate (FdUMP) metabolite of capecitabine inhibits the TYMS enzyme, and 
thereby induces DNA damage.42 Previous in vitro experiments indicated that the 
TYMS-TSER 3G allele results in higher expression of TYMS.33,34 The finding by Marcuello 
Discussion
We showed that a genetic interaction profile consisting of the VEGF +405G>C and 
TYMS-TSER polymorphisms correlates with PFS in mCRC patients treated with CAPOX-B. 
This approach provides a novel way to use pharmacogenetic variation to individualize 
treatment since individual polymorphisms were not associated with PFS. 
To exclude profound individual associations with PFS that could interfere with the 
genetic interaction analysis, we first tested for associations of the individual 
polymorphisms with PFS. No significant associations were detected, analogous to the 
absence of associations for other individual molecular markers in mCRC.38 
The genetic interaction analysis takes the complexity of interacting polymorphisms in 
genes encoding drug targets, metabolic enzymes and detoxification enzymes into 
account. Our study shows that – in mCRC patients treated with first-line CAPOX-B – 
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Figure 2    Distribution of the genetic profile across the four PFS quartiles  
The frequency of the unfavorable profile decreases for each quartile for PFS (P<0.001, χ2 test for trend). 
* Patients who were censored before the fourth quartile were included in the third quartile.
Figure 3    Kaplan Meier curves for the genetic profile for all mCRC patients treated 
with capecitabine, oxaliplatin and bevacizumab as first-line treatment  
137 and 109 patients were in the unfavorable and beneficial profile groups, respectively. The median PFS 
was 13.3 (95%CI, 11.4 to 15.3) and 9.7 (95%CI, 7.6 to 11.8) months for the beneficial and unfavorable profiles, 
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et al. that the TYMS-TSER 3G allele is associated with decreased efficacy of 5FU-based 
chemotherapy in mCRC patients15, is therefore only present for VEGF +405C-allele 
carriers in our study. However, further fundamental research should be undertaken to 
understand the exact biological mechanism of the genetic profile with regard to the 
efficacy of CAPOX-B.
For the genetic interaction analysis, the PFS endpoint initially was converted into a 
binary outcome. We assumed that the patients with beneficial genetic profiles have a 
PFS much longer than the median, whereas those with unfavorable genetic profiles 
have PFS much shorter than the median. By using the shortest and longest quartiles 
for PFS, we anticipated sufficient discriminating power, while keeping the groups 
reasonably large. This concept of enrichment is an accepted method in genetics.35-37 
Even though our choice of cut-off remains arbitrary, our sensitivity analysis showed 
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assess its clinical utility.43 
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In conclusion, we demonstrated a significant correlation between a genetic profile 
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improved PFS. This genetic profile is a novel marker that may identify a subgroup of 
mCRC patients with increased probability of benefit to CAPOX-B. To our knowledge, 
this is the first study to explore the interaction between polymorphisms in relation to 
the efficacy of cancer chemotherapy. Testing for the interaction between 
polymorphisms is probably more rational than testing of each individual polymorphism, 
since drug response is a complex phenomenon. If confirmed in independent studies, 
our results provide a novel tool to better select cancer patients for potentially toxic 
and expensive treatments. 
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A more optimal selection of patients that will benefit from the frequently used 
first-line treatment of advanced colorectal cancer (ACC) consisting of the combination 
of capecitabine, oxaliplatin and bevacizumab (CAPOX-B) is warranted. We used a 
genome-wide association study to find single nucleotide polymorphisms (SNPs) that 
are associated with the efficacy of CAPOX-B.
Methods
Germline DNA was obtained from 547 previously untreated ACC patients in the 
randomized phase III CAIRO2 trial, in which patients were randomized between 
CAPOX-B or CAPOX-B plus cetuximab. Whole-genome genotyping was performed 
using 700 k Illumina OmniExpress BeadChip arrays. Associations between SNPs and 
progression-free survival (PFS) were tested using Cox-proportional hazard models. 
Associations were considered significant when P < 5 x 10-8. 
Results
Three SNPs located at 8p23.1 showed a trend toward significance for association with 
PFS (rs292936519, P = 1.24 x 10-7; rs2912024, P = 1.38 x 10-7 and rs2978931, P = 6.75 x 
10-7). These SNPs are 20 kbp downstream of the AGPAT5 gene, which encodes a protein 
that is involved in phospholipid biosynthesis. 
Conclusion 
Even though these results possibly identify a novel genetic predictor for the efficacy 
of CAPOX-B, further analyses are required before definitive conclusions can be made 
based upon these data.  
Background 
A frequently used first-line treatment of advanced colorectal cancer (ACC) consists of 
the combination of capecitabine, oxaliplatin and bevacizumab (CAPOX-B).1 Even 
though this combination results in a prolongation of survival compared with no 
treatment, the one year progression-free survival (PFS) rate is below 50%.2,3 In order to 
reduce toxicity and costs, a more optimal selection of patients that will benefit from 
modern systemic treatment is warranted.
Heritable genetic variation has proven to predict variation in response to many 
therapeutics drugs.4 The basis of such research is currently limited to genetic variation 
in target or metabolic enzymes that have been selected using the candidate gene 
approach. The disadvantage of this approach is that it is limited to current knowledge 
of the mechanism of action of the investigated drugs. Since it is estimated that there 
are more than 10.000.000 single nucleotide polymorphisms (SNPs) in the human 
genome, it is very likely that many of these SNPs are not detected in the current 
approach of pathway based research. 
Genome-wide association studies, in which the entire genome is characterized for 
SNPs, have been applied in the past years to identify risk factors for several types of 
cancers in large case-control series.5 Regarding outcome of systemic therapy, 
genome-wide association studies have identified SNPs associated with muscoskeletal 
adverse reactions to aromatase inhibitors6, treatment response for childhood acute 
lymphoblastic lymphoma7 and pharmacokinetics of methotrexate8. All of these 
studies are based upon a case-control design with χ2-tests to test for associations, but 
survival could also be applied as an endpoint using Cox-proportional hazards models 
to test for associations. 
Here we present the first results of a genome-wide association study to find SNPs that 
are associated with the efficacy of first-line CAPOX-B for ACC in a clinical trial setting 
with PFS as the primary endpoint. 
Patients and Methods
Patients
Germline DNA was obtained from 547 of 736 previously untreated ACC patients who 
were randomized between treatment with CAPOX-B or CAPOX-B plus cetuximab in 
the multicenter randomized phase III CAIRO2 trial of the Dutch Colorectal Cancer 
Group (DCCG).9 Capecitabine 1000 mg/m2 (increased to 1250 mg/m2 from cycle 7) was 
administered orally twice daily on days 1–14 of each 3-week treatment cycle. Oxaliplatin 
130 mg/m2 (maximum of six cycles) and bevacizumab 7.5 mg/kg were administered 
intravenously on day 1 of each treatment cycle. For patients randomized to the 




quantiles for the P-values of the markers. Formal significance for a marker was assumed 
for P < 5 x 10-8. To check for effects that could be ascribed to the treatment arm, 
interaction between the marker and treatment arm was included in the model. The 
association was tested only in the CAPOX-B arm if the P-value of the marker*arm 
interaction term was < 0.001. Kaplan-Meier curves were estimated for the marker with 
the lowest P-value using SPSS version 17.0 (SPSS, Chicago, IL, USA). 
Results
Patients
At the time of the analysis (December 2010), the primary endpoint PFS was reached in 
459 patients (88.1%). Median PFS was 10.6 months (95% confidence interval [95%CI], 
9.5 to 11.6 months). In the CAPOX-B and the CAPOX-B plus cetuximab arms, median 
PFS was 10.8 months (95%CI, 9.0 to 12.5 months) and 10.1 months (95%CI, 9.0 to 11.3 
months), respectively. Baseline patient characteristics are described in Table 1. 
Genotype results
Three SNPs (rs2936519, rs2912024 and rs2978931) located on chromosome 8, cytogenic 
band 8p23.1, showed the lowest P-values (P = 1.24 x 10-7, P = 1.38 x 10-7 and P = 6.75 x 
CAPOX-B plus cetuximab arm, cetuximab was administered intravenously at a dose of 
400 mg/m2 on the first day, followed by 250 mg/m2 weekly thereafter. Treatment was 
continued until disease progression, death or unacceptable toxicity, whichever 
occurred first. Patient eligibility criteria are described in detail elsewhere.9  
The collection of a peripheral blood sample for pharmacogenetic research was 
pre-specified in the study protocol and required additional written informed consent. 
The protocol was approved by the local institutional review boards of all participating 
centers.
Genotyping and quality control
Germline DNA was isolated from peripheral white blood cells by the standard manual 
salting-out method. Genotyping was performed on Human OnmiExpress v12 
BeadChip arrays containing 733,202 markers (Illumina, San Diego, CA, USA) using 
technical facilities at the Leiden Genome Technology Center (LGTC, Leiden, The 
Netherlands). Genotype calls were set using GenomeStudio software (Illumina). 
Patients with a call-rate of < 0.98 were excluded from further analysis. The following 
cut-off values were used to filter out incorrectly called genotypes: GenCall ≥ 0.85; 
ClusterSep ≥ 0.3; CallFreq > 0.85; AB T-mean 0.2 – 0.8, resulting in the exclusion of 3172 
markers (0.43%). 
Further quality control of the data was performed using R (http://www.r-project.org/). 
Ten patients (1.83%) were excluded based upon the sex check, and 16 patients (2.92%) 
were excluded based upon 4-dimensional multi-dimensional scaling (MDS) analysis 
to detect possible population stratification. In total, 26 patients were excluded, 
resulting in 521 evaluable patients.
For the markers, a minimum allele frequency for this analysis was set at 0.05, resulting 
in excluding 125,800 markers (17.2%). The call-rate cut-off per marker was set at 0.98, 
resulting in excluding 16,981 markers (2.3%). The distribution of the marker-missing-
ness per chromosome showed no unexpected pattern. Hardy-Weinberg equilibrium 
(HWE) was evaluated per marker using a χ2 goodness-of-fit statistic. Based upon the 
QQ-plot of observed P-values against expected P-values for HWE, 1168 markers (0.2%) 
were excluded with a HWE P-value of ≤ 5.0 x 10-7. After these quality checks, 589,274 
markers remained for the statistical analysis. 
Statistical analysis
For each marker, a Cox proportional hazards model was calculated using R, which 
included age, gender and treatment arm as covariates. Since it is not known whether 
the effects of the markers are dominant, recessive or multiplicative, each marker was 
included in a multiplicative model (i.e. AA = 0, AB = 1 and BB = 2). Observed P-values 
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range 27.6 - 83.6
Sex - no (%)
male 316 (60.7%)
female 205 (39.3%)
Arm - no (%)
CAPOX-B 264 (50.7%)
CAPOX-B plus cetuximab 257 (49.3%)
Serum lactate dehydrogenase level - no (%)
normal* 307 (58.9%)
above normal* 213 (40.9%)
* according to the cutoff values of each individual center
140 141
This gene encodes an integral membrane protein that converts lysophosphatidic acid 
(LPA) to phosphatidic acid (PA), the second step in de novo phospholipid biosynthesis, 
the major constituent of the cell-membrane (http://www.ncbi.nlm.nih.gov). 
Additionally, LPA is a potent mitogen that has been linked to the development and 
progression of breast cancer.10 When these markers have been fully evaluated (i.e. 
functional analysis on gene-function or gene-expression level) and their associations 
have been confirmed in an independent cohort, they could be used to optimize 
selection of ACC patients for CAPOX-B treatment. 
This is the fist pharmacogenomic genome-wide study on the efficacy of palliative 
therapy for ACC. Unfortunately, the associations between the SNPs and PFS did not 
reach formal statistical significance at the 5 x 10-8 level, but a trend toward significance 
was found for 3 SNPs. This could be the result of insufficient power, possibly in 
combination with very stringent correction for multiple testing. Otherwise, the results 
may simply be false positive findings based upon the large number of statistical tests. 
There are 47 more patients that have to be genotyped, and were therefore not 
10-7, respectively; Table 2 and Figure 1), but did not reach the formal significance level 
of P < 5 x 10-8. These three SNPs were in linkage. None of ten most significant SNPs 
showed a significant interaction with treatment arm. The inflation factor for the 
analysis was 0.98, indicating that there was no population stratification or other bias 
in the analysis. 
In Figure 2, the Kaplan-Meier curves are shown for the most significant SNP, rs2936519. 
Median PFS was 8.1 months (95%CI, 6.6 to 9.7 months) and 11.4 (95%CI, 10.4 to 12.4 
months) for C/T and C/C genotypes, respectively. Only one patient was homozygous 
for the T-allele ( this patient did contribute to the P-value, but is not shown in figure 2). 
Discussion
In this first analysis, three SNPs – that are in linkage – located at 8p23.1 showed a trend 
toward significance for association with PFS in ACC patients treated with CAPOX-B. 
The top three most significant SNPs are not located within a known gene, but are 
approximately 20 kbp downstream of the AGPAT5 gene (1-acylglycerol-3-phosphate 
O-acyltransferase 5, also known as lysophosphatidic acid acyltransferase, epsilon). 
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Table 2    Top 10 SNPs with lowest P-values for association with PFS in a  
Cox-proportional hazards model with age, gender and treatment arm  
as covariates 
marker chr position gene allele 
frequency
P-value allelic HR (95%CI)
rs2936519 8 6626650 n.a. 0.104 1.24 x 10-7 0.545 (0.435 – 0.682)
rs2912024 8 6626309 n.a. 0.105 1.38 x 10-7 0.547 (0.437 – 0.685)
rs2978931 8 6625491 n.a. 0.101 6.75 x 10-7 0.561 (0.447 – 0.705)
rs4850159 2 131442241 ARHGEF4 0.136 2.58 x 10-6 0.627 (0.516 – 0.762)
rs6734725 2 46751074 n.a. 0.350 2.99 x 10-6 0.713 (0.619 – 0.822)
rs17688362 18 39999678 n.a. 0.185 4.68 x 10-6 0.657 (0.548 – 0.786)
rs17444829 4 113593423 n.a. 0.133 5.49 x 10-6 1.556 (1.285 – 1.884)
rs11730442 4 113581912 ALPK1 0.132 6.62 x 10-6 1.554 (1.282 – 1.884)
rs10089490 8 92317629 n.a. 0.061 7.20 x 10-6 1.849 ( 1.413 – 2.420)
rs17395916 4 86945264 ARHGAP24 0.402 7.61 x 10-6 0.739 (0.647 – 0.844)
Abbreviations: ALPK1, α-kinase 1; ARHGAP24, Rho GTPase activating protein 24; ARHGEF4, Rho guanine 
nucleotide exchange factor 4; chr, chromosome; 95%CI, 95% confidence interval; HR, hazards ratio; n.a., marker 
is not located within a gene
Figure 1    Manhattan plot of -log
10
(P-values) from the Cox-proportional hazards 
model adjusted for age, gender and treatment arm  





Since all patients in our study were treated with CAPOX-B, no distinction could be 
made between prognostic (i.e. not related to treatment) and predictive (i.e. related to 
treatment) effects. If true significant effects would be found, the effects of the markers 
could therefore also be unrelated to therapy. However, it would be difficult to test 
whether the associations are predictive or prognostic, since a no-treatment control 
arm in the first-line treatment of ACC would be unethical. When the same associations 
would be found in a cohort of ACC patients that are treated with other agents as 
first-line therapy, the markers could then be regarded as prognostic rather than 
predictive. However, such a cohort is not feasible with fluoropyrimidines currently 
being the backbone of first-line ACC treatment. 
The top three SNPs are in linkage, and are located near the AGPAT5 gene, which 
encodes a protein that converts LPA into PA, and is involved in phospholipid 
biosynthesis. It has to be elucidated whether these SNPs have an effect on the 
expression or function of this gene, or whether these SNPs are in linkage with a 
functional SNP in this gene. Possibly, fine-mapping or imputation in the region around 
the three significant SNPs could help finding the true causative SNP. 
LPA has been linked to development and progression of breast cancer. Downstream 
of LPA receptor activation, the GTPase rho is activated.16 Two other genes with SNPs 
that are in the top 10 of most significant SNPs are possibly also involved in this 
signaling route (ARHGEF4 and ARHGAP24), suggesting that the LPA signaling pathway 
could be important for CAPOX-B efficacy or prognosis of ACC. Moreover, as 
phospholipids make up an essential component of the cell-membrane, altered 
biosynthesis of phospholipids could have an effect on (tumor) cell division and 
therefore also efficacy of chemotherapy. However, such reasonings remain highly 
speculative, and the mechanism underlying the associations found in this study 
requires fundamental research.
Two SNPs in the top 10 are located in or near the gene encoding α-kinase 1 (ALPK1), 
which has been implicated in epithelial cell polarity and exocytic vesicular transport 
towards the apical plasma membrane.17 It is not clear how ALPK1 could be linked to 
(colorectal) cancer or the mechanism of action of CAPOX-B. Also, the consequence of 
the other SNPs in the top 10 is unknown. 
For this study, we included patients who were treated with CAPOX-B as well as patients 
who were treated with CAPOX-B plus cetuximab. In our analysis, treatment allocation 
was included as a covariate. It is unlikely that the effects of the SNPs are linked to the 
efficacy of cetuximab, since none of the polymorphisms showed significant interaction 
with the treatment arm. 
In conclusion, even though these results possibly identify a novel region that is 
associated with the efficacy of CAPOX-B, further analyses are required before firm 
conclusions can be made. A prediction model using the data from this study will 
probably better discriminate patients with long from short PFS than individual SNPs. 
included in this analysis. Possibly, including these patients would increase power 
enough for the results to become significant. 
On the other hand, it is unlikely that a complex phenotype such as drug response 
depends on only a handful single SNPs. As with other complex traits, a series of 
polymorphisms could contribute to the phenotype. A predictive model can be built 
to assess the combined contribution of SNPs to the phenotype – which will be further 
evaluated in our study. That this could be a feasible approach is illustrated by a recent 
example on human height, in which it initially seemed that only a few SNPs were 
associated with this phenotype. However, the explained variability was only ~5%.11-13 
When other genetic information from the same genome-wide studies was included 
in a predictive model for human height, 45% of the variability could be explained. This 
strategy has also been applied for the risk of schizophrenia and bipolar disorder.14 
Validation of such a predictive model in an independent cohort is very important 
because of the possibility of false positive findings due to the huge number of 
polymorphisms that are included, even though internal cross-validation can be used 
while developing the predictive model.15 
Genome wide association study of the efficacy of CAPOX-B
9
Chapter 9
Figure 2    Kaplan Meier curves of PFS for the rs2936519 SNP   
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It is evident that drug response varies among individual cancer patients, but the 
mechanisms underlying this variability are not fully understood. However, since many 
differences between people have a genetic background, it is likely that drug response 
also has a genetic – and therefore heritable – component. Over fifty years ago, the 
term pharmacogenetics was introduced when describing hemolytic anemia during 
treatment with primaquine for subjects with deficiency of the G6PD enzyme. Another 
classic example is the prolonged muscular relaxation following the administration of 
suxamethonium to patients who are deficient for the butyrylcholinesterase enzyme.  
In the early nineties, the molecular basis of variation in drug response in oncology was 
unraveled by the discovery of single nucleotide polymorphisms (SNPs) in genes 
encoding detoxifying enzymes. Severe toxicities of 6-mercaptopurine (6MP) and 
5-fluorouracil (5FU) were related to rare variants in the genes encoding thiopurine-S-
methyltransferase (TPMT) and dihydropyrimidine dehydrogenase (DPD), respectively.1-4 
In both cases, SNPs cause decreased functionality of these key detoxifying enzymes4-6, 
resulting in exposure to these drugs exceeding their toxic thresholds, leading to the 
development of severe toxicities. 
Many other pharmacogenetic markers are now identified that are correlated with 
drug response – being either toxicity or efficacy. However, unlike somatic molecular 
biomarkers7, and beside germline polymorphisms in the TPMT gene, no other germline 
polymorphism is applied in routine clinical practice to guide optimal use of anti-cancer 
drugs.8 The question is: why? In this discussion, the following fundamental points are 
evaluated:
• What are the results of pharmacogenetic studies when placed in perspective? 
•  Are pharmacogenetic studies properly designed in relation to the expected 
outcome? 
• Are the results of pharmacogenetic studies ‘ready to use’? 
• And finally: what would be the ideal pharmacogenetic study? 
The results of pharmacogenetic studies in perspective
Publication of results
Many studies have been published describing associations between genetic 
polymorphisms and drug response. In chapter 2 and 5, an overview is given for VEGF 
and EGFR targeting drugs, and for chemotherapeutic agents, respectively. These 
chapters describe the positive – or statistically significant – results of these studies, 
which therefore may be used as a tool for selecting promising predictive 
polymorphisms for future research. 
However, in many pharmacogenetic studies, an important aspect is frequently 




The hazard ratios for these polymorphisms were all very close to 1, indicating that the 
lack of association was not merely a question of (lack of) power. 
Even more striking was our finding that the high affinity Valine-allele of the FCGR3A 
polymorphism was associated with decreased progression-free survival (PFS) in 
metastatic colorectal cancer patients treated with cetuximab, bevacizumab and 
chemotherapy (chapter 3). This result was opposite of the expected outcome, as 
previous studies showed beneficial effect of the monoclonal antibodies cetuximab, 
rituximab and trastuzumab for the Valine allele compared with the Phenylalanine 
allele.13-16 An explanation for this opposite result could be our incomplete understanding 
of the mechanism of action of cetuximab. 
As a side note, the association of the FCGR3A polymorphism in the CAIRO2 study could 
be less unexpected than considered at first glance: The effect of cetuximab in the 
CAIRO2 was unintentionally decreasing PFS. The Valine allele was indeed associated 
with increased ‘efficacy’ – being decreased PFS – and therefore in line with the original 
hypothesis. 
In general terms, careful selection of an optimal replication cohort and confirmation 
of initial findings is crucial before solid conclusions can be drawn. Factors that vary 
almost by definition between cohorts, such as previous treatment, concomitant 
treatment and other clinical variables such as disease state, should be considered 
carefully. Other factors, such as gender, age, prognostic variables and other (somatic) 
genetic variation, should be used in covariate analyses to correct for confounding. 
Simply attempting to confirm an association between one polymorphism and one 
drug without considering other factors is inappropriate. 
The design of pharmacogenetic studies
Choice of polymorphisms
Most pharmacogenetic studies to date include a selection of candidate polymorphisms 
in so-called candidate genes. These genes are selected based upon knowledge of the 
pharmacokinetics and pharmacodynamics of the drug. The candidate polymorphisms 
generally have either impact on the function or the expression of the enzyme 
encoded by the gene.17 A more advanced method is to select tagging polymorphisms 
in candidate genes, in order to cover as much genetic variation with an optimal 
number of polymorphisms. To date, however, only single nucleotide polymorphism 
(SNPs), some short repeat polymorphisms and some insertion/deletion polymorphisms 
are studied in pharmacogenetic studies. Other heritable genetic variation, such as 
copy number alterations, could also play an important role in variability of drug 
response.18
in the same way as we selected five polymorphisms for our analysis for chapter 3. 
Regularly, ten or even more polymorphisms are selected for analysis in pharma-
cogenetic studies. The most striking results are subsequently highlighted in the 
results and discussion sections – usually being the significant findings – whereas the 
non-significant results are often not shown nor discussed, apart from the comment 
that they were not significant. 
There are two problems that result from highlighting significant results and not 
showing non-significant results. Firstly, the lack of confirmation of association between 
a polymorphism and drug response (that is: results from study A are not found in 
study B) is easily overlooked because of the attention paid to the other, significant, 
findings. As a result, the initial publication describing the significant association (study 
A) remains apparently undisputed, whereas doubts should have been placed based 
upon lack of confirmation in the second study (study B). Secondly, ‘absence of 
evidence’ does not necessarily imply ‘evidence of absence’.9 In an underpowered 
study, a lack of significant association could mean anything ranging from an actual 
lack of association to falsely missing a true association. A table with all results including 
the effect sizes would be very useful for gathering all available information to assess 
the quality of the evidence for a given polymorphism. 
Confirmation
Successful replication of initial findings is a requirement before solid conclusion 
regarding a polymorphism can be made, as these initial findings could have been 
false positives. With this in mind, we investigated the initial results from a previous 
hypothesis generating study in metastatic colorectal cancer patients who were 
treated with oxaliplatin based therapy (the CAIRO study10). In this study, 81 
polymorphisms in genes that encode DNA repair enzymes were studied.11 
Polymorphisms in the ATM and ERCC5 genes were significantly associated with PFS. In 
chapter 6, we show that the initial results could not be replicated in patients 
participating in another study (CAIRO2)12, from which we concluded that the initial 
significant results were probably false-positive findings. As a critical note, it could be 
possible that some of the non-significant results from the initial study were actually 
associated with response, but were missed because of lack of power. Another strategy 
of replication – such as replicating all polymorphisms instead of only the significant 
polymorphisms – could have revealed whether any of the initial 81 polymorphisms 
were associated with response. These, on their turn would have required confirmation 
in another cohort, indicating the complexity of the problem. 
For chapter 8, we selected 17 polymorphisms that had previously been associated 
with the response to fluoropyrimidines, oxaliplatin or bevacizumab. Surprisingly, none 





and other fluoropyrimidines – including our study presented in chapter 8 – include 
only polymorphisms in TYMS, DPD and MTHFR, thereby ignoring many other potentially 
relevant enzymes. 
In some cases, the mechanism of drug action is not completely understood. In this 
thesis, the pharmacogenetics of the monoclonal antibody cetuximab has been 
studied. Cetuximab was originally developed to inhibit the signaling of the growth 
factors EGF and transforming growth factor α (TGFα), by blocking their receptor 
EGFR.26 Both these growth factors are crucial for cell proliferation, and therefore also 
tumor growth. Since cetuximab is a monoclonal antibody of the IgG1 type, immune 
responses such as antibody-dependent cell-mediated cytotoxicity (ADCC) or 
activation of immune cells may also be triggered. Indeed, in vitro research models 
showed that cetuximab and the therapeutic monoclonal antibody against CD20, 
rituximab, trigger ADCC by NK cells, which was most pronounced for the FCGR3A 
Valine allele.27,28 
However, the clinical relevance of these findings relies on the assumption that ADCC 
plays a role in the mechanism of action of cetuximab, ignoring other possibilities in 
other settings. For instance, we and others showed that NK cells are not present in 
colorectal cancer tissue, whereas these tumors are infiltrated by macrophages.29 It has 
been described that tumors are infiltrated by a specific type of macrophages, tumor 
associated macrophages, which have anti-inflammatory and tumor-promoting 
properties.30,31 In experiments that we undertook with a model system for tumor 
associated macrophages, we show that cetuximab stimulates the release of anti-in-
flammatory – and possibly also pro-angiogenic32 – cytokines by type 2 macrophages 
(chapter 4). We hypothesized that the effect of these tumor associated macrophages 
in the CAIRO2 study was different from the previously published studies with 
cetuximab used in other settings13,33,34, as patients in the CAIRO2 study received 
bevacizumab, capecitabine and oxaliplatin combined with cetuximab, whereas the 
other studies included cetuximab as monotherapy or in combination with 
irinotecan.13,33,34 
The results described in chapter 4 – that cetuximab mediates production of anti-in-
flammatory cytokines by macrophages – indicates that the exact mechanism of 
action of cetuximab is not fully understood. Importantly, the development and 
application of therapeutic antibodies with increased affinity for the FCGR2A and 
FCGR3A receptors could be impacted by this finding.35,36
In summary, when our knowledge of the pharmacokinetics and pharmacodynamics is 
incomplete, it is even more challenging to select polymorphisms that are involved in 
drug response. Selecting only known polymorphisms in known genes could easily 
lead to an underestimation of the genetic impact on drug response. 
The first published pharmacogenetic studies reported associations between one 
single polymorphism in one single gene and drug response.2,3 Current studies include 
many polymorphisms in many potentially relevant genes.19-21 This candidate gene 
procedure can be taken one step further with the candidate pathway method, in 
which candidate polymorphisms in candidate genes are selected that encode 
enzymes involved in the entire – known – pathway for a (class of) drug. This approach 
was applied in the previous CAIRO study using polymorphisms in genes that encode 
enzymes involved in DNA repair11, but the results could not be confirmed (chapter 6). 
The weakness of the candidate polymorphism, candidate gene and candidate 
pathway methods, is that these depend on mechanistic knowledge and understanding 
of drug response. 
Pharmacokinetics
For a drug of which the rate-limiting detoxifying step is determined by a single 
enzyme, an alteration in function or expression of that enzyme may have direct 
impact on plasma drug levels. However, many drugs are absorbed in the gastro-intes-
tinal tract, distributed over tissues and cells, metabolized and excreted by many 
different enzymes and transporters. Also, metabolism at steady-state may differ from 
metabolism at first exposure, due to reduction and/or induction of enzymatic activity 
after some time.22 Since the relevant pharmacokinetic enzymes are usually determined 
in in vitro models or during the first phase clinical studies, our knowledge of which 
enzymes are important in the daily clinical setting may be inadequate for the 
candidate gene method. However, the most promising germline variants in oncology 
still are CYP2D6 polymorphisms for tamoxifen efficacy, UGT1A1 polymorphisms for 
irinotecan toxicity, CYP3A4 polymorphisms for dasatinib efficacy, TPMT polymorphisms 
for 6-mercaptopurine toxicity and DPYD polymorphisms for fluoropyrimidine toxicity 
– all genes encoding pharmacokinetic enzymes.8 Moreover, guidelines have been 
presented for the implementation of pharmacogenetics in daily routine – and these 
guidelines also include only polymorphisms in the pharmacokinetic enzymes CYP2D6, 
CYP2C9, CYP2C19 and UGT1A1.23 
Pharmacodynamics
In most cases, the principal mechanism of action of a drug is relatively well studied. 
For capecitabine for instance, the efficacy relies on RNA or DNA damage caused by 
the incorporation of fluorinated uracil residues in RNA and DNA, and by the inhibition 
of the enzyme thymidylate synthase (TYMS).24 However, at least both the pyrimidine 
and folate metabolism routes are involved, in which many enzymes play a role.25 
The pyrimidine and folate metabolism are crucial for cell proliferation, and it is likely 
that endogenous feedback loops may influence these pathways, and therefore the 





possibly leading to spurious findings. Internal validation – such as cross-validation – and 
confirmation in another cohort is required before definite conclusions can be drawn. 
The applicability of the results 
From retrospective analyses, it was concluded that cetuximab and panitumumab are 
ineffective for metastatic colorectal cancer patients with a somatic activating KRAS 
mutation.39 This even led to the alteration of the drug labels of both agents. The 
success of the implementation of the KRAS mutation to guide therapy is due to the 
fact that very few patients with KRAS mutations responded to either cetuximab or 
panitumumab. A KRAS mutation is therefore highly predictive for non-responders, 
and therefore readily applicable to exclude patients from cetuximab or panitumumab. 
Even though testing for KRAS mutations is widely accepted based upon retrospective 
studies, a recent analysis showed that cetuximab is effective in patients with the KRAS 
G13D mutation – which was previously considered as one of the activating mutations.40 
This finding demonstrates that patients with the KRAS mutated tumors are less 
homogeneous with respect to their response to anti-EGFR therapy than initially 
thought. It is also a lesson that it takes more to validate a biomarker than only 
retrospective analyses of several randomized studies, even when each of these 
included several hundreds of patients. 
The association between TPMT and DPYD polymorphisms and the incidence of severe 
toxicities of 6-MP and fluoropyrimidines, respectively, is relatively strong. However, 
the genetic variants involved are very rare (1% or less), and more importantly, no 
prospective studies have determined what the alternative should be for patients at 
risk of toxicity. Based upon retrospective analysis, 50% and 90% lower dosing of 6MP 
is suggested for TPMT heterozygotes and homozygotes, respectively.41 In the most 
recent pharmacogenetics guide of the WINAp, a 50% dose reduction is suggested for 
heterozygotes for DPYD polymorphisms treated with 5FU, UFT and capecitabine, 
whereas alternative therapy is advised for homozygotes.   
 
For most other pharmacogenetic markers, the effect on drug response is usually 
expressed as an odds-ratio (OR) or hazards ratio (HR). The effect sizes are relatively 
small - frequently in the order of 1.5 to 2.0, meaning that the chance of response for 
patients with one genotype is 1.5 to 2.0 higher compared with patients with the other 
genotype. Even though such results may be statistically significant, they are not 
readily applicable. As an example, there are many studies that report that the efficacy 
of gefitinib for NSCLC is increased for patients harboring a low number of CA-repeats 
in the EGFR gene.42 Even though all currently available studies show the same results, 
this polymorphism is not used to optimize gefitinib treatment. 
Method of statistical analysis
Currently, most pharmacogenetic studies apply simple statistical analyses for the 
associations between the polymorphisms and drug response. Usually, Chi square and 
Kaplan Meier tests are applied for univariate analyses. For multivariate analyses with 
possible confounders such as age and gender, logistic or Cox proportional hazard 
regression models are used. These types of analyses have in common that only the 
effect of one single polymorphism on drug response is studied. 
As described above, many biological molecules – such as metabolic enzymes, drug 
transporters or drug targets – contribute to drug response. It is likely that alterations 
in these enzymes have only impact on drug response under the condition that other 
alterations are also present. As a hypothetical example: for a drug that is metabolized 
by two enzymes, decreased activity of one of these enzymes may have no impact on 
metabolic activity, as the other enzyme may take over. Only when both enzymes have 
decreased activity, total metabolism could be impacted, resulting in increased plasma 
levels and potentially increased toxicity or efficacy. 
This concept is known as gene-gene interaction or epistasis, and can be analyzed 
using statistical interaction – not to be confused with biological interaction between 
enzymes.37 In the example described above with only two enzymes, the interaction 
can be detected relatively easily by including an interaction in a regression analysis. 
When the number of polymorphisms studied increases, the possible number of 
interactions increases exponentially, making it not feasible to use parametric statistical 
analyses such as regression. Other non-parametric methods exist, such as classification 
and regression analysis (CART) or multifactor dimensionality reduction (MDR) 
analysis.38 The underlying concepts of these methods were described and illustrated 
in chapter 7. 
In chapter 8, the MDR method was applied to the CAIRO2 study for the association 
between candidate polymorphisms in candidate genes for the efficacy of capecitabine, 
oxaliplatin and bevacizumab. Even though this study may not have been optimal in 
terms of selection of polymorphisms – by selecting 17 polymorphisms, other 
potentially relevant polymorphisms may have been overlooked, as described above 
– an interaction between the VEGF +405G>C and TYMS TSER polymorphisms was 
found. The exact underlying biological mechanism of this interaction – which was 
detected using a statistical method – is not exactly understood, but it is apparent that 
the impact of either of these polymorphisms depends on the presence of the other, 
and vice versa. 
Studying interaction seems more rational compared with the ‘classical’ method of testing 
one polymorphism at the time, since it takes the complexity underlying drug response 
into account. As a consequence, the results from such studies may provide more robust 
results that have more chance of successful replication. Unfortunately, the interaction 





The ideal pharmacogenetic study
Before a genetic test could be applied to adequately predict response to treatment, 
prospective testing would be required, as described above. The question remains: 
what would be the ideal study to find the optimal pharmacogenetic marker(s)? 
In this thesis, different approaches have been described for detecting potentially 
relevant pharmacogenetic markers: attempting to validate previous findings (chapter 
6), developing a predictive model (chapter 3) and developing a genetic interaction 
model (chapter 8). For these chapters, the candidate polymorphism method was 
applied. As described earlier, this method is not optimal. 
In chapter 9, we describe another approach - a genome wide association study 
(GWAS). In this study, patients from the CAIRO2 study were genotyped for more than 
700.000 polymorphisms across the entire genome. For the statistical analysis, each 
polymorphism was initially individually tested for correlation with PFS. No formal 
significant results (i.e. below the threshold of P = 5 x 10-8) were found, but three SNPs 
located on chromosome 8, down-stream of the AGPAT5 gene, had P-values close to 
this threshold. Further research is required before it can be concluded that this is 
indeed a true association, and that these SNPs affect the function or expression of 
this gene. 
However, as described above, considering each polymorphism as a single variable 
could underestimate the impact on drug response. Therefore, a predictive model will 
be developed, for which the top 100 SNPs with the lowest P-values will be included. 
Such an approach of developing a predictive model using GWAS data has recently 
been applied to explain variability in human height. Initial results from GWAS studies, 
being the associations between individual polymorphisms and human height, could 
explain only ~5% of the variation in human height.43-45 In contrast, a model that 
included also non-significant SNPs could explain 45% of the variation, indicating that 
the use of other non-significant SNPs to explain variability between patients is a 
feasible strategy.46 
As previously described, this predictive model requires confirmation and preferably 
also prospective testing - such as described previously for the genetic profile - before 
it could be applied in clinical practice for selecting treatment for metastatic colorectal 
cancer patients. 
A design such as applied in chapter 9 seems the most promising type of pharmaco-
genetic study: using a GWAS instead of candidate polymorphisms, and developing a 
predictive model including interaction. With the rapid development of whole genome 
genotyping platforms, it is likely that the costs of whole genome genotyping will 
drop within the next decade, making it increasingly affordable. Even whole genome 
sequencing might become feasible in the future, so that the entire genome of patients 
becomes available instead of a (large) selection of SNPs on a chip. For such studies 
It would be helpful if the response rate or survival of patients with an unfavorable 
genotype could be compared with the response rate of untreated patients. In that 
way, the absolute efficacy of the therapy for each genotype could be assessed and 
compared with no treatment. 
Predictive models including genetic and non-genetic information could help to 
better discriminate responders from non-responders. In chapter 3, we describe the 
development of a predictive model for cetuximab efficacy. As this model was 
developed using the CAIRO2 study in which patients were randomized to receive 
cetuximab or no cetuximab added to CAPOX-B, predictive variables for cetuximab 
(related to the outcome of therapy) could be discriminated from prognostic variables 
(variables that are related to survival regardless of the therapy). Surprisingly, KRAS 
mutation status was no predictor in this model, whereas the FCGR3A Phe158Val 
polymorphism, gender and white blood cell count were included in the model. This 
predictive model cannot be generalized for cetuximab therapy, since treatment with 
a combination of cetuximab and bevacizumab, as in the CAIRO2 study, will not be 
used in the clinic given the inferior outcome. 
In chapter 8, we describe the results from a genetic interaction analysis for the 
efficacy of capecitabine, oxaliplatin and bevacizumab. A genetic profile consisting of 
two polymorphisms, VEGF +405G>C and TYMS TSER, was associated with PFS. This 
profile was developed in the standard treatment arm of the CAIRO2 study. Since a 
no-treatment control arm would be unethical in the first-line treatment of metastatic 
colorectal cancer, no conclusion could be drawn whether the genetic profile was 
predictive for the efficacy of capecitabine, oxaliplatin and bevacizumab, or also 
prognostic (i.e. associated with outcome regardless of treatment). Because the 
polymorphisms in the genetic profile are in the pathway of the mechanism of action 
of bevacizumab (the VEGF polymorphism) and capecitabine (the TYMS polymorphism), 
a control group that was treated with other agents would also be possible. However, 
as long as a fluoropyrimidine is the cornerstone of first-line metastatic colorectal 
cancer treatment, this will not be possible. 
Apart from the question whether the genetic profile is predictive or prognostic, not 
only confirmation in another cohort would be required for the genetic profile before 
it could be applied in clinical practice to select patients for treatment. Prospective 
studies would also be needed to show that genotype guided treatment is better that 
standard care. A parallel could be drawn with drug development, in which it is not 
uncommon that compounds – even though these had been rationally designed and 
showed clinical efficacy in non-controlled studies – fail to demonstrate efficacy when 
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with enormous amounts of genotyping data, adequate quality and appropriate size 
of the cohort remains paramount: preferably patients included in large prospective 
trials should be included. 
Conclusion
In this thesis, different pharmacogenetic studies are presented for the efficacy of 
systemic treatment of metastatic colorectal cancer. The results that were obtained for 
cetuximab prompted the search for a mechanistic explanation, which could be the 
activation of tumor promoting macrophages mediated by cetuximab. 
Different approaches were used to find pharmacogenetic predictors for the efficacy 
of CAPOX-B, such as genetic interaction and a GWAS. A combination of a GWAS and 
development of a predictive model including interaction seems the most promising 
approach for a successful pharmacogenetic study. It remains important to confirm 
initial findings in a separate cohort. For a pharmacogenetic test to be implemented in 
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Even though treatment of several types of solid tumors has improved in the past few 
years with the introduction of the monoclonal antibodies against the epidermal 
growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), the 
clinical benefit of these targeted therapies is modest. Pharmacogenetics has the 
potential to select patients with higher chance of response to agents that target these 
pathways. Chapter 2 provides an overview of germ-line variations in genes that are 
involved in the pharmacodynamics of the anti-EGFR monoclonal antibodies cetuximab 
and panitumumab and the anti-VEGF monoclonal antibody bevacizumab, and which 
may underlie variable anti-tumor response. Based upon this review, we suggest 
further investigations on the prognostic or predictive role of the following 
polymorphisms for cetuximab: FCGR2A His131Arg, FCGR3A Phe158Val, EGF 61A>G, EGFR 
CA14-22 and CCND1 870G>A.
In chapter 3, we describe the association between these polymorphisms and pro-
gression-free survival (PFS) in 576 advanced colorectal cancer patients who were 
treated in the phase III CAIRO2 study of the Dutch Colorectal Cancer Group with 
capecitabine, oxaliplatin and bevacizumab or the same regimen plus cetuximab. The 
analysis was done with regard to KRAS mutation status, since this is a strong predictor 
for cetuximab efficacy. In the cetuximab arm, the FCGR3A 158 valine-allele was 
associated with a decreased PFS, both in the overall population and in the subgroup 
with KRAS wild-type tumors (HR=1.56, 95%CI=1.14-2.15 and HR=1.57, 95%CI=1.06-2.34, 
respectively) and with a decreased incidence of grade 2-3 skin toxicity (OR=0.48, 
95%CI=0.24-0.94). This association was not in agreement with previous research, in 
which the valine-allele was associated with increased benefit from monoclonal 
antibody therapy. 
The EGFR ≥20 genotype was associated with a decreased PFS, both in the overall 
population and in the subgroup with KRAS wild-type tumors (HR=1.60, 95%CI=1.17-
2.19 and HR=1.58, 95%CI=1.06-2.35, respectively). The FCGR3A and EGFR polymorphisms 
were not associated with PFS in patients treated without cetuximab. In patients with 
KRAS mutated tumors, the EGF 61G-allele was associated with decreased PFS in the 
cetuximab arm, and increased PFS in the no-cetuximab arm (HR=2.22, 95%CI=1.24-
3.96 and HR=0.59, 95%CI=0.36-0.98, respectively). We conclude that EGFR, FCGR3A and 
EGF polymorphisms are associated with PFS in advanced colorectal cancer patients 
treated with cetuximab, bevacizumab and chemotherapy, and that these results 
should be confirmed before these markers are used in general practice.
Since the association between the FCGR3A Phe158Val polymorphism was opposite 
from expected, as described in chapter 3, we performed in vitro experiments to 
better understand the underlying mechanism, which we describe in chapter 4. 
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underlying both techniques, we also illustrate their application in a recent pharmaco-
genetic study on pharmacogenetic determinants on sunitinib induced toxicity. 
In order to study the contribution of polygenic variation in relation to response to 
capecitabine, oxaliplatin and bevacizumab in advanced colorectal cancer patients, 
we applied the multifactor dimensionality reduction analysis in chapter 8. Based 
upon the data presented in chapter 2 and chapter 5, a selection of 17 polymorphisms 
in genes encoding drug targets, pathway molecules and detoxification enzymes was 
analyzed in 279 advanced colorectal cancer patients treated with capecitabine, 
oxaliplatin and bevacizumab in the CAIRO2 study. Multifactor dimensionality reduction 
analysis was used to identify a genetic interaction profile for PFS. A genetic interaction 
profile consisting of the TYMS enhancer region and VEGF +405G>C polymorphisms 
was significantly associated with PFS. Median PFS was 13.3 (95%CI, 11.4 to 15.3) and 9.7 
(95%CI, 7.6 to 11.8) months for the beneficial and unfavorable genetic profiles, 
respectively, corresponding to a hazards ratio for PFS of 1.58 (95%CI, 1.14 to 2.19). None 
of the studied polymorphisms were individually associated with PFS. We conclude 
that these results support a genetic interaction between the TYMS enhancer region 
and VEGF +405G>C polymorphisms as a predictor of the efficacy of capecitabine, 
oxaliplatin and bevacizumab in advanced colorectal cancer patients.
In chapter 9, we describe the preliminary results from a genome-wide association 
study to find single nucleotide polymorphisms that are associated with the efficacy of 
capecitabine, oxaliplatin and bevacizumab. We used germline DNA from 547 patients 
participating in the CAIRO2 study. Whole-genome genotyping was performed using 
700k Illumina OmniExpress BeadChip arrays. Associations between single nucleotide 
polymorphisms and PFS were tested using Cox-proportional hazard models. 
Associations were considered significant when P < 5 x 10-8. Three single nucleotide 
polymorphisms located at 8p23.1 showed a trend toward significance for association 
with PFS (rs2936519, P = 1.24 x 10-7; rs2912024, P = 1.38 x 10-7 and rs2978931, P = 6.75 x 
10-7). These SNPs are 20 kbp downstream of the AGPAT5 gene, which encodes a protein 
that converts lysophosphatidic acid (a mitogen that has been linked to cancer in 
different ways) to phosphatidic acid, which is also involved in phospholipid 
biosynthesis. We conclude that these results possibly identify a novel genetic predictor 
for the efficacy of capecitabine, oxaliplatin and bevacizumab. However, further 
analyses are required before definitive conclusions can be made based upon these 
data.  
General discussion
In chapter 10, the results presented in this thesis, as well as the question why hardly 
any pharmacogenetic test is currently applied in routing patient care, are discussed. 
Many pharmacogenetic studies have been published, and the significant results get 
most attention. Results from such studies are usually not validated in a systematic 
Therapeutic monoclonal antibodies, such as cetuximab, may trigger in vitro immune 
responses such as antibody-dependent cell-mediated cytotoxicity (ADCC) by natural 
killer (NK) cells through binding of their Fc region to Fc-gamma receptors. As solid 
tumors may be infiltrated by tumor-promoting tumor associated macrophages, 
monoclonal antibodies could also mediate tumor-promoting effects through the Fc 
region-FCGR interaction. In 10 tumor samples of previously untreated stage III 
colorectal cancer patients, we indeed observed infiltration of tumor-associated 
macrophages (CD68+CD163+ cells), but no NK cells. In a laboratory model for tumor-
associated macrophages, we cultured type 2 macrophages (MF2s) from monocytes 
derived from healthy donors. LPS activated MF2s produced IL10, IL8 and VEGF, but no 
IL12p70. Activation of MF2s showed a cetuximab concentration dependent effect in 
an A431/MF2/cetuximab co-culture, whereas no activation was observed for the A431/
MF2/rituximab co-culture. There was lower down-regulation of CD16 for FCGR3A 
158-valine carriers compared with FCGR3A 158-phenylalanine homozygotes 
(P=.048). These results indicate that tumor-promoting macrophages can be 
activated by therapeutic monoclonal antibodies. This could implicate the clinical 
development of engineered monoclonal antibodies with increased affinity for 
Fc-gamma receptors.  
Capecitabine, oxaliplatin and bevacizumab
Chapter 5 gives an overview of germline polymorphisms genes that have been 
studied most extensively in anti-cancer chemotherapy. Even though many pharmaco-
genetic association studies have been published, we conclude that there is need for 
more research. In particular, there is need for replication of results and development 
of predictive models. Prospective trials are required to establish the clinical value and 
cost-effectiveness of pharmacogenetic tests in oncology. 
A previous study indicated that SNPs in the genes encoding ataxia telangiectasia 
mutated (ATM rs1801516) and excision repair cross-complementing group 5 (ERCC5 
rs1047768) were significantly associated with PFS in advanced colorectal cancer 
patients treated with second-line oxaliplatin combined with capecitabine. We were 
not able to validate the results of these SNPs in the CAIRO2 study, as described in 
chapter 6. We conclude that these SNPs have no relevant impact on the PFS of oxali-
platin-based therapy for advanced colorectal cancer patients, and that the negative 
result of this study underlines the importance of validating and reporting the findings 
from retrospective explorative studies.
Disappointing results from replicating pharmacogenetic association studies have 
prompted the search for novel statistical techniques to analyze the data, while taking 
into account the biological complexity underlying drug response. In chapter 7, we 
describe two of these techniques – multifactor dimensionality reduction and 
classification and regression tree analysis. In addition to describing the concepts 
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way. Successful replication of results is important, since initial results could have been 
false positive findings based upon the large number of statistical tests that are 
frequently applied. 
When a pharmacogenetic study is set up, decisions have to be made regarding the 
selection of polymorphisms. Usually, candidate polymorphisms in candidate genes 
are selected, which is based upon our current understanding of the mechanism of 
drug action, and this may not be optimal. Genome-wide genotyping has the 
advantage that no prior selection of polymorphisms is required.  
Apart from selecting the polymorphisms, selecting a proper statistical technique 
could also impact the results. In most pharmacogenetic studies, every single 
polymorphism is individually tested for association with drug response. Using 
statistical techniques that take gene-gene interactions into account is more rational 
and could provide more robust results.
Still most pharmacogenetic studies identify risk factors, which are probabilistic in 
nature, and cannot easily be applied to select individual patients for treatment. 
Development of pharmacogenetic predictive tests may better discriminate responders 
from non-responders and prospective testing is warranted to show that genotype-
guided therapy is better than standard care.
The ideal pharmacogenetic study would therefore be a genome-wide study in 
combination with the development of a predictive model. Confirmation of the results 
in a separate cohort remains important. For a pharmacogenetic test to be implemented 





In de afgelopen jaren zijn monoclonale antilichamen bevacizumab (gericht tegen de 
vasculaire endotheliale groei factor, VEGF), cetuximab en panitumumab (gericht 
tegen de epidermale groei factor receptor, EGFR) beschikbaar gekomen voor de 
behandeling van verschillende soorten solide tumoren. Hoewel met deze middelen 
de behandeling is verbeterd, hebben niet alle patienten even veel baat bij de 
therapie. 
Farmacogenetica – waarbij gebruik wordt gemaakt van kiembaan polymorfismen om 
het effect van geneesmiddelen te voorspellen of te verklaren – zou ingezet kunnen 
worden om patienten op te sporen met een hogere kans op goede effectiviteit van 
dit soort middelen. Hoofdstuk 2 geeft een overzicht van kiembaan polymorfismen 
in genen die betrokken zijn bij de farmacodynamiek en farmacokinetiek van 
bevacizumab, cetuximab en panitumumab. Deze polymorfismen zouden kunnen 
bijdragen aan de variabele effectiviteit van deze middelen. Op basis van dit hoofdstuk 
concluderen we dat de volgende polymorfismes onderzocht zouden moeten worden 
in relatie tot de effectiviteit van cetuximab: FCGR2A His131Arg, FCGR3A Phe158Val, EGF 
61A>G, EGFR CA14-22 en CCND1 870G>A. 
In hoofdstuk 3 beschrijven we de correlatie tussen deze polymorfismen en progressie- 
vrije overleving van 576 gemetastaseerde dikke darm kanker patienten die behandeld 
werden met capecitabine, oxaliplatin en bevacizumab, of met dezelfde combinatie 
plus cetuximab in de gerandomiseerde fase III CAIRO2 studie. Omdat KRAS mutatie 
status een sterke voorspeller is voor de effectiviteit van cetuximab, werden dit 
meegenomen in de analyses. In de behandelarm met cetuximab was het FCGR3A 
158-valine allel geassocieerd met een kortere progressie-vrije overleving, zowel in de 
totale populatie als in de subgroep van patienten met een KRAS wild-type tumor 
(HR=1,56, 95%CI=1,14-2,15 en HR=1,57, 95%CI=1,06-2,34, respectievelijk) en met een 
lagere incidentie van graad 2-3 huidtoxiciteit (OR=0,48, 95%CI=0,24-0,94). Deze 
resultaten waren niet in overeenstemming met eerdere studies, waaruit bleek dat het 
valine allel met betere effectiviteit van monoclonale antilichamen geassocieerd was.  
Het EGFR ≥20 polymorfisme was geassocieerd met een kortere progressie-vrije 
overleving, zowel in de totale populatie als in de subgroep van patienten met een 
KRAS wild-type tumor (HR=1,60, 95%CI=1,17-2,19 en HR=1,58, 95%CI=1,06-2,35, 
 respectievelijk). De FCGR3A en EGFR polymorfismen waren niet geassocieerd met 
 progressie-vrije overleving in de patienten die niet werden behandeld met cetuximab. 
In de patienten met een KRAS gemuteerde tumor was het EGF 61-allel geassocieerd 
met een kortere progressie-vrije overleving In patienten in de behandel-arm met 
cetuximab, en met een langere progressie-vrije overleving in de behandel-arm zonder 
cetuximab (HR=2,22, 95%CI=1,24-3,96 en HR=0,59, 95%CI=0,36-0,98, respectievelijk). 
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Omdat de resultaten van replicatie studies in de farmacogenetica tegen vallen, wordt 
er gezocht naar nieuwe statistische methoden om de data te analyseren, waarbij 
rekening wordt gehouden met de complexiteit die aan de geneesmiddelenwerking 
ten grondslag ligt. In hoofdstuk 7 beschrijven we twee technieken waarbij gen-gen 
interactie wordt meegenomen in de analyse: multifactor dimensionality reduction 
(MDR) en classification and regression tree (CART) analyse. Daarnaast illustreren we 
deze toepassing van deze technieken met data van een recente studie naar toxiciteit 
van sunitinib. 
De MDR analysetechniek werd toegepast om de bijdrage van verschillende 
polymorfismen op de effectiviteit van capecitabine, oxaliplatin en bevacizumab te 
bestuderen, zoals beschreven in hoofdstuk 8. Op basis van de gegevens beschreven 
in hoofdstukken 2 en 5, werden in totaal 17 verschillende polymorfismen meegenomen 
in de analyse in 279 patienten uit de CAIRO2 studie, die werden behandeld met 
capecitabine, oxaliplatin en bevacizumab. We vonden een genetisch interactieprofiel 
tussen de VEGF +405G>C en TYMS-TSER polymorfismen, welke was geassocieerd met 
progressie-vrije overleving. De mediane progressie-vrije overleving was 13,3 
(95%CI=11,4-15,3) en 9,7 (95%CI=7,6-11,8) maanden voor het gunstige en ongunstige 
profiel, respectievelijk. De bijbehorende HR voor progressie-vrije overleving was 1,58 
(95%CI=1,14-2,19). Opvallend was dat geen van de 17 polymorfismen afzonderlijk met 
progressie-vrije overleving was geassocieerd. We concluderen dat een genetisch in-
teractieprofiel tussen de VEGF +405G>C en TYMS-TSER polymorfismen de effectiviteit 
van capecitabine, oxaliplatin en bevacizumab in gemetastaseerde dikke darm kanker 
kan voorspellen. 
In hoofdstuk 9 presenteren we de eerste resultaten van een genome-wide onderzoek 
om polymorfismen op te sporen die geassocieerd zijn met de effectiviteit van 
capecitabine, oxaliplatin en bevacizumab. Hiervoor werd DNA van 541 patienten uit 
de CAIRO2 studie gebruikt. Het genotyperen werd gedaan met OmniExpress arrays 
van Illumina, waar meer dan 700.000 polymorfismen gelijktijdig kunnen worden 
bepaald. Drie polymorfismen op de genomische lokatie 8p23.1 lieten een trend zien 
voor de associatie met progressie-vrije overleving (rs2936519, P = 1,24 x 10-7; rs2912024, 
P = 1,38 x 10-7 en rs2978931, P = 6,75 x 10-7). Deze polymorfismen liggen in de buurt 
van het AGPAT5 gen, dat een enzym codeert welke betrokken is bij de omzetting van 
lysofosfatidezuur naar fosfatidezuur. Deze stoffen zijn betrokken bij de fosfolipide 
synthese en zijn eerder onderzocht bij kanker. Hieruit concluderen we dat deze 
resultaten mogelijk leiden tot een nieuwe genetische voorspeller voor de effectiviteit 
van capecitabine, oxaliplatin en bevacizumab bij de behandeling van gemetastaseer-
de dikke darm kanker. Nader onderzoek is echter nodig voordat definitieve conclusies 
kunnen worden getrokken. 
We concluderen dat polymorfismen in FCGR3A, EGFR en EGF zijn geassocieerd met de 
effectiviteit van cetuximab in combinatie met bevacizumab en chemotherapie voor 
de behandeling van gemetastaseerde dikke darm kanker. Voordat deze polymorfismes 
kunnen worden gebruikt in de dagelijkse klinische praktijk, is bevestiging van de 
resultaten vereist. 
Omdat het FCGR3A 158-valine allel onverwacht was geassocieerd met kortere 
 progressie-vrije overleving (zoals beschreven in hoofdstuk 3), hebben we in vitro 
experimenten gedaan om het onderliggende mechanisme op te helderen. Deze 
experimenten zijn beschreven in hoofdstuk 4. Monoclonale antilichamen zoals 
cetuximab kunnen immuun reacties opwekken door binding van hun Fc-staart aan 
Fc-receptoren op immuuncellen zoals natural killer (NK) cellen en macrofagen. Eerdere 
onderzoeken waren gericht op immuun effecten van NK cellen, waardoor de tumor 
werd bestreden. Wij tonen echter aan dat dikke darm kanker tumoren zogenaamde 
tumor geassocieerde, type 2 macrofagen bevatten, maar geen NK cellen. Deze 
macrofagen zijn bekend om hun tumorgroei bevorderende eigenschappen. In een 
laboratoriumsetting toonden we aan dat activatie (met de bekende activator LPS) van 
deze macrofagen leidde tot uitscheiding van IL10, IL8 en VEGF. In een experiment 
waarbij tumorcellen, cetuximab en type 2 macrofagen gezamenlijk werden 
geincubeerd, zagen wij een cetuximab concentratie afhankelijke activatie van de type 
2 macrofagen. Deze activatie was sterker voor type 2 macrofagen met het FCGR3A 
158-valine allel (P=0,048). Hieruit concluderen we dat tumorgroei bevorderende 
macrofagen geactiveerd kunnen worden door cetuximab. 
Capecitabine, oxaliplatin en bevacizumab
Hoofdstuk 5 geeft een overzicht van kiembaan polymorfismen die uitvoerig 
bestudeerd zijn voor verschillende soorten chemotherapie. Hoewel er veel studies 
over dit onderwerp zijn gepubliceerd, concluderen we dat er meer onderzoek nodig 
is. Vooral replicatie van de resultaten en ontwikkelen van voorspellende modellen is 
nodig. Prospectieve studies zijn nodig om de klinische toepasbaarheid en kosten-ef-
fectiviteit van farmacogenetische tests aan te tonen. 
In een eerder onderzoek bleek dat twee polymorfismen waren geassocieerd met pro-
gressie-vrije overleving van gemetastaseerde dikke darm kanker patienten die werden 
behandeld met oxaliplatin bevattende therapie: ATM rs1801516 en ERCC5 rs1047768. 
Deze associaties konden we echter niet bevestigen in de CAIRO2 studie, zoals 
beschreven in hoofdstuk 6. Hieruit concluderen we dat deze polymorfismen geen 
relevante invloed hebben op de progressie-vrije overleving van oxaliplatin bevattende 
therapie van gemetastaseerde dikke darm kanker patienten. Dit resultaat toont verder 
aan dat het belangrijk is om eerdere resultaten van exploratieve onderzoeken te 
valideren. 
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Algemene discussie
In hoofdstuk 10 worden de resultaten van de onderzoeken in dit proefschrift 
bediscussieerd. Daarnaast wordt de vraag gesteld waarom vrijwel geen farmaco-
genetische test routinematig wordt ingezet om anti-kanker behandeling te 
optimaliseren. Er wordt weliswaar veel onderzoek gedaan naar farmacogetica, maar 
de significante resultaten krijgen in het algemeen de meeste aandacht, en initiele 
resultaten worden niet systematisch gevalideerd. Validatie is van belang omdat de 
kans aanwezig is dat initiele significante resultaten vals positief zijn door het grote 
aantal statistische tests dat vaak wordt toegepast. 
Bij het ontwerpen van een farmacogenetisch onderzoek wordt meestal een selectie 
gemaakt van (bekende) polymorfismen in genen waarvan bekend is dat zij betrokken 
zijn bij de werking van het geneesmiddel. Hiervoor is gedetailleerde kennis over de 
werking van het geneesmiddel vereist, wat niet altijd optimaal is. Genome-wide 
genotyperen heeft als voordeel dat er vooraf geen selectie van polymorfismen nodig is. 
Naast het selecteren van de polymorfismen, is het van belang welke statistische 
analysemethode wordt gekozen. In de meeste farmacogenetische studies wordt elk 
polymorfisme afzonderlijk getest of het geassocieerd is met de werking van het 
geneesmiddel. Omdat er complexe biologische mechanismen aan geneesmiddel-
werking ten grondslag liggen, is het rationeel om dit mee te nemen in de statistische 
analyse. Hiervoor kunnen technieken worden gebruikt die gen-gen interactie 
meenemen in de analyse. 
In de meeste gevallen is de uitkomst van een farmacogenetische studie dat een 
genotype leidt tot verhoogde kans op goede werking van een geneesmiddel. Het 
vertalen van een dergelijke risicofactor naar dagelijkse praktijk is niet eenvoudig. 
Voorspellende testen op basis van farmacogenetische informatie zou beter 
onderscheid kunnen maken tussen patienten met goede of minder goede effectiviteit 
van een geneesmiddel. Prospectief onderzoek is nodig om aan te tonen dat 
behandeling op geleide van een genetische test is beter dan standaard 
behandeling.  
De ideale farmacogenetische studie zou daarom als volgt zijn: een genome-wide 
onderzoek in combinatie met een voorspellende test. Bevestiging van de resultaten 
in een aparte groep patienten is noodzakelijk, en prospectief onderzoek is nodig 
voordat een farmacogenetische test in de dagelijkse klinische praktijk kan worden 
toegepast. 
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